id	sid	tid	token	lemma	pos
ajlm-840	1	1	abstract	abstract	ADJ
ajlm-840	1	2	introduction	introduction	NOUN
ajlm-840	1	3	methods	method	NOUN
ajlm-840	1	4	results	result	VERB
ajlm-840	1	5	discussion	discussion	NOUN
ajlm-840	1	6	acknowledgements	acknowledgement	NOUN
ajlm-840	1	7	references	reference	NOUN
ajlm-840	1	8	about	about	ADP
ajlm-840	1	9	the	the	DET
ajlm-840	1	10	author(s	author(s	NOUN
ajlm-840	1	11	)	)	PUNCT
ajlm-840	1	12	prenika	prenika	PROPN
ajlm-840	1	13	jaglal	jaglal	PROPN
ajlm-840	1	14	department	department	PROPN
ajlm-840	1	15	of	of	ADP
ajlm-840	1	16	medical	medical	ADJ
ajlm-840	1	17	microbiology	microbiology	NOUN
ajlm-840	1	18	,	,	PUNCT
ajlm-840	1	19	national	national	PROPN
ajlm-840	1	20	health	health	PROPN
ajlm-840	1	21	laboratory	laboratory	PROPN
ajlm-840	1	22	services	service	NOUN
ajlm-840	1	23	,	,	PUNCT
ajlm-840	1	24	school	school	NOUN
ajlm-840	1	25	of	of	ADP
ajlm-840	1	26	laboratory	laboratory	NOUN
ajlm-840	1	27	medicine	medicine	NOUN
ajlm-840	1	28	and	and	CCONJ
ajlm-840	1	29	medical	medical	ADJ
ajlm-840	1	30	science	science	NOUN
ajlm-840	1	31	,	,	PUNCT
ajlm-840	1	32	university	university	NOUN
ajlm-840	1	33	of	of	ADP
ajlm-840	1	34	kwazulu	kwazulu	PROPN
ajlm-840	1	35	-	-	PUNCT
ajlm-840	1	36	natal	natal	ADJ
ajlm-840	1	37	,	,	PUNCT
ajlm-840	1	38	durban	durban	PROPN
ajlm-840	1	39	,	,	PUNCT
ajlm-840	1	40	south	south	PROPN
ajlm-840	1	41	africa	africa	PROPN
ajlm-840	1	42	melendhran	melendhran	PROPN
ajlm-840	1	43	pillay	pillay	PROPN
ajlm-840	1	44	department	department	PROPN
ajlm-840	1	45	of	of	ADP
ajlm-840	1	46	medical	medical	ADJ
ajlm-840	1	47	microbiology	microbiology	NOUN
ajlm-840	1	48	/	/	SYM
ajlm-840	1	49	virology	virology	NOUN
ajlm-840	1	50	,	,	PUNCT
ajlm-840	1	51	national	national	PROPN
ajlm-840	1	52	health	health	PROPN
ajlm-840	1	53	laboratory	laboratory	PROPN
ajlm-840	1	54	service	service	PROPN
ajlm-840	1	55	,	,	PUNCT
ajlm-840	1	56	durban	durban	PROPN
ajlm-840	1	57	,	,	PUNCT
ajlm-840	1	58	south	south	PROPN
ajlm-840	1	59	africa	africa	PROPN
ajlm-840	1	60	koleka	koleka	PROPN
ajlm-840	1	61	mlisana	mlisana	PROPN
ajlm-840	1	62	department	department	PROPN
ajlm-840	1	63	of	of	ADP
ajlm-840	1	64	medical	medical	ADJ
ajlm-840	1	65	microbiology	microbiology	NOUN
ajlm-840	1	66	,	,	PUNCT
ajlm-840	1	67	national	national	PROPN
ajlm-840	1	68	health	health	PROPN
ajlm-840	1	69	laboratory	laboratory	PROPN
ajlm-840	1	70	services	service	NOUN
ajlm-840	1	71	,	,	PUNCT
ajlm-840	1	72	school	school	NOUN
ajlm-840	1	73	of	of	ADP
ajlm-840	1	74	laboratory	laboratory	NOUN
ajlm-840	1	75	medicine	medicine	NOUN
ajlm-840	1	76	and	and	CCONJ
ajlm-840	1	77	medical	medical	ADJ
ajlm-840	1	78	science	science	NOUN
ajlm-840	1	79	,	,	PUNCT
ajlm-840	1	80	university	university	NOUN
ajlm-840	1	81	of	of	ADP
ajlm-840	1	82	kwazulu	kwazulu	PROPN
ajlm-840	1	83	-	-	PUNCT
ajlm-840	1	84	natal	natal	ADJ
ajlm-840	1	85	,	,	PUNCT
ajlm-840	1	86	durban	durban	PROPN
ajlm-840	1	87	,	,	PUNCT
ajlm-840	1	88	south	south	PROPN
ajlm-840	1	89	africa	africa	PROPN
ajlm-840	1	90	citation	citation	PROPN
ajlm-840	1	91	jaglal	jaglal	VERB
ajlm-840	1	92	p	p	X
ajlm-840	1	93	,	,	PUNCT
ajlm-840	1	94	pillay	pillay	PROPN
ajlm-840	1	95	m	m	PROPN
ajlm-840	1	96	,	,	PUNCT
ajlm-840	2	1	mlisana	mlisana	PROPN
ajlm-840	2	2	k.	k.	PROPN
ajlm-840	2	3	resazurin	resazurin	PROPN
ajlm-840	2	4	microtitre	microtitre	PROPN
ajlm-840	2	5	plate	plate	NOUN
ajlm-840	2	6	assay	assay	PROPN
ajlm-840	2	7	and	and	CCONJ
ajlm-840	2	8	sensititre	sensititre	PROPN
ajlm-840	2	9	®	®	PROPN
ajlm-840	2	10	mycotb	mycotb	NOUN
ajlm-840	2	11	for	for	ADP
ajlm-840	2	12	detection	detection	NOUN
ajlm-840	2	13	of	of	ADP
ajlm-840	2	14	mycobacterium	mycobacterium	NOUN
ajlm-840	2	15	tuberculosis	tuberculosis	NOUN
ajlm-840	2	16	resistance	resistance	NOUN
ajlm-840	2	17	in	in	ADP
ajlm-840	2	18	a	a	DET
ajlm-840	2	19	high	high	ADJ
ajlm-840	2	20	tuberculosis	tuberculosis	NOUN
ajlm-840	2	21	resistance	resistance	NOUN
ajlm-840	2	22	setting	setting	NOUN
ajlm-840	2	23	.	.	PUNCT
ajlm-840	3	1	afr	afr	PROPN
ajlm-840	3	2	j	j	PROPN
ajlm-840	3	3	lab	lab	PROPN
ajlm-840	3	4	med	med	PROPN
ajlm-840	3	5	.	.	PUNCT
ajlm-840	3	6	2019;8(1	2019;8(1	NOUN
ajlm-840	3	7	)	)	PUNCT
ajlm-840	3	8	,	,	PUNCT
ajlm-840	3	9	a840	a840	PROPN
ajlm-840	3	10	.	.	PUNCT
ajlm-840	4	1	https://doi.org/10.4102/ajlm.v8i1.840	https://doi.org/10.4102/ajlm.v8i1.840	NUM
ajlm-840	4	2	original	original	ADJ
ajlm-840	4	3	research	research	NOUN
ajlm-840	4	4	resazurin	resazurin	NOUN
ajlm-840	4	5	microtitre	microtitre	PROPN
ajlm-840	4	6	plate	plate	NOUN
ajlm-840	4	7	assay	assay	PROPN
ajlm-840	4	8	and	and	CCONJ
ajlm-840	4	9	sensititre	sensititre	PROPN
ajlm-840	4	10	®	®	PROPN
ajlm-840	4	11	mycotb	mycotb	NOUN
ajlm-840	4	12	for	for	ADP
ajlm-840	4	13	detection	detection	NOUN
ajlm-840	4	14	of	of	ADP
ajlm-840	4	15	mycobacterium	mycobacterium	NOUN
ajlm-840	4	16	tuberculosis	tuberculosis	NOUN
ajlm-840	4	17	resistance	resistance	NOUN
ajlm-840	4	18	in	in	ADP
ajlm-840	4	19	a	a	DET
ajlm-840	4	20	high	high	ADJ
ajlm-840	4	21	tuberculosis	tuberculosis	NOUN
ajlm-840	4	22	resistance	resistance	NOUN
ajlm-840	4	23	setting	set	VERB
ajlm-840	4	24	prenika	prenika	NOUN
ajlm-840	4	25	jaglal	jaglal	PROPN
ajlm-840	4	26	,	,	PUNCT
ajlm-840	4	27	melendhran	melendhran	PROPN
ajlm-840	4	28	pillay	pillay	PROPN
ajlm-840	4	29	,	,	PUNCT
ajlm-840	4	30	koleka	koleka	PROPN
ajlm-840	4	31	mlisana	mlisana	PROPN
ajlm-840	4	32	received	receive	VERB
ajlm-840	4	33	:	:	PUNCT
ajlm-840	4	34	30	30	NUM
ajlm-840	4	35	may	may	PROPN
ajlm-840	4	36	2018	2018	NUM
ajlm-840	4	37	;	;	PUNCT
ajlm-840	4	38	accepted	accept	VERB
ajlm-840	4	39	:	:	PUNCT
ajlm-840	4	40	13	13	NUM
ajlm-840	4	41	mar	mar	PROPN
ajlm-840	4	42	.	.	PROPN
ajlm-840	4	43	2019	2019	NUM
ajlm-840	4	44	;	;	PUNCT
ajlm-840	4	45	published	publish	VERB
ajlm-840	4	46	:	:	PUNCT
ajlm-840	4	47	13	13	NUM
ajlm-840	4	48	dec	dec	PROPN
ajlm-840	4	49	.	.	PROPN
ajlm-840	5	1	2019	2019	NUM
ajlm-840	5	2	copyright	copyright	NOUN
ajlm-840	5	3	:	:	PUNCT
ajlm-840	5	4	©	©	PROPN
ajlm-840	5	5	2019	2019	NUM
ajlm-840	5	6	.	.	PUNCT
ajlm-840	6	1	the	the	DET
ajlm-840	6	2	author(s	author(s	PROPN
ajlm-840	6	3	)	)	PUNCT
ajlm-840	6	4	.	.	PUNCT
ajlm-840	7	1	licensee	licensee	NOUN
ajlm-840	7	2	:	:	PUNCT
ajlm-840	7	3	aosis	aosis	NOUN
ajlm-840	7	4	.	.	PUNCT
ajlm-840	8	1	this	this	PRON
ajlm-840	8	2	is	be	AUX
ajlm-840	8	3	an	an	DET
ajlm-840	8	4	open	open	ADJ
ajlm-840	8	5	access	access	NOUN
ajlm-840	8	6	article	article	NOUN
ajlm-840	8	7	distributed	distribute	VERB
ajlm-840	8	8	under	under	ADP
ajlm-840	8	9	the	the	DET
ajlm-840	8	10	terms	term	NOUN
ajlm-840	8	11	of	of	ADP
ajlm-840	8	12	the	the	DET
ajlm-840	8	13	creative	creative	ADJ
ajlm-840	8	14	commons	common	NOUN
ajlm-840	8	15	attribution	attribution	NOUN
ajlm-840	8	16	license	license	NOUN
ajlm-840	8	17	,	,	PUNCT
ajlm-840	8	18	which	which	PRON
ajlm-840	8	19	permits	permit	VERB
ajlm-840	8	20	unrestricted	unrestricted	ADJ
ajlm-840	8	21	use	use	NOUN
ajlm-840	8	22	,	,	PUNCT
ajlm-840	8	23	distribution	distribution	NOUN
ajlm-840	8	24	,	,	PUNCT
ajlm-840	8	25	and	and	CCONJ
ajlm-840	8	26	reproduction	reproduction	NOUN
ajlm-840	8	27	in	in	ADP
ajlm-840	8	28	any	any	DET
ajlm-840	8	29	medium	medium	NOUN
ajlm-840	8	30	,	,	PUNCT
ajlm-840	8	31	provided	provide	VERB
ajlm-840	8	32	the	the	DET
ajlm-840	8	33	original	original	ADJ
ajlm-840	8	34	work	work	NOUN
ajlm-840	8	35	is	be	AUX
ajlm-840	8	36	properly	properly	ADV
ajlm-840	8	37	cited	cite	VERB
ajlm-840	8	38	.	.	PUNCT
ajlm-840	9	1	abstract	abstract	ADJ
ajlm-840	9	2	background	background	NOUN
ajlm-840	9	3	:	:	PUNCT
ajlm-840	9	4	rapid	rapid	ADJ
ajlm-840	9	5	diagnosis	diagnosis	NOUN
ajlm-840	9	6	of	of	ADP
ajlm-840	9	7	drug	drug	NOUN
ajlm-840	9	8	-	-	PUNCT
ajlm-840	9	9	resistant	resistant	ADJ
ajlm-840	9	10	mycobacterium	mycobacterium	NOUN
ajlm-840	9	11	tuberculosis	tuberculosis	NOUN
ajlm-840	9	12	is	be	AUX
ajlm-840	9	13	a	a	DET
ajlm-840	9	14	challenge	challenge	NOUN
ajlm-840	9	15	in	in	ADP
ajlm-840	9	16	low	low	ADJ
ajlm-840	9	17	-	-	PUNCT
ajlm-840	9	18	income	income	NOUN
ajlm-840	9	19	countries	country	NOUN
ajlm-840	9	20	.	.	PUNCT
ajlm-840	10	1	phenotypic	phenotypic	ADJ
ajlm-840	10	2	drug	drug	NOUN
ajlm-840	10	3	susceptibility	susceptibility	NOUN
ajlm-840	10	4	testing	testing	NOUN
ajlm-840	10	5	using	use	VERB
ajlm-840	10	6	sensititre	sensititre	PROPN
ajlm-840	10	7	®	®	PROPN
ajlm-840	10	8	mycotb	mycotb	NOUN
ajlm-840	10	9	assay	assay	PROPN
ajlm-840	10	10	and	and	CCONJ
ajlm-840	10	11	the	the	DET
ajlm-840	10	12	resazurin	resazurin	NOUN
ajlm-840	10	13	microtitre	microtitre	PROPN
ajlm-840	10	14	plate	plate	NOUN
ajlm-840	10	15	assay	assay	PROPN
ajlm-840	10	16	(	(	PUNCT
ajlm-840	10	17	rema	rema	PROPN
ajlm-840	10	18	)	)	PUNCT
ajlm-840	10	19	are	be	AUX
ajlm-840	10	20	relatively	relatively	ADV
ajlm-840	10	21	new	new	ADJ
ajlm-840	10	22	innovative	innovative	ADJ
ajlm-840	10	23	methods	method	NOUN
ajlm-840	10	24	to	to	PART
ajlm-840	10	25	determine	determine	VERB
ajlm-840	10	26	drug	drug	NOUN
ajlm-840	10	27	susceptibility	susceptibility	NOUN
ajlm-840	10	28	.	.	PUNCT
ajlm-840	11	1	objectives	objective	NOUN
ajlm-840	11	2	:	:	PUNCT
ajlm-840	11	3	this	this	DET
ajlm-840	11	4	study	study	NOUN
ajlm-840	11	5	aimed	aim	VERB
ajlm-840	11	6	to	to	PART
ajlm-840	11	7	determine	determine	VERB
ajlm-840	11	8	the	the	DET
ajlm-840	11	9	performance	performance	NOUN
ajlm-840	11	10	of	of	ADP
ajlm-840	11	11	the	the	DET
ajlm-840	11	12	sensititre	sensititre	NOUN
ajlm-840	11	13	and	and	CCONJ
ajlm-840	11	14	rema	rema	NOUN
ajlm-840	11	15	for	for	ADP
ajlm-840	11	16	m.	m.	NOUN
ajlm-840	11	17	tuberculosis	tuberculosis	NOUN
ajlm-840	11	18	drug	drug	NOUN
ajlm-840	11	19	susceptibility	susceptibility	NOUN
ajlm-840	11	20	testing	testing	NOUN
ajlm-840	11	21	in	in	ADP
ajlm-840	11	22	a	a	DET
ajlm-840	11	23	high	high	ADJ
ajlm-840	11	24	-	-	PUNCT
ajlm-840	11	25	volume	volume	NOUN
ajlm-840	11	26	tuberculosis	tuberculosis	NOUN
ajlm-840	11	27	reference	reference	NOUN
ajlm-840	11	28	laboratory	laboratory	NOUN
ajlm-840	11	29	.	.	PUNCT
ajlm-840	12	1	methods	method	NOUN
ajlm-840	12	2	:	:	PUNCT
ajlm-840	12	3	a	a	DET
ajlm-840	12	4	laboratory	laboratory	NOUN
ajlm-840	12	5	-	-	PUNCT
ajlm-840	12	6	based	base	VERB
ajlm-840	12	7	study	study	NOUN
ajlm-840	12	8	was	be	AUX
ajlm-840	12	9	performed	perform	VERB
ajlm-840	12	10	at	at	ADP
ajlm-840	12	11	the	the	DET
ajlm-840	12	12	inkosi	inkosi	PROPN
ajlm-840	12	13	albert	albert	PROPN
ajlm-840	12	14	luthuli	luthuli	PROPN
ajlm-840	12	15	central	central	ADJ
ajlm-840	12	16	hospital	hospital	NOUN
ajlm-840	12	17	tuberculosis	tuberculosis	NOUN
ajlm-840	12	18	laboratory	laboratory	NOUN
ajlm-840	12	19	from	from	ADP
ajlm-840	12	20	january	january	PROPN
ajlm-840	12	21	2014	2014	NUM
ajlm-840	12	22	to	to	ADP
ajlm-840	12	23	june	june	PROPN
ajlm-840	12	24	2015	2015	NUM
ajlm-840	12	25	.	.	PUNCT
ajlm-840	13	1	the	the	DET
ajlm-840	13	2	sensititre	sensititre	PROPN
ajlm-840	13	3	®	®	PROPN
ajlm-840	13	4	mycotb	mycotb	ADJ
ajlm-840	13	5	plate	plate	NOUN
ajlm-840	13	6	and	and	CCONJ
ajlm-840	13	7	rema	rema	NOUN
ajlm-840	13	8	were	be	AUX
ajlm-840	13	9	compared	compare	VERB
ajlm-840	13	10	to	to	ADP
ajlm-840	13	11	the	the	DET
ajlm-840	13	12	gold	gold	ADJ
ajlm-840	13	13	standard	standard	ADJ
ajlm-840	13	14	agar	agar	NOUN
ajlm-840	13	15	proportion	proportion	NOUN
ajlm-840	13	16	method	method	NOUN
ajlm-840	13	17	(	(	PUNCT
ajlm-840	13	18	apm	apm	NOUN
ajlm-840	13	19	)	)	PUNCT
ajlm-840	13	20	using	use	VERB
ajlm-840	13	21	134	134	NUM
ajlm-840	13	22	stored	store	VERB
ajlm-840	13	23	isolates	isolate	NOUN
ajlm-840	13	24	.	.	PUNCT
ajlm-840	14	1	results	result	NOUN
ajlm-840	14	2	:	:	PUNCT
ajlm-840	14	3	agreement	agreement	NOUN
ajlm-840	14	4	between	between	ADP
ajlm-840	14	5	the	the	DET
ajlm-840	14	6	sensititre	sensititre	NOUN
ajlm-840	14	7	®	®	PROPN
ajlm-840	14	8	mycotb	mycotb	ADJ
ajlm-840	14	9	plate	plate	NOUN
ajlm-840	14	10	and	and	CCONJ
ajlm-840	14	11	apm	apm	NOUN
ajlm-840	14	12	was	be	AUX
ajlm-840	14	13	observed	observe	VERB
ajlm-840	14	14	with	with	ADP
ajlm-840	14	15	98	98	NUM
ajlm-840	14	16	%	%	NOUN
ajlm-840	14	17	sensitivity	sensitivity	NOUN
ajlm-840	14	18	,	,	PUNCT
ajlm-840	14	19	82	82	NUM
ajlm-840	14	20	%	%	NOUN
ajlm-840	14	21	specificity	specificity	NOUN
ajlm-840	14	22	,	,	PUNCT
ajlm-840	14	23	94	94	NUM
ajlm-840	14	24	%	%	NOUN
ajlm-840	14	25	positive	positive	ADJ
ajlm-840	14	26	and	and	CCONJ
ajlm-840	14	27	93	93	NUM
ajlm-840	14	28	%	%	NOUN
ajlm-840	14	29	negative	negative	ADJ
ajlm-840	14	30	predictive	predictive	ADJ
ajlm-840	14	31	values	value	NOUN
ajlm-840	14	32	of	of	ADP
ajlm-840	14	33	the	the	DET
ajlm-840	14	34	sensititre	sensititre	PROPN
ajlm-840	14	35	®	®	PROPN
ajlm-840	14	36	mycotb	mycotb	NOUN
ajlm-840	14	37	assay	assay	PROPN
ajlm-840	14	38	for	for	ADP
ajlm-840	14	39	the	the	DET
ajlm-840	14	40	detection	detection	NOUN
ajlm-840	14	41	of	of	ADP
ajlm-840	14	42	rifampicin	rifampicin	VERB
ajlm-840	14	43	resistance	resistance	NOUN
ajlm-840	14	44	and	and	CCONJ
ajlm-840	14	45	97	97	NUM
ajlm-840	14	46	%	%	NOUN
ajlm-840	14	47	,	,	PUNCT
ajlm-840	14	48	96	96	NUM
ajlm-840	14	49	%	%	NOUN
ajlm-840	14	50	,	,	PUNCT
ajlm-840	14	51	99	99	NUM
ajlm-840	14	52	%	%	NOUN
ajlm-840	14	53	and	and	CCONJ
ajlm-840	14	54	88	88	NUM
ajlm-840	14	55	%	%	NOUN
ajlm-840	14	56	for	for	ADP
ajlm-840	14	57	isoniazid	isoniazid	NOUN
ajlm-840	14	58	resistance	resistance	NOUN
ajlm-840	14	59	.	.	PUNCT
ajlm-840	15	1	good	good	ADJ
ajlm-840	15	2	categorical	categorical	ADJ
ajlm-840	15	3	agreement	agreement	NOUN
ajlm-840	15	4	between	between	ADP
ajlm-840	15	5	the	the	DET
ajlm-840	15	6	rema	rema	NOUN
ajlm-840	15	7	and	and	CCONJ
ajlm-840	15	8	the	the	DET
ajlm-840	15	9	apm	apm	NOUN
ajlm-840	15	10	was	be	AUX
ajlm-840	15	11	observed	observe	VERB
ajlm-840	15	12	among	among	ADP
ajlm-840	15	13	isolates	isolate	NOUN
ajlm-840	15	14	with	with	ADP
ajlm-840	15	15	89	89	NUM
ajlm-840	15	16	%	%	NOUN
ajlm-840	15	17	sensitivity	sensitivity	NOUN
ajlm-840	15	18	,	,	PUNCT
ajlm-840	15	19	68	68	NUM
ajlm-840	15	20	%	%	NOUN
ajlm-840	15	21	specificity	specificity	NOUN
ajlm-840	15	22	,	,	PUNCT
ajlm-840	15	23	89	89	NUM
ajlm-840	15	24	%	%	NOUN
ajlm-840	15	25	positive	positive	ADJ
ajlm-840	15	26	and	and	CCONJ
ajlm-840	15	27	68	68	NUM
ajlm-840	15	28	%	%	NOUN
ajlm-840	15	29	negative	negative	ADJ
ajlm-840	15	30	predictive	predictive	ADJ
ajlm-840	15	31	value	value	NOUN
ajlm-840	15	32	for	for	ADP
ajlm-840	15	33	the	the	DET
ajlm-840	15	34	detection	detection	NOUN
ajlm-840	15	35	of	of	ADP
ajlm-840	15	36	rifampicin	rifampicin	VERB
ajlm-840	15	37	resistance	resistance	NOUN
ajlm-840	15	38	and	and	CCONJ
ajlm-840	15	39	95	95	NUM
ajlm-840	15	40	%	%	NOUN
ajlm-840	15	41	,	,	PUNCT
ajlm-840	15	42	96	96	NUM
ajlm-840	15	43	%	%	NOUN
ajlm-840	15	44	,	,	PUNCT
ajlm-840	15	45	99	99	NUM
ajlm-840	15	46	%	%	NOUN
ajlm-840	15	47	and	and	CCONJ
ajlm-840	15	48	81	81	NUM
ajlm-840	15	49	%	%	NOUN
ajlm-840	15	50	for	for	ADP
ajlm-840	15	51	isoniazid	isoniazid	NOUN
ajlm-840	15	52	resistance	resistance	NOUN
ajlm-840	15	53	.	.	PUNCT
ajlm-840	16	1	results	result	NOUN
ajlm-840	16	2	for	for	ADP
ajlm-840	16	3	the	the	DET
ajlm-840	16	4	second	second	ADJ
ajlm-840	16	5	-	-	PUNCT
ajlm-840	16	6	line	line	NOUN
ajlm-840	16	7	drugs	drug	NOUN
ajlm-840	16	8	showed	show	VERB
ajlm-840	16	9	elevated	elevated	ADJ
ajlm-840	16	10	minimum	minimum	ADJ
ajlm-840	16	11	inhibitory	inhibitory	ADJ
ajlm-840	16	12	concentrations	concentration	NOUN
ajlm-840	16	13	for	for	ADP
ajlm-840	16	14	multidrug	multidrug	NOUN
ajlm-840	16	15	-	-	PUNCT
ajlm-840	16	16	resistant	resistant	ADJ
ajlm-840	16	17	and	and	CCONJ
ajlm-840	16	18	extensively	extensively	ADV
ajlm-840	16	19	drug	drug	NOUN
ajlm-840	16	20	-	-	PUNCT
ajlm-840	16	21	resistant	resistant	ADJ
ajlm-840	16	22	tuberculosis	tuberculosis	NOUN
ajlm-840	16	23	isolates	isolate	NOUN
ajlm-840	16	24	.	.	PUNCT
ajlm-840	17	1	conclusion	conclusion	NOUN
ajlm-840	17	2	:	:	PUNCT
ajlm-840	17	3	the	the	DET
ajlm-840	17	4	rema	rema	PROPN
ajlm-840	17	5	and	and	CCONJ
ajlm-840	17	6	sensititre	sensititre	PROPN
ajlm-840	17	7	®	®	PROPN
ajlm-840	17	8	mycotb	mycotb	ADJ
ajlm-840	17	9	plate	plate	NOUN
ajlm-840	17	10	are	be	AUX
ajlm-840	17	11	attractive	attractive	ADJ
ajlm-840	17	12	alternatives	alternative	NOUN
ajlm-840	17	13	to	to	ADP
ajlm-840	17	14	the	the	DET
ajlm-840	17	15	gold	gold	ADJ
ajlm-840	17	16	standard	standard	NOUN
ajlm-840	17	17	apm	apm	NOUN
ajlm-840	17	18	for	for	ADP
ajlm-840	17	19	the	the	DET
ajlm-840	17	20	phenotypic	phenotypic	ADJ
ajlm-840	17	21	detection	detection	NOUN
ajlm-840	17	22	of	of	ADP
ajlm-840	17	23	m.	m.	NOUN
ajlm-840	17	24	tuberculosis	tuberculosis	NOUN
ajlm-840	17	25	drug	drug	NOUN
ajlm-840	17	26	resistance	resistance	NOUN
ajlm-840	17	27	.	.	PUNCT
ajlm-840	18	1	keywords	keyword	NOUN
ajlm-840	18	2	:	:	PUNCT
ajlm-840	18	3	mycobacterium	mycobacterium	NOUN
ajlm-840	18	4	tuberculosis	tuberculosis	NOUN
ajlm-840	18	5	;	;	PUNCT
ajlm-840	18	6	agar	agar	NOUN
ajlm-840	18	7	proportion	proportion	NOUN
ajlm-840	18	8	method	method	NOUN
ajlm-840	18	9	;	;	PUNCT
ajlm-840	18	10	multidrug	multidrug	NOUN
ajlm-840	18	11	-	-	PUNCT
ajlm-840	18	12	resistant	resistant	ADJ
ajlm-840	18	13	tuberculosis	tuberculosis	NOUN
ajlm-840	18	14	;	;	PUNCT
ajlm-840	18	15	extensively	extensively	ADV
ajlm-840	18	16	drug	drug	NOUN
ajlm-840	18	17	-	-	PUNCT
ajlm-840	18	18	resistant	resistant	ADJ
ajlm-840	18	19	tuberculosis	tuberculosis	NOUN
ajlm-840	18	20	;	;	PUNCT
ajlm-840	18	21	sensititre	sensititre	PROPN
ajlm-840	18	22	®	®	PROPN
ajlm-840	18	23	mycotb	mycotb	PROPN
ajlm-840	18	24	assay	assay	PROPN
ajlm-840	18	25	;	;	PUNCT
ajlm-840	18	26	resazurin	resazurin	NOUN
ajlm-840	18	27	microtitre	microtitre	PROPN
ajlm-840	18	28	plate	plate	NOUN
ajlm-840	18	29	assay	assay	VERB
ajlm-840	18	30	.	.	PUNCT
ajlm-840	19	1	introduction	introduction	NOUN
ajlm-840	19	2	multidrug	multidrug	NOUN
ajlm-840	19	3	-	-	PUNCT
ajlm-840	19	4	resistant	resistant	ADJ
ajlm-840	19	5	tuberculosis	tuberculosis	NOUN
ajlm-840	19	6	has	have	AUX
ajlm-840	19	7	been	be	AUX
ajlm-840	19	8	declared	declare	VERB
ajlm-840	19	9	a	a	DET
ajlm-840	19	10	public	public	ADJ
ajlm-840	19	11	health	health	NOUN
ajlm-840	19	12	crisis	crisis	NOUN
ajlm-840	19	13	by	by	ADP
ajlm-840	19	14	the	the	DET
ajlm-840	19	15	world	world	PROPN
ajlm-840	19	16	health	health	PROPN
ajlm-840	19	17	organization	organization	NOUN
ajlm-840	19	18	(	(	PUNCT
ajlm-840	19	19	who).1	who).1	X
ajlm-840	19	20	the	the	DET
ajlm-840	19	21	global	global	ADJ
ajlm-840	19	22	burden	burden	NOUN
ajlm-840	19	23	of	of	ADP
ajlm-840	19	24	tuberculosis	tuberculosis	NOUN
ajlm-840	19	25	remains	remain	VERB
ajlm-840	19	26	enormous	enormous	ADJ
ajlm-840	19	27	with	with	ADP
ajlm-840	19	28	an	an	DET
ajlm-840	19	29	incidence	incidence	NOUN
ajlm-840	19	30	of	of	ADP
ajlm-840	19	31	10	10	NUM
ajlm-840	19	32	million	million	NUM
ajlm-840	19	33	new	new	ADJ
ajlm-840	19	34	cases	case	NOUN
ajlm-840	19	35	and	and	CCONJ
ajlm-840	19	36	a	a	DET
ajlm-840	19	37	mortality	mortality	NOUN
ajlm-840	19	38	of	of	ADP
ajlm-840	19	39	1.3	1.3	NUM
ajlm-840	19	40	million	million	NUM
ajlm-840	19	41	attributed	attribute	VERB
ajlm-840	19	42	to	to	ADP
ajlm-840	19	43	the	the	DET
ajlm-840	19	44	disease	disease	NOUN
ajlm-840	19	45	worldwide	worldwide	ADV
ajlm-840	19	46	in	in	ADP
ajlm-840	19	47	2017.1	2017.1	NUM
ajlm-840	19	48	the	the	DET
ajlm-840	19	49	2018	2018	NUM
ajlm-840	19	50	who	who	PRON
ajlm-840	19	51	global	global	ADJ
ajlm-840	19	52	tuberculosis	tuberculosis	NOUN
ajlm-840	19	53	report	report	NOUN
ajlm-840	19	54	documented	document	VERB
ajlm-840	19	55	new	new	ADJ
ajlm-840	19	56	tuberculosis	tuberculosis	NOUN
ajlm-840	19	57	cases	case	NOUN
ajlm-840	19	58	,	,	PUNCT
ajlm-840	19	59	which	which	PRON
ajlm-840	19	60	included	include	VERB
ajlm-840	19	61	an	an	DET
ajlm-840	19	62	additional	additional	ADJ
ajlm-840	19	63	300	300	NUM
ajlm-840	19	64	000	000	NUM
ajlm-840	19	65	tuberculosis	tuberculosis	NOUN
ajlm-840	19	66	cases	case	NOUN
ajlm-840	19	67	among	among	ADP
ajlm-840	19	68	hiv	hiv	PROPN
ajlm-840	19	69	-	-	PUNCT
ajlm-840	19	70	positive	positive	ADJ
ajlm-840	19	71	tuberculosis	tuberculosis	NOUN
ajlm-840	19	72	patients.1	patients.1	PROPN
ajlm-840	19	73	south	south	PROPN
ajlm-840	19	74	africa	africa	PROPN
ajlm-840	19	75	is	be	AUX
ajlm-840	19	76	among	among	ADP
ajlm-840	19	77	the	the	DET
ajlm-840	19	78	top	top	ADJ
ajlm-840	19	79	20	20	NUM
ajlm-840	19	80	high	high	ADJ
ajlm-840	19	81	-	-	PUNCT
ajlm-840	19	82	tuberculosis	tuberculosis	NOUN
ajlm-840	19	83	-	-	PUNCT
ajlm-840	19	84	burden	burden	NOUN
ajlm-840	19	85	countries	country	NOUN
ajlm-840	19	86	worldwide	worldwide	ADV
ajlm-840	19	87	and	and	CCONJ
ajlm-840	19	88	was	be	AUX
ajlm-840	19	89	previously	previously	ADV
ajlm-840	19	90	ranked	rank	VERB
ajlm-840	19	91	third	third	ADV
ajlm-840	19	92	following	follow	VERB
ajlm-840	19	93	india	india	PROPN
ajlm-840	19	94	and	and	CCONJ
ajlm-840	19	95	china.1,2	china.1,2	ADJ
ajlm-840	19	96	multidrug	multidrug	NOUN
ajlm-840	19	97	-	-	PUNCT
ajlm-840	19	98	resistant	resistant	ADJ
ajlm-840	19	99	(	(	PUNCT
ajlm-840	19	100	mdr	mdr	NOUN
ajlm-840	19	101	)	)	PUNCT
ajlm-840	19	102	tuberculosis	tuberculosis	NOUN
ajlm-840	19	103	is	be	AUX
ajlm-840	19	104	steadily	steadily	ADV
ajlm-840	19	105	increasing	increase	VERB
ajlm-840	19	106	in	in	ADP
ajlm-840	19	107	south	south	PROPN
ajlm-840	19	108	africa	africa	PROPN
ajlm-840	19	109	;	;	PUNCT
ajlm-840	19	110	cases	case	NOUN
ajlm-840	19	111	doubled	double	VERB
ajlm-840	19	112	from	from	ADP
ajlm-840	19	113	7350	7350	NUM
ajlm-840	19	114	in	in	ADP
ajlm-840	19	115	2007	2007	NUM
ajlm-840	19	116	to	to	ADP
ajlm-840	19	117	14	14	NUM
ajlm-840	19	118	000	000	NUM
ajlm-840	19	119	in	in	ADP
ajlm-840	19	120	2017.1,3	2017.1,3	NUM
ajlm-840	19	121	a	a	DET
ajlm-840	19	122	form	form	NOUN
ajlm-840	19	123	of	of	ADP
ajlm-840	19	124	tuberculosis	tuberculosis	NOUN
ajlm-840	19	125	known	know	VERB
ajlm-840	19	126	as	as	ADP
ajlm-840	19	127	extensively	extensively	ADV
ajlm-840	19	128	drug	drug	NOUN
ajlm-840	19	129	-	-	PUNCT
ajlm-840	19	130	resistant	resistant	ADJ
ajlm-840	19	131	(	(	PUNCT
ajlm-840	19	132	xdr	xdr	NOUN
ajlm-840	19	133	)	)	PUNCT
ajlm-840	19	134	tuberculosis	tuberculosis	NOUN
ajlm-840	19	135	has	have	AUX
ajlm-840	19	136	been	be	AUX
ajlm-840	19	137	reported	report	VERB
ajlm-840	19	138	in	in	ADP
ajlm-840	19	139	92	92	NUM
ajlm-840	19	140	countries	country	NOUN
ajlm-840	19	141	.	.	PUNCT
ajlm-840	20	1	south	south	PROPN
ajlm-840	20	2	africa	africa	PROPN
ajlm-840	20	3	has	have	AUX
ajlm-840	20	4	reported	report	VERB
ajlm-840	20	5	73	73	NUM
ajlm-840	20	6	%	%	NOUN
ajlm-840	20	7	of	of	ADP
ajlm-840	20	8	the	the	DET
ajlm-840	20	9	global	global	ADJ
ajlm-840	20	10	xdr	xdr	PROPN
ajlm-840	20	11	cases	case	NOUN
ajlm-840	20	12	following	follow	VERB
ajlm-840	20	13	the	the	DET
ajlm-840	20	14	historical	historical	ADJ
ajlm-840	20	15	outbreak	outbreak	NOUN
ajlm-840	20	16	of	of	ADP
ajlm-840	20	17	xdr	xdr	PROPN
ajlm-840	20	18	tuberculosis	tuberculosis	NOUN
ajlm-840	20	19	in	in	ADP
ajlm-840	20	20	tugela	tugela	NOUN
ajlm-840	20	21	ferry.4	ferry.4	VERB
ajlm-840	20	22	the	the	DET
ajlm-840	20	23	standard	standard	ADJ
ajlm-840	20	24	tuberculosis	tuberculosis	NOUN
ajlm-840	20	25	treatment	treatment	NOUN
ajlm-840	20	26	regimen	regimen	NOUN
ajlm-840	20	27	lasts	last	VERB
ajlm-840	20	28	for	for	ADP
ajlm-840	20	29	a	a	DET
ajlm-840	20	30	minimum	minimum	NOUN
ajlm-840	20	31	of	of	ADP
ajlm-840	20	32	6	6	NUM
ajlm-840	20	33	months	month	NOUN
ajlm-840	20	34	.	.	PUNCT
ajlm-840	21	1	treatments	treatment	NOUN
ajlm-840	21	2	regimens	regimen	NOUN
ajlm-840	21	3	for	for	ADP
ajlm-840	21	4	mdr	mdr	PROPN
ajlm-840	21	5	tuberculosis	tuberculosis	NOUN
ajlm-840	21	6	(	(	PUNCT
ajlm-840	21	7	resistance	resistance	NOUN
ajlm-840	21	8	to	to	ADP
ajlm-840	21	9	isoniazid	isoniazid	NOUN
ajlm-840	21	10	and	and	CCONJ
ajlm-840	21	11	rifampicin	rifampicin	VERB
ajlm-840	21	12	)	)	PUNCT
ajlm-840	21	13	and	and	CCONJ
ajlm-840	21	14	xdr	xdr	PROPN
ajlm-840	21	15	tuberculosis	tuberculosis	NOUN
ajlm-840	21	16	(	(	PUNCT
ajlm-840	21	17	resistance	resistance	NOUN
ajlm-840	21	18	to	to	ADP
ajlm-840	21	19	any	any	PRON
ajlm-840	21	20	of	of	ADP
ajlm-840	21	21	the	the	DET
ajlm-840	21	22	injectable	injectable	ADJ
ajlm-840	21	23	drugs	drug	NOUN
ajlm-840	21	24	including	include	VERB
ajlm-840	21	25	fluoroquinolone	fluoroquinolone	NOUN
ajlm-840	21	26	,	,	PUNCT
ajlm-840	21	27	plus	plus	CCONJ
ajlm-840	21	28	mdr	mdr	PROPN
ajlm-840	21	29	tuberculosis),5,6	tuberculosis),5,6	NUM
ajlm-840	21	30	have	have	VERB
ajlm-840	21	31	an	an	DET
ajlm-840	21	32	extended	extended	ADJ
ajlm-840	21	33	treatment	treatment	NOUN
ajlm-840	21	34	duration	duration	NOUN
ajlm-840	21	35	of	of	ADP
ajlm-840	21	36	18–24	18–24	NUM
ajlm-840	21	37	months	month	NOUN
ajlm-840	21	38	with	with	ADP
ajlm-840	21	39	harmful	harmful	ADJ
ajlm-840	21	40	second	second	ADJ
ajlm-840	21	41	-	-	PUNCT
ajlm-840	21	42	line	line	NOUN
ajlm-840	21	43	anti	anti	ADJ
ajlm-840	21	44	-	-	ADJ
ajlm-840	21	45	tuberculosis	tuberculosis	ADJ
ajlm-840	21	46	drugs	drug	NOUN
ajlm-840	21	47	.	.	PUNCT
ajlm-840	22	1	the	the	PRON
ajlm-840	22	2	who	who	PRON
ajlm-840	22	3	has	have	AUX
ajlm-840	22	4	recently	recently	ADV
ajlm-840	22	5	proposed	propose	VERB
ajlm-840	22	6	a	a	DET
ajlm-840	22	7	9–12	9–12	NOUN
ajlm-840	22	8	-	-	PUNCT
ajlm-840	22	9	month	month	NOUN
ajlm-840	22	10	shortened	shorten	VERB
ajlm-840	22	11	regimen	regimen	NOUN
ajlm-840	22	12	duration	duration	NOUN
ajlm-840	22	13	for	for	ADP
ajlm-840	22	14	mdr	mdr	PROPN
ajlm-840	22	15	tuberculosis	tuberculosis	NOUN
ajlm-840	22	16	,	,	PUNCT
ajlm-840	22	17	with	with	ADP
ajlm-840	22	18	moxifloxacin	moxifloxacin	NOUN
ajlm-840	22	19	replacing	replace	VERB
ajlm-840	22	20	gatifloxacin	gatifloxacin	NOUN
ajlm-840	22	21	(	(	PUNCT
ajlm-840	22	22	used	use	VERB
ajlm-840	22	23	in	in	ADP
ajlm-840	22	24	the	the	DET
ajlm-840	22	25	original	original	ADJ
ajlm-840	22	26	bangladesh	bangladesh	NOUN
ajlm-840	22	27	regimen).7,8	regimen).7,8	PRON
ajlm-840	22	28	the	the	DET
ajlm-840	22	29	conventional	conventional	ADJ
ajlm-840	22	30	,	,	PUNCT
ajlm-840	22	31	culture	culture	NOUN
ajlm-840	22	32	-	-	PUNCT
ajlm-840	22	33	based	base	VERB
ajlm-840	22	34	phenotypic	phenotypic	ADJ
ajlm-840	22	35	method	method	NOUN
ajlm-840	22	36	is	be	AUX
ajlm-840	22	37	recognized	recognize	VERB
ajlm-840	22	38	as	as	ADP
ajlm-840	22	39	the	the	DET
ajlm-840	22	40	gold	gold	ADJ
ajlm-840	22	41	standard	standard	NOUN
ajlm-840	22	42	for	for	ADP
ajlm-840	22	43	confirmation	confirmation	NOUN
ajlm-840	22	44	of	of	ADP
ajlm-840	22	45	disease	disease	NOUN
ajlm-840	22	46	and	and	CCONJ
ajlm-840	22	47	tuberculosis	tuberculosis	NOUN
ajlm-840	22	48	drug	drug	NOUN
ajlm-840	22	49	susceptibility	susceptibility	NOUN
ajlm-840	22	50	testing	testing	NOUN
ajlm-840	22	51	(	(	PUNCT
ajlm-840	22	52	dst	dst	PROPN
ajlm-840	22	53	)	)	PUNCT
ajlm-840	22	54	.	.	PUNCT
ajlm-840	23	1	the	the	DET
ajlm-840	23	2	agar	agar	NOUN
ajlm-840	23	3	proportion	proportion	NOUN
ajlm-840	23	4	method	method	NOUN
ajlm-840	23	5	(	(	PUNCT
ajlm-840	23	6	apm	apm	NOUN
ajlm-840	23	7	)	)	PUNCT
ajlm-840	23	8	compares	compare	VERB
ajlm-840	23	9	growth	growth	NOUN
ajlm-840	23	10	of	of	ADP
ajlm-840	23	11	mycobacterium	mycobacterium	NOUN
ajlm-840	23	12	colonies	colony	NOUN
ajlm-840	23	13	on	on	ADP
ajlm-840	23	14	drug	drug	NOUN
ajlm-840	23	15	-	-	PUNCT
ajlm-840	23	16	free	free	ADJ
ajlm-840	23	17	and	and	CCONJ
ajlm-840	23	18	drug	drug	NOUN
ajlm-840	23	19	-	-	PUNCT
ajlm-840	23	20	containing	contain	VERB
ajlm-840	23	21	mediums	medium	NOUN
ajlm-840	23	22	,	,	PUNCT
ajlm-840	23	23	where	where	SCONJ
ajlm-840	23	24	growth	growth	NOUN
ajlm-840	23	25	in	in	ADP
ajlm-840	23	26	a	a	DET
ajlm-840	23	27	particular	particular	ADJ
ajlm-840	23	28	antibiotic	antibiotic	NOUN
ajlm-840	23	29	-	-	PUNCT
ajlm-840	23	30	containing	contain	VERB
ajlm-840	23	31	medium	medium	ADJ
ajlm-840	23	32	determines	determine	NOUN
ajlm-840	23	33	resistance	resistance	NOUN
ajlm-840	23	34	.	.	PUNCT
ajlm-840	24	1	it	it	PRON
ajlm-840	24	2	is	be	AUX
ajlm-840	24	3	a	a	DET
ajlm-840	24	4	low	low	ADJ
ajlm-840	24	5	-	-	PUNCT
ajlm-840	24	6	cost	cost	NOUN
ajlm-840	24	7	method	method	NOUN
ajlm-840	24	8	requiring	require	VERB
ajlm-840	24	9	no	no	DET
ajlm-840	24	10	special	special	ADJ
ajlm-840	24	11	equipment	equipment	NOUN
ajlm-840	24	12	,	,	PUNCT
ajlm-840	24	13	but	but	CCONJ
ajlm-840	24	14	with	with	ADP
ajlm-840	24	15	a	a	DET
ajlm-840	24	16	turnaround	turnaround	NOUN
ajlm-840	24	17	time	time	NOUN
ajlm-840	24	18	of	of	ADP
ajlm-840	24	19	up	up	ADP
ajlm-840	24	20	to	to	PART
ajlm-840	24	21	6	6	NUM
ajlm-840	24	22	weeks.9,10	weeks.9,10	PRON
ajlm-840	24	23	bactec	bactec	ADJ
ajlm-840	24	24	mycobacterium	mycobacterium	NOUN
ajlm-840	24	25	growth	growth	NOUN
ajlm-840	24	26	indicator	indicator	NOUN
ajlm-840	24	27	tubes	tube	NOUN
ajlm-840	24	28	(	(	PUNCT
ajlm-840	24	29	mgit	mgit	PROPN
ajlm-840	24	30	)	)	PUNCT
ajlm-840	24	31	960	960	NUM
ajlm-840	24	32	liquid	liquid	ADJ
ajlm-840	24	33	culture	culture	NOUN
ajlm-840	24	34	system	system	NOUN
ajlm-840	24	35	(	(	PUNCT
ajlm-840	24	36	becton	becton	PROPN
ajlm-840	24	37	dickinson	dickinson	PROPN
ajlm-840	24	38	)	)	PUNCT
ajlm-840	24	39	is	be	AUX
ajlm-840	24	40	expensive	expensive	ADJ
ajlm-840	24	41	and	and	CCONJ
ajlm-840	24	42	prone	prone	ADJ
ajlm-840	24	43	to	to	ADP
ajlm-840	24	44	contamination	contamination	NOUN
ajlm-840	24	45	but	but	CCONJ
ajlm-840	24	46	has	have	VERB
ajlm-840	24	47	the	the	DET
ajlm-840	24	48	advantage	advantage	NOUN
ajlm-840	24	49	of	of	ADP
ajlm-840	24	50	a	a	DET
ajlm-840	24	51	rapid	rapid	ADJ
ajlm-840	24	52	turnaround	turnaround	NOUN
ajlm-840	24	53	time.2	time.2	PROPN
ajlm-840	24	54	the	the	DET
ajlm-840	24	55	who	who	PRON
ajlm-840	24	56	has	have	AUX
ajlm-840	24	57	endorsed	endorse	VERB
ajlm-840	24	58	the	the	DET
ajlm-840	24	59	genexpert	genexpert	PROPN
ajlm-840	24	60	mtb	mtb	PROPN
ajlm-840	24	61	/	/	SYM
ajlm-840	24	62	rif	rif	PROPN
ajlm-840	24	63	ultra	ultra	ADJ
ajlm-840	24	64	system	system	NOUN
ajlm-840	24	65	,	,	PUNCT
ajlm-840	24	66	which	which	PRON
ajlm-840	24	67	is	be	AUX
ajlm-840	24	68	a	a	DET
ajlm-840	24	69	real	real	ADJ
ajlm-840	24	70	-	-	PUNCT
ajlm-840	24	71	time	time	NOUN
ajlm-840	24	72	polymerase	polymerase	NOUN
ajlm-840	24	73	chain	chain	NOUN
ajlm-840	24	74	reaction	reaction	NOUN
ajlm-840	24	75	-	-	PUNCT
ajlm-840	24	76	based	base	VERB
ajlm-840	24	77	assay	assay	NOUN
ajlm-840	24	78	for	for	ADP
ajlm-840	24	79	tuberculosis	tuberculosis	NOUN
ajlm-840	24	80	diagnosis	diagnosis	NOUN
ajlm-840	24	81	and	and	CCONJ
ajlm-840	24	82	detection	detection	NOUN
ajlm-840	24	83	of	of	ADP
ajlm-840	24	84	rifampicin	rifampicin	VERB
ajlm-840	24	85	resistance	resistance	NOUN
ajlm-840	24	86	,	,	PUNCT
ajlm-840	24	87	yielding	yield	VERB
ajlm-840	24	88	results	result	NOUN
ajlm-840	24	89	within	within	ADP
ajlm-840	24	90	2	2	NUM
ajlm-840	24	91	hours	hour	NOUN
ajlm-840	24	92	.	.	PUNCT
ajlm-840	25	1	the	the	DET
ajlm-840	25	2	genotype	genotype	NOUN
ajlm-840	25	3	mtbdr	mtbdr	NOUN
ajlm-840	25	4	plus	plus	CCONJ
ajlm-840	25	5	identifies	identify	VERB
ajlm-840	25	6	common	common	ADJ
ajlm-840	25	7	mutations	mutation	NOUN
ajlm-840	25	8	for	for	ADP
ajlm-840	25	9	rifampicin	rifampicin	VERB
ajlm-840	25	10	and	and	CCONJ
ajlm-840	25	11	isoniazid.1,11	isoniazid.1,11	NOUN
ajlm-840	25	12	although	although	SCONJ
ajlm-840	25	13	molecular	molecular	ADJ
ajlm-840	25	14	methods	method	NOUN
ajlm-840	25	15	are	be	AUX
ajlm-840	25	16	rapid	rapid	ADJ
ajlm-840	25	17	,	,	PUNCT
ajlm-840	25	18	they	they	PRON
ajlm-840	25	19	require	require	VERB
ajlm-840	25	20	costly	costly	ADJ
ajlm-840	25	21	equipment	equipment	NOUN
ajlm-840	25	22	and	and	CCONJ
ajlm-840	25	23	staff	staff	NOUN
ajlm-840	25	24	expertise	expertise	NOUN
ajlm-840	25	25	,	,	PUNCT
ajlm-840	25	26	and	and	CCONJ
ajlm-840	25	27	can	can	AUX
ajlm-840	25	28	not	not	PART
ajlm-840	25	29	detect	detect	VERB
ajlm-840	25	30	resistant	resistant	ADJ
ajlm-840	25	31	strains	strain	NOUN
ajlm-840	25	32	caused	cause	VERB
ajlm-840	25	33	by	by	ADP
ajlm-840	25	34	unidentified	unidentified	ADJ
ajlm-840	25	35	mutations.11	mutations.11	NOUN
ajlm-840	25	36	an	an	DET
ajlm-840	25	37	innovative	innovative	ADJ
ajlm-840	25	38	colorimetric	colorimetric	ADJ
ajlm-840	25	39	assay	assay	NOUN
ajlm-840	25	40	has	have	AUX
ajlm-840	25	41	been	be	AUX
ajlm-840	25	42	designed	design	VERB
ajlm-840	25	43	using	use	VERB
ajlm-840	25	44	redox	redox	ADJ
ajlm-840	25	45	indicators	indicator	NOUN
ajlm-840	25	46	to	to	PART
ajlm-840	25	47	detect	detect	VERB
ajlm-840	25	48	tuberculosis	tuberculosis	NOUN
ajlm-840	25	49	cell	cell	NOUN
ajlm-840	25	50	viability	viability	NOUN
ajlm-840	25	51	by	by	ADP
ajlm-840	25	52	a	a	DET
ajlm-840	25	53	simple	simple	ADJ
ajlm-840	25	54	colour	colour	NOUN
ajlm-840	25	55	change	change	NOUN
ajlm-840	25	56	.	.	PUNCT
ajlm-840	26	1	the	the	DET
ajlm-840	26	2	resazurin	resazurin	PROPN
ajlm-840	26	3	microtitre	microtitre	PROPN
ajlm-840	26	4	plate	plate	NOUN
ajlm-840	26	5	assay	assay	PROPN
ajlm-840	26	6	(	(	PUNCT
ajlm-840	26	7	rema	rema	PROPN
ajlm-840	26	8	)	)	PUNCT
ajlm-840	26	9	uses	use	VERB
ajlm-840	26	10	resazurin	resazurin	NOUN
ajlm-840	26	11	salts	salt	NOUN
ajlm-840	26	12	in	in	ADP
ajlm-840	26	13	a	a	DET
ajlm-840	26	14	liquid	liquid	ADJ
ajlm-840	26	15	culture	culture	NOUN
ajlm-840	26	16	medium.12,13	medium.12,13	NOUN
ajlm-840	26	17	this	this	DET
ajlm-840	26	18	nontoxic	nontoxic	ADJ
ajlm-840	26	19	compound	compound	NOUN
ajlm-840	26	20	incorporates	incorporate	VERB
ajlm-840	26	21	into	into	ADP
ajlm-840	26	22	living	live	VERB
ajlm-840	26	23	cells	cell	NOUN
ajlm-840	26	24	and	and	CCONJ
ajlm-840	26	25	is	be	AUX
ajlm-840	26	26	reduced	reduce	VERB
ajlm-840	26	27	to	to	ADP
ajlm-840	26	28	the	the	DET
ajlm-840	26	29	fluorescent	fluorescent	ADJ
ajlm-840	26	30	molecule	molecule	NOUN
ajlm-840	26	31	resorufin	resorufin	NOUN
ajlm-840	26	32	via	via	ADP
ajlm-840	26	33	a	a	DET
ajlm-840	26	34	reduction	reduction	NOUN
ajlm-840	26	35	and	and	CCONJ
ajlm-840	26	36	oxidation	oxidation	NOUN
ajlm-840	26	37	reaction.14	reaction.14	NOUN
ajlm-840	26	38	visible	visible	ADJ
ajlm-840	26	39	colour	colour	NOUN
ajlm-840	26	40	change	change	NOUN
ajlm-840	26	41	of	of	ADP
ajlm-840	26	42	the	the	DET
ajlm-840	26	43	reagent	reagent	NOUN
ajlm-840	26	44	from	from	ADP
ajlm-840	26	45	blue	blue	ADJ
ajlm-840	26	46	to	to	AUX
ajlm-840	26	47	pink	pink	ADJ
ajlm-840	26	48	demonstrates	demonstrate	VERB
ajlm-840	26	49	cell	cell	NOUN
ajlm-840	26	50	viability	viability	NOUN
ajlm-840	26	51	and	and	CCONJ
ajlm-840	26	52	therefore	therefore	ADV
ajlm-840	26	53	drug	drug	NOUN
ajlm-840	26	54	resistance	resistance	NOUN
ajlm-840	26	55	.	.	PUNCT
ajlm-840	27	1	this	this	DET
ajlm-840	27	2	technique	technique	NOUN
ajlm-840	27	3	has	have	AUX
ajlm-840	27	4	been	be	AUX
ajlm-840	27	5	applied	apply	VERB
ajlm-840	27	6	for	for	ADP
ajlm-840	27	7	high	high	ADJ
ajlm-840	27	8	throughput	throughput	NOUN
ajlm-840	27	9	screening	screening	NOUN
ajlm-840	27	10	and	and	CCONJ
ajlm-840	27	11	determining	determine	VERB
ajlm-840	27	12	minimum	minimum	ADJ
ajlm-840	27	13	inhibitory	inhibitory	ADJ
ajlm-840	27	14	concentrations	concentration	NOUN
ajlm-840	27	15	(	(	PUNCT
ajlm-840	27	16	mic	mic	ADJ
ajlm-840	27	17	)	)	PUNCT
ajlm-840	27	18	of	of	ADP
ajlm-840	27	19	anti	anti	ADJ
ajlm-840	27	20	-	-	ADJ
ajlm-840	27	21	tuberculosis	tuberculosis	ADJ
ajlm-840	27	22	drugs.14,15	drugs.14,15	ADJ
ajlm-840	27	23	another	another	DET
ajlm-840	27	24	advance	advance	NOUN
ajlm-840	27	25	in	in	ADP
ajlm-840	27	26	determining	determine	VERB
ajlm-840	27	27	the	the	DET
ajlm-840	27	28	phenotypic	phenotypic	ADJ
ajlm-840	27	29	susceptibility	susceptibility	NOUN
ajlm-840	27	30	of	of	ADP
ajlm-840	27	31	m.	m.	NOUN
ajlm-840	27	32	tuberculosis	tuberculosis	NOUN
ajlm-840	27	33	is	be	AUX
ajlm-840	27	34	the	the	DET
ajlm-840	27	35	sensititre	sensititre	PROPN
ajlm-840	27	36	®	®	PROPN
ajlm-840	27	37	mycotb	mycotb	PROPN
ajlm-840	27	38	(	(	PUNCT
ajlm-840	27	39	mycotb	mycotb	ADJ
ajlm-840	27	40	trek	trek	PROPN
ajlm-840	27	41	diagnostics	diagnostic	NOUN
ajlm-840	27	42	)	)	PUNCT
ajlm-840	27	43	plate	plate	NOUN
ajlm-840	27	44	method	method	NOUN
ajlm-840	27	45	.	.	PUNCT
ajlm-840	28	1	the	the	DET
ajlm-840	28	2	sensititre	sensititre	PROPN
ajlm-840	28	3	®	®	PROPN
ajlm-840	28	4	mycotb	mycotb	ADJ
ajlm-840	28	5	plate	plate	NOUN
ajlm-840	28	6	method	method	NOUN
ajlm-840	28	7	is	be	AUX
ajlm-840	28	8	a	a	DET
ajlm-840	28	9	novel	novel	ADJ
ajlm-840	28	10	96	96	NUM
ajlm-840	28	11	-	-	PUNCT
ajlm-840	28	12	well	well	NOUN
ajlm-840	28	13	microtitre	microtitre	NOUN
ajlm-840	28	14	plate	plate	NOUN
ajlm-840	28	15	broth	broth	NOUN
ajlm-840	28	16	microdilution	microdilution	NOUN
ajlm-840	28	17	dst	dst	NOUN
ajlm-840	28	18	method	method	NOUN
ajlm-840	28	19	incorporating	incorporate	VERB
ajlm-840	28	20	drug	drug	NOUN
ajlm-840	28	21	concentrations	concentration	NOUN
ajlm-840	28	22	of	of	ADP
ajlm-840	28	23	12	12	NUM
ajlm-840	28	24	anti	anti	ADJ
ajlm-840	28	25	-	-	ADJ
ajlm-840	28	26	tuberculosis	tuberculosis	ADJ
ajlm-840	28	27	drugs	drug	NOUN
ajlm-840	28	28	for	for	ADP
ajlm-840	28	29	mic	mic	ADJ
ajlm-840	28	30	determination.16	determination.16	VERB
ajlm-840	28	31	the	the	DET
ajlm-840	28	32	drugs	drug	NOUN
ajlm-840	28	33	included	include	VERB
ajlm-840	28	34	consist	consist	NOUN
ajlm-840	28	35	of	of	ADP
ajlm-840	28	36	both	both	CCONJ
ajlm-840	28	37	first	first	ADJ
ajlm-840	28	38	-	-	PUNCT
ajlm-840	28	39	line	line	NOUN
ajlm-840	28	40	(	(	PUNCT
ajlm-840	28	41	rifampicin	rifampicin	VERB
ajlm-840	28	42	,	,	PUNCT
ajlm-840	28	43	isoniazid	isoniazid	NOUN
ajlm-840	28	44	and	and	CCONJ
ajlm-840	28	45	ethambutol	ethambutol	ADJ
ajlm-840	28	46	)	)	PUNCT
ajlm-840	28	47	as	as	ADV
ajlm-840	28	48	well	well	ADV
ajlm-840	28	49	as	as	ADP
ajlm-840	28	50	second	second	ADJ
ajlm-840	28	51	-	-	PUNCT
ajlm-840	28	52	line	line	NOUN
ajlm-840	28	53	drugs	drug	NOUN
ajlm-840	28	54	(	(	PUNCT
ajlm-840	28	55	moxifloxacin	moxifloxacin	ADJ
ajlm-840	28	56	,	,	PUNCT
ajlm-840	28	57	ofloxacin	ofloxacin	NOUN
ajlm-840	28	58	,	,	PUNCT
ajlm-840	28	59	para	para	NOUN
ajlm-840	28	60	-	-	PUNCT
ajlm-840	28	61	aminosalicylic	aminosalicylic	NOUN
ajlm-840	28	62	acid	acid	NOUN
ajlm-840	28	63	,	,	PUNCT
ajlm-840	28	64	rifabutin	rifabutin	NOUN
ajlm-840	28	65	,	,	PUNCT
ajlm-840	28	66	streptomycin	streptomycin	PROPN
ajlm-840	28	67	,	,	PUNCT
ajlm-840	28	68	amikacin	amikacin	PROPN
ajlm-840	28	69	,	,	PUNCT
ajlm-840	28	70	cycloserine	cycloserine	ADJ
ajlm-840	28	71	,	,	PUNCT
ajlm-840	28	72	ethionamide	ethionamide	NOUN
ajlm-840	28	73	and	and	CCONJ
ajlm-840	28	74	kanamycin	kanamycin	NOUN
ajlm-840	28	75	)	)	PUNCT
ajlm-840	28	76	existing	exist	VERB
ajlm-840	28	77	as	as	ADP
ajlm-840	28	78	lyophilised	lyophilise	VERB
ajlm-840	28	79	forms	form	NOUN
ajlm-840	28	80	in	in	ADP
ajlm-840	28	81	microtitre	microtitre	PROPN
ajlm-840	28	82	wells	well	NOUN
ajlm-840	28	83	.	.	PUNCT
ajlm-840	29	1	a	a	DET
ajlm-840	29	2	7–21	7–21	NOUN
ajlm-840	29	3	-	-	PUNCT
ajlm-840	29	4	day	day	NOUN
ajlm-840	29	5	period	period	NOUN
ajlm-840	29	6	of	of	ADP
ajlm-840	29	7	incubation	incubation	NOUN
ajlm-840	29	8	is	be	AUX
ajlm-840	29	9	needed	need	VERB
ajlm-840	29	10	to	to	PART
ajlm-840	29	11	observe	observe	VERB
ajlm-840	29	12	culture	culture	NOUN
ajlm-840	29	13	growth	growth	NOUN
ajlm-840	29	14	noted	note	VERB
ajlm-840	29	15	as	as	ADP
ajlm-840	29	16	turbidity	turbidity	NOUN
ajlm-840	29	17	or	or	CCONJ
ajlm-840	29	18	cellular	cellular	ADJ
ajlm-840	29	19	deposits	deposit	NOUN
ajlm-840	29	20	at	at	ADP
ajlm-840	29	21	the	the	DET
ajlm-840	29	22	base	base	NOUN
ajlm-840	29	23	of	of	ADP
ajlm-840	29	24	a	a	DET
ajlm-840	29	25	well.14,16	well.14,16	NOUN
ajlm-840	29	26	the	the	DET
ajlm-840	29	27	aim	aim	NOUN
ajlm-840	29	28	of	of	ADP
ajlm-840	29	29	this	this	DET
ajlm-840	29	30	study	study	NOUN
ajlm-840	29	31	was	be	AUX
ajlm-840	29	32	to	to	PART
ajlm-840	29	33	determine	determine	VERB
ajlm-840	29	34	the	the	DET
ajlm-840	29	35	performance	performance	NOUN
ajlm-840	29	36	of	of	ADP
ajlm-840	29	37	the	the	DET
ajlm-840	29	38	sensititre	sensititre	NOUN
ajlm-840	29	39	®	®	PROPN
ajlm-840	29	40	mycotb	mycotb	ADJ
ajlm-840	29	41	plate	plate	NOUN
ajlm-840	29	42	and	and	CCONJ
ajlm-840	29	43	rema	rema	NOUN
ajlm-840	29	44	as	as	ADP
ajlm-840	29	45	potential	potential	ADJ
ajlm-840	29	46	tools	tool	NOUN
ajlm-840	29	47	for	for	ADP
ajlm-840	29	48	tuberculosis	tuberculosis	NOUN
ajlm-840	29	49	dst	dst	NOUN
ajlm-840	29	50	in	in	ADP
ajlm-840	29	51	a	a	DET
ajlm-840	29	52	high	high	ADJ
ajlm-840	29	53	tuberculosis	tuberculosis	NOUN
ajlm-840	29	54	-	-	PUNCT
ajlm-840	29	55	burden	burden	NOUN
ajlm-840	29	56	reference	reference	NOUN
ajlm-840	29	57	laboratory	laboratory	NOUN
ajlm-840	29	58	.	.	PUNCT
ajlm-840	30	1	this	this	DET
ajlm-840	30	2	entailed	entailed	ADJ
ajlm-840	30	3	comparison	comparison	NOUN
ajlm-840	30	4	of	of	ADP
ajlm-840	30	5	the	the	DET
ajlm-840	30	6	rema	rema	NOUN
ajlm-840	30	7	and	and	CCONJ
ajlm-840	30	8	sensititre	sensititre	NOUN
ajlm-840	30	9	assay	assay	VERB
ajlm-840	30	10	using	use	VERB
ajlm-840	30	11	the	the	DET
ajlm-840	30	12	apm	apm	NOUN
ajlm-840	30	13	as	as	ADP
ajlm-840	30	14	a	a	DET
ajlm-840	30	15	gold	gold	NOUN
ajlm-840	30	16	standard	standard	NOUN
ajlm-840	30	17	in	in	ADP
ajlm-840	30	18	order	order	NOUN
ajlm-840	30	19	to	to	PART
ajlm-840	30	20	evaluate	evaluate	VERB
ajlm-840	30	21	turnaround	turnaround	NOUN
ajlm-840	30	22	times	time	NOUN
ajlm-840	30	23	,	,	PUNCT
ajlm-840	30	24	sensitivity	sensitivity	NOUN
ajlm-840	30	25	,	,	PUNCT
ajlm-840	30	26	specificity	specificity	NOUN
ajlm-840	30	27	,	,	PUNCT
ajlm-840	30	28	and	and	CCONJ
ajlm-840	30	29	positive	positive	ADJ
ajlm-840	30	30	and	and	CCONJ
ajlm-840	30	31	negative	negative	ADJ
ajlm-840	30	32	predictive	predictive	ADJ
ajlm-840	30	33	values	value	NOUN
ajlm-840	30	34	.	.	PUNCT
ajlm-840	31	1	methods	method	NOUN
ajlm-840	31	2	ethical	ethical	ADJ
ajlm-840	31	3	considerations	consideration	NOUN
ajlm-840	31	4	the	the	DET
ajlm-840	31	5	biomedical	biomedical	ADJ
ajlm-840	31	6	ethics	ethic	NOUN
ajlm-840	31	7	research	research	PROPN
ajlm-840	31	8	committee	committee	PROPN
ajlm-840	31	9	(	(	PUNCT
ajlm-840	31	10	university	university	NOUN
ajlm-840	31	11	of	of	ADP
ajlm-840	31	12	kwazulu	kwazulu	PROPN
ajlm-840	31	13	-	-	PUNCT
ajlm-840	31	14	natal	natal	NOUN
ajlm-840	31	15	)	)	PUNCT
ajlm-840	31	16	granted	grant	VERB
ajlm-840	31	17	ethical	ethical	ADJ
ajlm-840	31	18	approval	approval	NOUN
ajlm-840	31	19	for	for	ADP
ajlm-840	31	20	the	the	DET
ajlm-840	31	21	use	use	NOUN
ajlm-840	31	22	of	of	ADP
ajlm-840	31	23	stored	store	VERB
ajlm-840	31	24	study	study	NOUN
ajlm-840	31	25	isolates	isolate	NOUN
ajlm-840	31	26	(	(	PUNCT
ajlm-840	31	27	reference	reference	NOUN
ajlm-840	31	28	number	number	NOUN
ajlm-840	31	29	be	be	VERB
ajlm-840	31	30	268/12	268/12	NUM
ajlm-840	31	31	)	)	PUNCT
ajlm-840	31	32	.	.	PUNCT
ajlm-840	32	1	processing	processing	NOUN
ajlm-840	32	2	and	and	CCONJ
ajlm-840	32	3	culture	culture	NOUN
ajlm-840	32	4	of	of	ADP
ajlm-840	32	5	sputum	sputum	PROPN
ajlm-840	32	6	specimens	specimen	NOUN
ajlm-840	32	7	previously	previously	ADV
ajlm-840	32	8	stored	store	VERB
ajlm-840	32	9	m.	m.	NOUN
ajlm-840	32	10	tuberculosis	tuberculosis	NOUN
ajlm-840	32	11	strains	strain	NOUN
ajlm-840	32	12	isolated	isolate	VERB
ajlm-840	32	13	from	from	ADP
ajlm-840	32	14	sputum	sputum	NOUN
ajlm-840	32	15	samples	sample	NOUN
ajlm-840	32	16	received	receive	VERB
ajlm-840	32	17	at	at	ADP
ajlm-840	32	18	the	the	DET
ajlm-840	32	19	tuberculosis	tuberculosis	NOUN
ajlm-840	32	20	laboratory	laboratory	NOUN
ajlm-840	32	21	based	base	VERB
ajlm-840	32	22	at	at	ADP
ajlm-840	32	23	the	the	DET
ajlm-840	32	24	inkosi	inkosi	PROPN
ajlm-840	32	25	albert	albert	PROPN
ajlm-840	32	26	luthuli	luthuli	PROPN
ajlm-840	32	27	central	central	PROPN
ajlm-840	32	28	hospital	hospital	NOUN
ajlm-840	32	29	,	,	PUNCT
ajlm-840	32	30	durban	durban	PROPN
ajlm-840	32	31	,	,	PUNCT
ajlm-840	32	32	south	south	PROPN
ajlm-840	32	33	africa	africa	PROPN
ajlm-840	32	34	,	,	PUNCT
ajlm-840	32	35	from	from	ADP
ajlm-840	32	36	january	january	PROPN
ajlm-840	32	37	2014	2014	NUM
ajlm-840	32	38	to	to	ADP
ajlm-840	32	39	june	june	PROPN
ajlm-840	32	40	2015	2015	NUM
ajlm-840	32	41	were	be	AUX
ajlm-840	32	42	used	use	VERB
ajlm-840	32	43	in	in	ADP
ajlm-840	32	44	this	this	DET
ajlm-840	32	45	study	study	NOUN
ajlm-840	32	46	.	.	PUNCT
ajlm-840	33	1	briefly	briefly	ADV
ajlm-840	33	2	,	,	PUNCT
ajlm-840	33	3	sputum	sputum	PROPN
ajlm-840	33	4	samples	sample	NOUN
ajlm-840	33	5	were	be	AUX
ajlm-840	33	6	digested	digest	VERB
ajlm-840	33	7	and	and	CCONJ
ajlm-840	33	8	decontaminated	decontaminate	VERB
ajlm-840	33	9	using	use	VERB
ajlm-840	33	10	the	the	DET
ajlm-840	33	11	n	n	CCONJ
ajlm-840	33	12	-	-	PUNCT
ajlm-840	33	13	acetyl	acetyl	NOUN
ajlm-840	33	14	-	-	PUNCT
ajlm-840	33	15	l	l	NOUN
ajlm-840	33	16	-	-	PUNCT
ajlm-840	33	17	cysteine	cysteine	ADJ
ajlm-840	33	18	–	–	PUNCT
ajlm-840	33	19	naoh	naoh	ADJ
ajlm-840	33	20	-	-	PUNCT
ajlm-840	33	21	sodium	sodium	NOUN
ajlm-840	33	22	citrate	citrate	NOUN
ajlm-840	33	23	(	(	PUNCT
ajlm-840	33	24	nalc	nalc	PROPN
ajlm-840	33	25	–	–	PUNCT
ajlm-840	33	26	naoh	naoh	NOUN
ajlm-840	33	27	,	,	PUNCT
ajlm-840	33	28	2	2	NUM
ajlm-840	33	29	%	%	NOUN
ajlm-840	33	30	naoh	naoh	ADJ
ajlm-840	33	31	final	final	ADJ
ajlm-840	33	32	concentration	concentration	NOUN
ajlm-840	33	33	)	)	PUNCT
ajlm-840	33	34	method	method	NOUN
ajlm-840	33	35	and	and	CCONJ
ajlm-840	33	36	cultured	cultured	ADJ
ajlm-840	33	37	in	in	ADP
ajlm-840	33	38	mycobacterium	mycobacterium	NOUN
ajlm-840	33	39	growth	growth	NOUN
ajlm-840	33	40	indicator	indicator	NOUN
ajlm-840	33	41	tubes	tube	NOUN
ajlm-840	33	42	(	(	PUNCT
ajlm-840	33	43	mgit	mgit	PROPN
ajlm-840	33	44	)	)	PUNCT
ajlm-840	33	45	.	.	PUNCT
ajlm-840	34	1	positive	positive	ADJ
ajlm-840	34	2	cultures	culture	NOUN
ajlm-840	34	3	were	be	AUX
ajlm-840	34	4	confirmed	confirm	VERB
ajlm-840	34	5	for	for	ADP
ajlm-840	34	6	the	the	DET
ajlm-840	34	7	presence	presence	NOUN
ajlm-840	34	8	of	of	ADP
ajlm-840	34	9	m.	m.	NOUN
ajlm-840	34	10	tuberculosis	tuberculosis	NOUN
ajlm-840	34	11	using	use	VERB
ajlm-840	34	12	the	the	DET
ajlm-840	34	13	ziehl	ziehl	PROPN
ajlm-840	34	14	neelsen	neelsen	PROPN
ajlm-840	34	15	or	or	CCONJ
ajlm-840	34	16	mpt64	mpt64	PROPN
ajlm-840	34	17	antigen	antigen	PROPN
ajlm-840	34	18	assay	assay	PROPN
ajlm-840	34	19	(	(	PUNCT
ajlm-840	34	20	sd	sd	ADP
ajlm-840	34	21	bioline	bioline	NOUN
ajlm-840	34	22	,	,	PUNCT
ajlm-840	34	23	gyeonggi	gyeonggi	NOUN
ajlm-840	34	24	-	-	PUNCT
ajlm-840	34	25	do	do	VERB
ajlm-840	34	26	,	,	PUNCT
ajlm-840	34	27	south	south	PROPN
ajlm-840	34	28	korea	korea	PROPN
ajlm-840	34	29	)	)	PUNCT
ajlm-840	34	30	.	.	PUNCT
ajlm-840	35	1	mdr	mdr	PROPN
ajlm-840	35	2	and	and	CCONJ
ajlm-840	35	3	xdr	xdr	PROPN
ajlm-840	35	4	m.	m.	NOUN
ajlm-840	35	5	tuberculosis	tuberculosis	NOUN
ajlm-840	35	6	isolates	isolate	NOUN
ajlm-840	35	7	were	be	AUX
ajlm-840	35	8	routinely	routinely	ADV
ajlm-840	35	9	stored	store	VERB
ajlm-840	35	10	in	in	ADP
ajlm-840	35	11	the	the	DET
ajlm-840	35	12	laboratory	laboratory	NOUN
ajlm-840	35	13	.	.	PUNCT
ajlm-840	36	1	one	one	NUM
ajlm-840	36	2	hundred	hundred	NUM
ajlm-840	36	3	and	and	CCONJ
ajlm-840	36	4	fifty	fifty	NUM
ajlm-840	36	5	stored	store	VERB
ajlm-840	36	6	m.	m.	NOUN
ajlm-840	36	7	tuberculosis	tuberculosis	NOUN
ajlm-840	36	8	isolates	isolate	NOUN
ajlm-840	36	9	were	be	AUX
ajlm-840	36	10	subcultured	subculture	VERB
ajlm-840	36	11	onto	onto	ADP
ajlm-840	36	12	middlebrook	middlebrook	PROPN
ajlm-840	36	13	7h11	7h11	PROPN
ajlm-840	36	14	agar	agar	NOUN
ajlm-840	36	15	and	and	CCONJ
ajlm-840	36	16	incubated	incubate	VERB
ajlm-840	36	17	at	at	ADP
ajlm-840	36	18	37	37	NUM
ajlm-840	36	19	°	°	ADP
ajlm-840	36	20	c	c	NOUN
ajlm-840	36	21	for	for	ADP
ajlm-840	36	22	21	21	NUM
ajlm-840	36	23	days	day	NOUN
ajlm-840	36	24	.	.	PUNCT
ajlm-840	37	1	a	a	DET
ajlm-840	37	2	total	total	NOUN
ajlm-840	37	3	of	of	ADP
ajlm-840	37	4	134	134	NUM
ajlm-840	37	5	isolates	isolate	NOUN
ajlm-840	37	6	had	have	VERB
ajlm-840	37	7	confluent	confluent	ADJ
ajlm-840	37	8	growth	growth	NOUN
ajlm-840	37	9	and	and	CCONJ
ajlm-840	37	10	were	be	AUX
ajlm-840	37	11	used	use	VERB
ajlm-840	37	12	in	in	ADP
ajlm-840	37	13	the	the	DET
ajlm-840	37	14	study	study	NOUN
ajlm-840	37	15	.	.	PUNCT
ajlm-840	38	1	drug	drug	NOUN
ajlm-840	38	2	susceptibility	susceptibility	NOUN
ajlm-840	38	3	testing	testing	NOUN
ajlm-840	38	4	by	by	ADP
ajlm-840	38	5	the	the	DET
ajlm-840	38	6	agar	agar	NOUN
ajlm-840	38	7	proportion	proportion	NOUN
ajlm-840	38	8	method	method	NOUN
ajlm-840	38	9	drug	drug	NOUN
ajlm-840	38	10	susceptibility	susceptibility	NOUN
ajlm-840	38	11	of	of	ADP
ajlm-840	38	12	tuberculosis	tuberculosis	NOUN
ajlm-840	38	13	-	-	PUNCT
ajlm-840	38	14	positive	positive	ADJ
ajlm-840	38	15	cultures	culture	NOUN
ajlm-840	38	16	was	be	AUX
ajlm-840	38	17	determined	determine	VERB
ajlm-840	38	18	using	use	VERB
ajlm-840	38	19	the	the	DET
ajlm-840	38	20	indirect	indirect	ADJ
ajlm-840	38	21	apm	apm	NOUN
ajlm-840	38	22	on	on	ADP
ajlm-840	38	23	middlebrook	middlebrook	PROPN
ajlm-840	38	24	7h10	7h10	PROPN
ajlm-840	38	25	agar2,16	agar2,16	PROPN
ajlm-840	39	1	for	for	ADP
ajlm-840	39	2	firstand	firstand	NOUN
ajlm-840	39	3	second	second	ADJ
ajlm-840	39	4	-	-	PUNCT
ajlm-840	39	5	line	line	NOUN
ajlm-840	39	6	anti	anti	ADJ
ajlm-840	39	7	-	-	ADJ
ajlm-840	39	8	tuberculosis	tuberculosis	ADJ
ajlm-840	39	9	drugs	drug	NOUN
ajlm-840	39	10	(	(	PUNCT
ajlm-840	39	11	rifampicin	rifampicin	VERB
ajlm-840	39	12	,	,	PUNCT
ajlm-840	39	13	isoniazid	isoniazid	NOUN
ajlm-840	39	14	,	,	PUNCT
ajlm-840	39	15	kanamycin	kanamycin	PROPN
ajlm-840	39	16	,	,	PUNCT
ajlm-840	39	17	moxifloxacin	moxifloxacin	PRON
ajlm-840	39	18	and	and	CCONJ
ajlm-840	39	19	capreomycin	capreomycin	NOUN
ajlm-840	39	20	)	)	PUNCT
ajlm-840	39	21	.	.	PUNCT
ajlm-840	40	1	one	one	NUM
ajlm-840	40	2	hundred	hundred	NUM
ajlm-840	40	3	microlitres	microlitre	NOUN
ajlm-840	40	4	from	from	ADP
ajlm-840	40	5	a	a	DET
ajlm-840	40	6	positive	positive	ADJ
ajlm-840	40	7	mgit	mgit	NOUN
ajlm-840	40	8	was	be	AUX
ajlm-840	40	9	inoculated	inoculate	VERB
ajlm-840	40	10	into	into	ADP
ajlm-840	40	11	each	each	DET
ajlm-840	40	12	quadrant	quadrant	NOUN
ajlm-840	40	13	of	of	ADP
ajlm-840	40	14	the	the	DET
ajlm-840	40	15	middlebrook	middlebrook	PROPN
ajlm-840	40	16	7h10	7h10	PROPN
ajlm-840	40	17	dst	dst	NOUN
ajlm-840	40	18	agar	agar	NOUN
ajlm-840	40	19	plate	plate	NOUN
ajlm-840	40	20	and	and	CCONJ
ajlm-840	40	21	incubated	incubate	VERB
ajlm-840	40	22	for	for	ADP
ajlm-840	40	23	21	21	NUM
ajlm-840	40	24	days	day	NOUN
ajlm-840	40	25	.	.	PUNCT
ajlm-840	41	1	growth	growth	NOUN
ajlm-840	41	2	of	of	ADP
ajlm-840	41	3	more	more	ADJ
ajlm-840	41	4	than	than	ADP
ajlm-840	41	5	1	1	NUM
ajlm-840	41	6	%	%	NOUN
ajlm-840	41	7	on	on	ADP
ajlm-840	41	8	the	the	DET
ajlm-840	41	9	antibiotic	antibiotic	NOUN
ajlm-840	41	10	-	-	PUNCT
ajlm-840	41	11	containing	contain	VERB
ajlm-840	41	12	quadrant	quadrant	NOUN
ajlm-840	41	13	when	when	SCONJ
ajlm-840	41	14	compared	compare	VERB
ajlm-840	41	15	to	to	ADP
ajlm-840	41	16	the	the	DET
ajlm-840	41	17	antibiotic	antibiotic	ADJ
ajlm-840	41	18	-	-	PUNCT
ajlm-840	41	19	free	free	ADJ
ajlm-840	41	20	growth	growth	NOUN
ajlm-840	41	21	control	control	NOUN
ajlm-840	41	22	was	be	AUX
ajlm-840	41	23	regarded	regard	VERB
ajlm-840	41	24	as	as	ADV
ajlm-840	41	25	resistant	resistant	ADJ
ajlm-840	41	26	to	to	ADP
ajlm-840	41	27	the	the	DET
ajlm-840	41	28	corresponding	corresponding	ADJ
ajlm-840	41	29	antibiotic	antibiotic	NOUN
ajlm-840	41	30	.	.	PUNCT
ajlm-840	42	1	a	a	DET
ajlm-840	42	2	susceptible	susceptible	ADJ
ajlm-840	42	3	growth	growth	NOUN
ajlm-840	42	4	control	control	NOUN
ajlm-840	42	5	isolate	isolate	NOUN
ajlm-840	42	6	,	,	PUNCT
ajlm-840	42	7	h37rv	h37rv	PROPN
ajlm-840	42	8	(	(	PUNCT
ajlm-840	42	9	american	american	ADJ
ajlm-840	42	10	type	type	NOUN
ajlm-840	42	11	culture	culture	NOUN
ajlm-840	42	12	collection	collection	NOUN
ajlm-840	42	13	,	,	PUNCT
ajlm-840	42	14	25618	25618	NUM
ajlm-840	42	15	)	)	PUNCT
ajlm-840	42	16	,	,	PUNCT
ajlm-840	42	17	was	be	AUX
ajlm-840	42	18	used	use	VERB
ajlm-840	42	19	in	in	ADP
ajlm-840	42	20	the	the	DET
ajlm-840	42	21	study	study	NOUN
ajlm-840	42	22	.	.	PUNCT
ajlm-840	43	1	resazurin	resazurin	NOUN
ajlm-840	43	2	microtitre	microtitre	PROPN
ajlm-840	43	3	plate	plate	NOUN
ajlm-840	43	4	assay	assay	VERB
ajlm-840	43	5	the	the	DET
ajlm-840	43	6	susceptibility	susceptibility	NOUN
ajlm-840	43	7	of	of	ADP
ajlm-840	43	8	mdr	mdr	PROPN
ajlm-840	43	9	,	,	PUNCT
ajlm-840	43	10	xdr	xdr	PROPN
ajlm-840	43	11	and	and	CCONJ
ajlm-840	43	12	sensitive	sensitive	ADJ
ajlm-840	43	13	tuberculosis	tuberculosis	NOUN
ajlm-840	43	14	isolates	isolate	NOUN
ajlm-840	43	15	were	be	AUX
ajlm-840	43	16	evaluated	evaluate	VERB
ajlm-840	43	17	against	against	ADP
ajlm-840	43	18	firstand	firstand	NOUN
ajlm-840	43	19	second	second	ADJ
ajlm-840	43	20	-	-	PUNCT
ajlm-840	43	21	line	line	NOUN
ajlm-840	43	22	anti	anti	ADJ
ajlm-840	43	23	-	-	ADJ
ajlm-840	43	24	tuberculosis	tuberculosis	ADJ
ajlm-840	43	25	drugs	drug	NOUN
ajlm-840	43	26	by	by	ADP
ajlm-840	43	27	the	the	DET
ajlm-840	43	28	colorimetric	colorimetric	ADJ
ajlm-840	43	29	rema	rema	NOUN
ajlm-840	43	30	method	method	NOUN
ajlm-840	43	31	for	for	ADP
ajlm-840	43	32	the	the	DET
ajlm-840	43	33	134	134	NUM
ajlm-840	43	34	isolates	isolate	NOUN
ajlm-840	43	35	.	.	PUNCT
ajlm-840	44	1	one	one	NUM
ajlm-840	44	2	hundred	hundred	NUM
ajlm-840	44	3	microlitres	microlitre	NOUN
ajlm-840	44	4	of	of	ADP
ajlm-840	44	5	middlebrook	middlebrook	PROPN
ajlm-840	44	6	7h9	7h9	NUM
ajlm-840	44	7	(	(	PUNCT
ajlm-840	44	8	m7h9	m7h9	NOUN
ajlm-840	44	9	)	)	PUNCT
ajlm-840	44	10	broth	broth	NOUN
ajlm-840	44	11	was	be	AUX
ajlm-840	44	12	aseptically	aseptically	ADV
ajlm-840	44	13	prepared	prepare	VERB
ajlm-840	44	14	and	and	CCONJ
ajlm-840	44	15	dispensed	dispense	VERB
ajlm-840	44	16	carefully	carefully	ADV
ajlm-840	44	17	into	into	ADP
ajlm-840	44	18	each	each	PRON
ajlm-840	44	19	of	of	ADP
ajlm-840	44	20	the	the	DET
ajlm-840	44	21	wells	well	NOUN
ajlm-840	44	22	of	of	ADP
ajlm-840	44	23	a	a	DET
ajlm-840	44	24	flat	flat	ADV
ajlm-840	44	25	-	-	PUNCT
ajlm-840	44	26	bottomed	bottom	VERB
ajlm-840	44	27	,	,	PUNCT
ajlm-840	44	28	96	96	NUM
ajlm-840	44	29	-	-	PUNCT
ajlm-840	44	30	well	well	PROPN
ajlm-840	44	31	microtitre	microtitre	NOUN
ajlm-840	44	32	plate	plate	NOUN
ajlm-840	44	33	with	with	ADP
ajlm-840	44	34	lid	lid	NOUN
ajlm-840	44	35	(	(	PUNCT
ajlm-840	44	36	lasec	lasec	ADJ
ajlm-840	44	37	,	,	PUNCT
ajlm-840	44	38	midrand	midrand	PROPN
ajlm-840	44	39	,	,	PUNCT
ajlm-840	44	40	south	south	PROPN
ajlm-840	44	41	africa	africa	PROPN
ajlm-840	44	42	)	)	PUNCT
ajlm-840	44	43	.	.	PUNCT
ajlm-840	45	1	the	the	DET
ajlm-840	45	2	anti	anti	ADJ
ajlm-840	45	3	-	-	ADJ
ajlm-840	45	4	tuberculosis	tuberculosis	ADJ
ajlm-840	45	5	drugs	drug	NOUN
ajlm-840	45	6	that	that	PRON
ajlm-840	45	7	were	be	AUX
ajlm-840	45	8	tested	test	VERB
ajlm-840	45	9	using	use	VERB
ajlm-840	45	10	the	the	DET
ajlm-840	45	11	rema	rema	NOUN
ajlm-840	45	12	method	method	NOUN
ajlm-840	45	13	included	include	VERB
ajlm-840	45	14	rifampicin	rifampicin	VERB
ajlm-840	45	15	,	,	PUNCT
ajlm-840	45	16	isoniazid	isoniazid	NOUN
ajlm-840	45	17	,	,	PUNCT
ajlm-840	45	18	kanamycin	kanamycin	PROPN
ajlm-840	45	19	,	,	PUNCT
ajlm-840	45	20	moxifloxacin	moxifloxacin	PRON
ajlm-840	45	21	and	and	CCONJ
ajlm-840	45	22	capreomycin	capreomycin	PRON
ajlm-840	45	23	.	.	PUNCT
ajlm-840	46	1	working	work	VERB
ajlm-840	46	2	solutions	solution	NOUN
ajlm-840	46	3	of	of	ADP
ajlm-840	46	4	the	the	DET
ajlm-840	46	5	drugs	drug	NOUN
ajlm-840	46	6	were	be	AUX
ajlm-840	46	7	initially	initially	ADV
ajlm-840	46	8	prepared	prepare	VERB
ajlm-840	46	9	(	(	PUNCT
ajlm-840	46	10	four	four	NUM
ajlm-840	46	11	times	time	NOUN
ajlm-840	46	12	the	the	DET
ajlm-840	46	13	final	final	ADJ
ajlm-840	46	14	concentration	concentration	NOUN
ajlm-840	46	15	)	)	PUNCT
ajlm-840	46	16	in	in	ADP
ajlm-840	46	17	m7h9	m7h9	NOUN
ajlm-840	46	18	broth	broth	NOUN
ajlm-840	46	19	supplemented	supplement	VERB
ajlm-840	46	20	with	with	ADP
ajlm-840	46	21	0.5	0.5	NUM
ajlm-840	46	22	%	%	NOUN
ajlm-840	46	23	glycerol	glycerol	NOUN
ajlm-840	46	24	,	,	PUNCT
ajlm-840	46	25	0.1	0.1	NUM
ajlm-840	46	26	%	%	NOUN
ajlm-840	46	27	casitone	casitone	NOUN
ajlm-840	46	28	and	and	CCONJ
ajlm-840	46	29	10	10	NUM
ajlm-840	46	30	%	%	NOUN
ajlm-840	46	31	oadc	oadc	NOUN
ajlm-840	46	32	(	(	PUNCT
ajlm-840	46	33	oleic	oleic	ADV
ajlm-840	46	34	acid	acid	NOUN
ajlm-840	46	35	,	,	PUNCT
ajlm-840	46	36	albumin	albumin	NOUN
ajlm-840	46	37	,	,	PUNCT
ajlm-840	46	38	dextrose	dextrose	NOUN
ajlm-840	46	39	and	and	CCONJ
ajlm-840	46	40	catalase	catalase	NOUN
ajlm-840	46	41	)	)	PUNCT
ajlm-840	46	42	.	.	PUNCT
ajlm-840	47	1	one	one	NUM
ajlm-840	47	2	hundred	hundred	NUM
ajlm-840	47	3	microlitres	microlitre	NOUN
ajlm-840	47	4	of	of	ADP
ajlm-840	47	5	the	the	DET
ajlm-840	47	6	working	work	VERB
ajlm-840	47	7	drug	drug	NOUN
ajlm-840	47	8	concentrations	concentration	NOUN
ajlm-840	47	9	(	(	PUNCT
ajlm-840	47	10	isoniazid	isoniazid	NOUN
ajlm-840	47	11	1.0	1.0	NUM
ajlm-840	47	12	µg	µg	NOUN
ajlm-840	47	13	/	/	SYM
ajlm-840	47	14	ml	ml	NOUN
ajlm-840	47	15	,	,	PUNCT
ajlm-840	47	16	rifampicin	rifampicin	VERB
ajlm-840	47	17	8.0	8.0	NUM
ajlm-840	47	18	µg	µg	NOUN
ajlm-840	47	19	/	/	SYM
ajlm-840	47	20	ml	ml	NOUN
ajlm-840	47	21	,	,	PUNCT
ajlm-840	47	22	kanamycin	kanamycin	PROPN
ajlm-840	47	23	10.0	10.0	NUM
ajlm-840	47	24	µg	µg	NOUN
ajlm-840	47	25	/	/	SYM
ajlm-840	47	26	ml	ml	NOUN
ajlm-840	47	27	,	,	PUNCT
ajlm-840	47	28	capreomycin	capreomycin	VERB
ajlm-840	47	29	8.0	8.0	NUM
ajlm-840	47	30	µg	µg	NOUN
ajlm-840	47	31	/	/	SYM
ajlm-840	47	32	ml	ml	NOUN
ajlm-840	47	33	and	and	CCONJ
ajlm-840	47	34	moxifloxacin	moxifloxacin	NOUN
ajlm-840	47	35	2.0	2.0	NUM
ajlm-840	47	36	µg	µg	NOUN
ajlm-840	47	37	/	/	SYM
ajlm-840	47	38	ml	ml	NOUN
ajlm-840	47	39	)	)	PUNCT
ajlm-840	47	40	were	be	AUX
ajlm-840	47	41	added	add	VERB
ajlm-840	47	42	to	to	ADP
ajlm-840	47	43	the	the	DET
ajlm-840	47	44	wells	well	NOUN
ajlm-840	47	45	containing	contain	VERB
ajlm-840	47	46	middlebrook	middlebrook	PROPN
ajlm-840	47	47	7h9	7h9	NUM
ajlm-840	47	48	broth	broth	NOUN
ajlm-840	47	49	.	.	PUNCT
ajlm-840	48	1	the	the	DET
ajlm-840	48	2	anti	anti	ADJ
ajlm-840	48	3	-	-	ADJ
ajlm-840	48	4	tuberculosis	tuberculosis	ADJ
ajlm-840	48	5	drugs	drug	NOUN
ajlm-840	48	6	were	be	AUX
ajlm-840	48	7	then	then	ADV
ajlm-840	48	8	further	far	ADV
ajlm-840	48	9	serially	serially	ADV
ajlm-840	48	10	diluted	dilute	VERB
ajlm-840	48	11	twofold	twofold	ADV
ajlm-840	48	12	to	to	ADP
ajlm-840	48	13	a	a	DET
ajlm-840	48	14	final	final	ADJ
ajlm-840	48	15	concentration	concentration	NOUN
ajlm-840	48	16	consisting	consist	VERB
ajlm-840	48	17	of	of	ADP
ajlm-840	48	18	isoniazid	isoniazid	NOUN
ajlm-840	48	19	(	(	PUNCT
ajlm-840	48	20	0.03	0.03	NUM
ajlm-840	48	21	µg	µg	NOUN
ajlm-840	48	22	/	/	SYM
ajlm-840	48	23	ml	ml	NOUN
ajlm-840	48	24	)	)	PUNCT
ajlm-840	48	25	,	,	PUNCT
ajlm-840	48	26	rifampicin	rifampicin	VERB
ajlm-840	48	27	(	(	PUNCT
ajlm-840	48	28	0.25	0.25	NUM
ajlm-840	48	29	µg	µg	NOUN
ajlm-840	48	30	/	/	SYM
ajlm-840	48	31	ml	ml	NOUN
ajlm-840	48	32	)	)	PUNCT
ajlm-840	48	33	,	,	PUNCT
ajlm-840	48	34	kanamycin	kanamycin	PROPN
ajlm-840	48	35	(	(	PUNCT
ajlm-840	48	36	2.5	2.5	NUM
ajlm-840	48	37	µg	µg	NOUN
ajlm-840	48	38	/	/	SYM
ajlm-840	48	39	ml	ml	NOUN
ajlm-840	48	40	)	)	PUNCT
ajlm-840	48	41	,	,	PUNCT
ajlm-840	48	42	capreomycin	capreomycin	VERB
ajlm-840	48	43	(	(	PUNCT
ajlm-840	48	44	1.0	1.0	NUM
ajlm-840	48	45	µg	µg	NOUN
ajlm-840	48	46	/	/	SYM
ajlm-840	48	47	ml	ml	NOUN
ajlm-840	48	48	)	)	PUNCT
ajlm-840	48	49	and	and	CCONJ
ajlm-840	48	50	moxifloxacin	moxifloxacin	NUM
ajlm-840	48	51	(	(	PUNCT
ajlm-840	48	52	0.06	0.06	NUM
ajlm-840	48	53	µg	µg	NOUN
ajlm-840	48	54	/	/	SYM
ajlm-840	48	55	ml	ml	NOUN
ajlm-840	48	56	)	)	PUNCT
ajlm-840	48	57	.	.	PUNCT
ajlm-840	49	1	an	an	DET
ajlm-840	49	2	inoculum	inoculum	NOUN
ajlm-840	49	3	turbidity	turbidity	NOUN
ajlm-840	49	4	of	of	ADP
ajlm-840	49	5	mcfarland	mcfarland	PROPN
ajlm-840	49	6	standard	standard	ADJ
ajlm-840	49	7	number	number	NOUN
ajlm-840	49	8	1	1	NUM
ajlm-840	49	9	was	be	AUX
ajlm-840	49	10	prepared	prepare	VERB
ajlm-840	49	11	from	from	ADP
ajlm-840	49	12	middlebrook	middlebrook	PROPN
ajlm-840	49	13	7h11	7h11	PROPN
ajlm-840	49	14	(	(	PUNCT
ajlm-840	49	15	m7h11	m7h11	NOUN
ajlm-840	49	16	)	)	PUNCT
ajlm-840	49	17	agar	agar	NOUN
ajlm-840	49	18	,	,	PUNCT
ajlm-840	49	19	diluted	dilute	VERB
ajlm-840	49	20	in	in	ADP
ajlm-840	49	21	m7h9	m7h9	PROPN
ajlm-840	49	22	(	(	PUNCT
ajlm-840	49	23	1:10	1:10	NUM
ajlm-840	49	24	)	)	PUNCT
ajlm-840	49	25	broth	broth	NOUN
ajlm-840	49	26	and	and	CCONJ
ajlm-840	49	27	thereafter	thereafter	ADV
ajlm-840	49	28	added	add	VERB
ajlm-840	49	29	(	(	PUNCT
ajlm-840	49	30	100	100	NUM
ajlm-840	49	31	µl	µl	NOUN
ajlm-840	49	32	)	)	PUNCT
ajlm-840	49	33	to	to	ADP
ajlm-840	49	34	each	each	PRON
ajlm-840	49	35	of	of	ADP
ajlm-840	49	36	the	the	DET
ajlm-840	49	37	drug	drug	NOUN
ajlm-840	49	38	-	-	PUNCT
ajlm-840	49	39	free	free	ADJ
ajlm-840	49	40	and	and	CCONJ
ajlm-840	49	41	drug	drug	NOUN
ajlm-840	49	42	-	-	PUNCT
ajlm-840	49	43	containing	contain	VERB
ajlm-840	49	44	wells.10,12	wells.10,12	NOUN
ajlm-840	49	45	a	a	DET
ajlm-840	49	46	sterile	sterile	ADJ
ajlm-840	49	47	control	control	NOUN
ajlm-840	49	48	and	and	CCONJ
ajlm-840	49	49	a	a	DET
ajlm-840	49	50	growth	growth	NOUN
ajlm-840	49	51	control	control	NOUN
ajlm-840	49	52	for	for	ADP
ajlm-840	49	53	each	each	DET
ajlm-840	49	54	isolate	isolate	NOUN
ajlm-840	49	55	were	be	AUX
ajlm-840	49	56	also	also	ADV
ajlm-840	49	57	included	include	VERB
ajlm-840	49	58	.	.	PUNCT
ajlm-840	50	1	to	to	PART
ajlm-840	50	2	prevent	prevent	VERB
ajlm-840	50	3	evaporation	evaporation	NOUN
ajlm-840	50	4	during	during	ADP
ajlm-840	50	5	incubation	incubation	NOUN
ajlm-840	50	6	,	,	PUNCT
ajlm-840	50	7	sterile	sterile	ADJ
ajlm-840	50	8	m7h9	m7h9	NOUN
ajlm-840	50	9	broth	broth	NOUN
ajlm-840	50	10	was	be	AUX
ajlm-840	50	11	added	add	VERB
ajlm-840	50	12	to	to	ADP
ajlm-840	50	13	all	all	DET
ajlm-840	50	14	perimeter	perimeter	PROPN
ajlm-840	50	15	wells	wells	PROPN
ajlm-840	50	16	.	.	PUNCT
ajlm-840	51	1	the	the	DET
ajlm-840	51	2	plate	plate	NOUN
ajlm-840	51	3	was	be	AUX
ajlm-840	51	4	incubated	incubate	VERB
ajlm-840	51	5	at	at	ADP
ajlm-840	51	6	37	37	NUM
ajlm-840	51	7	°	°	NOUN
ajlm-840	51	8	c	c	NOUN
ajlm-840	51	9	after	after	ADP
ajlm-840	51	10	being	be	AUX
ajlm-840	51	11	sealed	seal	VERB
ajlm-840	51	12	in	in	ADP
ajlm-840	51	13	a	a	DET
ajlm-840	51	14	plastic	plastic	ADJ
ajlm-840	51	15	bag	bag	NOUN
ajlm-840	51	16	.	.	PUNCT
ajlm-840	52	1	a	a	DET
ajlm-840	52	2	working	work	VERB
ajlm-840	52	3	solution	solution	NOUN
ajlm-840	52	4	of	of	ADP
ajlm-840	52	5	resazurin	resazurin	NOUN
ajlm-840	52	6	salt	salt	NOUN
ajlm-840	52	7	(	(	PUNCT
ajlm-840	52	8	30	30	NUM
ajlm-840	52	9	µl	µl	NOUN
ajlm-840	52	10	of	of	ADP
ajlm-840	52	11	0.02	0.02	NUM
ajlm-840	52	12	%	%	NOUN
ajlm-840	52	13	concentration	concentration	NOUN
ajlm-840	52	14	)	)	PUNCT
ajlm-840	52	15	was	be	AUX
ajlm-840	52	16	inoculated	inoculate	VERB
ajlm-840	52	17	after	after	ADP
ajlm-840	52	18	8	8	NUM
ajlm-840	52	19	days	day	NOUN
ajlm-840	52	20	of	of	ADP
ajlm-840	52	21	incubation	incubation	NOUN
ajlm-840	52	22	into	into	ADP
ajlm-840	52	23	each	each	DET
ajlm-840	52	24	microtitre	microtitre	PROPN
ajlm-840	52	25	well.10	well.10	PROPN
ajlm-840	52	26	after	after	ADP
ajlm-840	52	27	overnight	overnight	ADJ
ajlm-840	52	28	incubation	incubation	NOUN
ajlm-840	52	29	,	,	PUNCT
ajlm-840	52	30	plates	plate	NOUN
ajlm-840	52	31	were	be	AUX
ajlm-840	52	32	then	then	ADV
ajlm-840	52	33	read	read	VERB
ajlm-840	52	34	the	the	DET
ajlm-840	52	35	next	next	ADJ
ajlm-840	52	36	day	day	NOUN
ajlm-840	52	37	,	,	PUNCT
ajlm-840	52	38	a	a	DET
ajlm-840	52	39	total	total	NOUN
ajlm-840	52	40	of	of	ADP
ajlm-840	52	41	9	9	NUM
ajlm-840	52	42	days	day	NOUN
ajlm-840	52	43	turnaround	turnaround	NOUN
ajlm-840	52	44	time	time	NOUN
ajlm-840	52	45	for	for	ADP
ajlm-840	52	46	results	result	NOUN
ajlm-840	52	47	interpretation	interpretation	NOUN
ajlm-840	52	48	.	.	PUNCT
ajlm-840	53	1	a	a	DET
ajlm-840	53	2	colour	colour	NOUN
ajlm-840	53	3	change	change	NOUN
ajlm-840	53	4	from	from	ADP
ajlm-840	53	5	blue	blue	ADJ
ajlm-840	53	6	to	to	PART
ajlm-840	53	7	pink	pink	ADV
ajlm-840	53	8	denoted	denote	VERB
ajlm-840	53	9	a	a	DET
ajlm-840	53	10	positive	positive	ADJ
ajlm-840	53	11	reaction	reaction	NOUN
ajlm-840	53	12	(	(	PUNCT
ajlm-840	53	13	reduction	reduction	NOUN
ajlm-840	53	14	of	of	ADP
ajlm-840	53	15	resazurin	resazurin	NOUN
ajlm-840	53	16	to	to	ADP
ajlm-840	53	17	resorufin	resorufin	NOUN
ajlm-840	53	18	)	)	PUNCT
ajlm-840	53	19	confirming	confirm	VERB
ajlm-840	53	20	drug	drug	NOUN
ajlm-840	53	21	resistance	resistance	NOUN
ajlm-840	53	22	due	due	ADP
ajlm-840	53	23	to	to	ADP
ajlm-840	53	24	m.	m.	NOUN
ajlm-840	53	25	tuberculosis	tuberculosis	PRON
ajlm-840	53	26	cell	cell	NOUN
ajlm-840	53	27	viability.10	viability.10	NOUN
ajlm-840	53	28	sensititre	sensititre	PROPN
ajlm-840	53	29	®	®	PROPN
ajlm-840	53	30	mycotb	mycotb	ADJ
ajlm-840	53	31	assay	assay	NOUN
ajlm-840	53	32	setting	set	VERB
ajlm-840	53	33	up	up	ADP
ajlm-840	53	34	the	the	DET
ajlm-840	53	35	microtitre	microtitre	NOUN
ajlm-840	53	36	plates	plate	NOUN
ajlm-840	53	37	and	and	CCONJ
ajlm-840	53	38	their	their	PRON
ajlm-840	53	39	interpretation	interpretation	NOUN
ajlm-840	53	40	were	be	AUX
ajlm-840	53	41	performed	perform	VERB
ajlm-840	53	42	according	accord	VERB
ajlm-840	53	43	to	to	ADP
ajlm-840	53	44	manufacturer	manufacturer	NOUN
ajlm-840	53	45	’s	’s	PART
ajlm-840	53	46	instructions	instruction	NOUN
ajlm-840	53	47	.	.	PUNCT
ajlm-840	54	1	colonies	colony	NOUN
ajlm-840	54	2	from	from	ADP
ajlm-840	54	3	a	a	DET
ajlm-840	54	4	culture	culture	NOUN
ajlm-840	54	5	plate	plate	NOUN
ajlm-840	54	6	(	(	PUNCT
ajlm-840	54	7	m7h11	m7h11	NOUN
ajlm-840	54	8	)	)	PUNCT
ajlm-840	54	9	were	be	AUX
ajlm-840	54	10	emulsified	emulsify	VERB
ajlm-840	54	11	in	in	ADP
ajlm-840	54	12	a	a	DET
ajlm-840	54	13	glass	glass	NOUN
ajlm-840	54	14	tube	tube	NOUN
ajlm-840	54	15	containing	contain	VERB
ajlm-840	54	16	saline	saline	NOUN
ajlm-840	54	17	,	,	PUNCT
ajlm-840	54	18	tween	tween	NOUN
ajlm-840	54	19	and	and	CCONJ
ajlm-840	54	20	glass	glass	NOUN
ajlm-840	54	21	beads	bead	NOUN
ajlm-840	54	22	until	until	SCONJ
ajlm-840	54	23	a	a	DET
ajlm-840	54	24	0.5	0.5	NUM
ajlm-840	54	25	mcfarland	mcfarland	PROPN
ajlm-840	54	26	standard	standard	NOUN
ajlm-840	54	27	was	be	AUX
ajlm-840	54	28	obtained	obtain	VERB
ajlm-840	54	29	.	.	PUNCT
ajlm-840	55	1	one	one	NUM
ajlm-840	55	2	hundred	hundred	NUM
ajlm-840	55	3	microlitres	microlitre	NOUN
ajlm-840	55	4	of	of	ADP
ajlm-840	55	5	the	the	DET
ajlm-840	55	6	suspension	suspension	NOUN
ajlm-840	55	7	was	be	AUX
ajlm-840	55	8	inoculated	inoculate	VERB
ajlm-840	55	9	into	into	ADP
ajlm-840	55	10	each	each	DET
ajlm-840	55	11	well	well	NOUN
ajlm-840	55	12	.	.	PUNCT
ajlm-840	56	1	the	the	DET
ajlm-840	56	2	plates	plate	NOUN
ajlm-840	56	3	were	be	AUX
ajlm-840	56	4	then	then	ADV
ajlm-840	56	5	incubated	incubate	VERB
ajlm-840	56	6	at	at	ADP
ajlm-840	56	7	37	37	NUM
ajlm-840	56	8	°	°	NOUN
ajlm-840	56	9	c	c	X
ajlm-840	56	10	.	.	PUNCT
ajlm-840	57	1	drug	drug	NOUN
ajlm-840	57	2	concentrations	concentration	NOUN
ajlm-840	57	3	present	present	ADJ
ajlm-840	57	4	in	in	ADP
ajlm-840	57	5	each	each	DET
ajlm-840	57	6	plate	plate	NOUN
ajlm-840	57	7	were	be	AUX
ajlm-840	57	8	:	:	PUNCT
ajlm-840	57	9	4	4	NUM
ajlm-840	57	10	µg	µg	ADJ
ajlm-840	57	11	/	/	SYM
ajlm-840	57	12	ml	ml	NOUN
ajlm-840	57	13	isoniazid	isoniazid	NOUN
ajlm-840	57	14	,	,	PUNCT
ajlm-840	57	15	16	16	NUM
ajlm-840	57	16	µg	µg	NOUN
ajlm-840	57	17	/	/	SYM
ajlm-840	57	18	ml	ml	VERB
ajlm-840	57	19	rifampicin	rifampicin	VERB
ajlm-840	57	20	,	,	PUNCT
ajlm-840	57	21	32	32	NUM
ajlm-840	57	22	µg	µg	NOUN
ajlm-840	57	23	/	/	SYM
ajlm-840	57	24	ml	ml	NOUN
ajlm-840	57	25	ethambutol	ethambutol	ADJ
ajlm-840	57	26	,	,	PUNCT
ajlm-840	57	27	40	40	NUM
ajlm-840	57	28	µg	µg	NOUN
ajlm-840	57	29	/	/	SYM
ajlm-840	57	30	ml	ml	NOUN
ajlm-840	57	31	ethionamide	ethionamide	NOUN
ajlm-840	57	32	,	,	PUNCT
ajlm-840	57	33	40	40	NUM
ajlm-840	57	34	µg	µg	NOUN
ajlm-840	57	35	/	/	SYM
ajlm-840	57	36	ml	ml	NOUN
ajlm-840	57	37	kanamycin	kanamycin	NOUN
ajlm-840	57	38	,	,	PUNCT
ajlm-840	57	39	32	32	NUM
ajlm-840	57	40	µg	µg	NOUN
ajlm-840	57	41	/	/	SYM
ajlm-840	57	42	ml	ml	NOUN
ajlm-840	57	43	ofloxacin	ofloxacin	NOUN
ajlm-840	57	44	,	,	PUNCT
ajlm-840	57	45	64	64	NUM
ajlm-840	57	46	µg	µg	NOUN
ajlm-840	57	47	/	/	SYM
ajlm-840	57	48	ml	ml	NOUN
ajlm-840	57	49	para	para	NOUN
ajlm-840	57	50	-	-	PUNCT
ajlm-840	57	51	aminosalicyclic	aminosalicyclic	ADJ
ajlm-840	57	52	acid	acid	NOUN
ajlm-840	57	53	,	,	PUNCT
ajlm-840	57	54	16	16	NUM
ajlm-840	57	55	µg	µg	NOUN
ajlm-840	57	56	/	/	SYM
ajlm-840	57	57	ml	ml	NOUN
ajlm-840	57	58	rifabutin	rifabutin	NOUN
ajlm-840	57	59	,	,	PUNCT
ajlm-840	57	60	32	32	NUM
ajlm-840	57	61	µg	µg	NOUN
ajlm-840	57	62	/	/	SYM
ajlm-840	57	63	ml	ml	NOUN
ajlm-840	57	64	streptomycin	streptomycin	PROPN
ajlm-840	57	65	,	,	PUNCT
ajlm-840	57	66	256	256	NUM
ajlm-840	57	67	µg	µg	ADV
ajlm-840	57	68	/	/	SYM
ajlm-840	57	69	ml	ml	NOUN
ajlm-840	57	70	cycloserine	cycloserine	ADJ
ajlm-840	57	71	,	,	PUNCT
ajlm-840	57	72	16	16	NUM
ajlm-840	57	73	µg	µg	NOUN
ajlm-840	57	74	/	/	SYM
ajlm-840	57	75	ml	ml	ADP
ajlm-840	57	76	amikacin	amikacin	PROPN
ajlm-840	57	77	and	and	CCONJ
ajlm-840	57	78	8.0	8.0	NUM
ajlm-840	57	79	µg	µg	NOUN
ajlm-840	57	80	/	/	SYM
ajlm-840	57	81	ml	ml	NOUN
ajlm-840	57	82	moxifloixacin	moxifloixacin	NOUN
ajlm-840	57	83	.	.	PUNCT
ajlm-840	58	1	observations	observation	NOUN
ajlm-840	58	2	of	of	ADP
ajlm-840	58	3	the	the	DET
ajlm-840	58	4	plates	plate	NOUN
ajlm-840	58	5	were	be	AUX
ajlm-840	58	6	made	make	VERB
ajlm-840	58	7	from	from	ADP
ajlm-840	58	8	day	day	NOUN
ajlm-840	58	9	7	7	NUM
ajlm-840	58	10	to	to	PART
ajlm-840	58	11	10	10	NUM
ajlm-840	58	12	for	for	ADP
ajlm-840	58	13	the	the	DET
ajlm-840	58	14	presence	presence	NOUN
ajlm-840	58	15	of	of	ADP
ajlm-840	58	16	turbidity	turbidity	NOUN
ajlm-840	58	17	or	or	CCONJ
ajlm-840	58	18	cellular	cellular	ADJ
ajlm-840	58	19	material	material	NOUN
ajlm-840	58	20	confirming	confirm	VERB
ajlm-840	58	21	growth	growth	NOUN
ajlm-840	58	22	of	of	ADP
ajlm-840	58	23	m.	m.	NOUN
ajlm-840	58	24	tuberculosis	tuberculosis	NOUN
ajlm-840	58	25	and	and	CCONJ
ajlm-840	58	26	therefore	therefore	ADV
ajlm-840	58	27	resistance.14,16	resistance.14,16	ADJ
ajlm-840	58	28	time	time	NOUN
ajlm-840	58	29	to	to	ADP
ajlm-840	58	30	results	result	NOUN
ajlm-840	58	31	was	be	AUX
ajlm-840	58	32	calculated	calculate	VERB
ajlm-840	58	33	as	as	ADP
ajlm-840	58	34	the	the	DET
ajlm-840	58	35	number	number	NOUN
ajlm-840	58	36	of	of	ADP
ajlm-840	58	37	days	day	NOUN
ajlm-840	58	38	from	from	ADP
ajlm-840	58	39	plate	plate	NOUN
ajlm-840	58	40	inoculation	inoculation	NOUN
ajlm-840	58	41	(	(	PUNCT
ajlm-840	58	42	day	day	NOUN
ajlm-840	58	43	0	0	NUM
ajlm-840	58	44	)	)	PUNCT
ajlm-840	58	45	to	to	PART
ajlm-840	58	46	plate	plate	VERB
ajlm-840	58	47	reading	read	VERB
ajlm-840	58	48	with	with	ADP
ajlm-840	58	49	visible	visible	ADJ
ajlm-840	58	50	growth	growth	NOUN
ajlm-840	58	51	(	(	PUNCT
ajlm-840	58	52	day	day	NOUN
ajlm-840	58	53	7–10	7–10	PROPN
ajlm-840	58	54	)	)	PUNCT
ajlm-840	58	55	.	.	PUNCT
ajlm-840	59	1	interpretation	interpretation	NOUN
ajlm-840	59	2	of	of	ADP
ajlm-840	59	3	results	result	NOUN
ajlm-840	59	4	currently	currently	ADV
ajlm-840	59	5	,	,	PUNCT
ajlm-840	59	6	there	there	PRON
ajlm-840	59	7	are	be	VERB
ajlm-840	59	8	no	no	DET
ajlm-840	59	9	mic	mic	ADJ
ajlm-840	59	10	-	-	PUNCT
ajlm-840	59	11	interpretative	interpretative	ADJ
ajlm-840	59	12	breakpoints	breakpoint	NOUN
ajlm-840	59	13	for	for	ADP
ajlm-840	59	14	the	the	DET
ajlm-840	59	15	broth	broth	ADJ
ajlm-840	59	16	microdilution	microdilution	NOUN
ajlm-840	59	17	assays	assay	NOUN
ajlm-840	59	18	when	when	SCONJ
ajlm-840	59	19	testing	testing	NOUN
ajlm-840	59	20	m.	m.	NOUN
ajlm-840	59	21	tuberculosis	tuberculosis	PRON
ajlm-840	59	22	isolates	isolate	NOUN
ajlm-840	59	23	on	on	ADP
ajlm-840	59	24	sensititre	sensititre	NOUN
ajlm-840	59	25	plates	plate	NOUN
ajlm-840	59	26	;	;	PUNCT
ajlm-840	59	27	accordingly	accordingly	ADV
ajlm-840	59	28	,	,	PUNCT
ajlm-840	59	29	the	the	DET
ajlm-840	59	30	endpoint	endpoint	NOUN
ajlm-840	59	31	was	be	AUX
ajlm-840	59	32	determined	determine	VERB
ajlm-840	59	33	as	as	ADP
ajlm-840	59	34	the	the	DET
ajlm-840	59	35	first	first	ADJ
ajlm-840	59	36	well	well	INTJ
ajlm-840	59	37	that	that	PRON
ajlm-840	59	38	did	do	AUX
ajlm-840	59	39	not	not	PART
ajlm-840	59	40	contain	contain	VERB
ajlm-840	59	41	any	any	DET
ajlm-840	59	42	growth	growth	NOUN
ajlm-840	59	43	.	.	PUNCT
ajlm-840	60	1	these	these	DET
ajlm-840	60	2	antimicrobial	antimicrobial	ADJ
ajlm-840	60	3	drug	drug	NOUN
ajlm-840	60	4	mic	mic	ADJ
ajlm-840	60	5	results	result	NOUN
ajlm-840	60	6	were	be	AUX
ajlm-840	60	7	recorded	record	VERB
ajlm-840	60	8	on	on	ADP
ajlm-840	60	9	a	a	DET
ajlm-840	60	10	data	data	NOUN
ajlm-840	60	11	sheet	sheet	NOUN
ajlm-840	60	12	per	per	ADP
ajlm-840	60	13	isolate	isolate	NOUN
ajlm-840	60	14	tested	test	VERB
ajlm-840	60	15	.	.	PUNCT
ajlm-840	61	1	the	the	DET
ajlm-840	61	2	reproducibility	reproducibility	NOUN
ajlm-840	61	3	of	of	ADP
ajlm-840	61	4	sensititre	sensititre	PROPN
ajlm-840	61	5	®	®	PROPN
ajlm-840	61	6	mycotb	mycotb	NOUN
ajlm-840	61	7	assay	assay	ADV
ajlm-840	61	8	by	by	ADP
ajlm-840	61	9	duplicate	duplicate	ADJ
ajlm-840	61	10	testing	testing	NOUN
ajlm-840	61	11	of	of	ADP
ajlm-840	61	12	the	the	DET
ajlm-840	61	13	isolates	isolate	NOUN
ajlm-840	61	14	was	be	AUX
ajlm-840	61	15	not	not	PART
ajlm-840	61	16	performed	perform	VERB
ajlm-840	61	17	for	for	ADP
ajlm-840	61	18	conditional	conditional	ADJ
ajlm-840	61	19	(	(	PUNCT
ajlm-840	61	20	or	or	CCONJ
ajlm-840	61	21	categorical	categorical	ADJ
ajlm-840	61	22	)	)	PUNCT
ajlm-840	61	23	agreement	agreement	NOUN
ajlm-840	61	24	between	between	ADP
ajlm-840	61	25	the	the	DET
ajlm-840	61	26	sensititre	sensititre	NOUN
ajlm-840	61	27	®	®	PROPN
ajlm-840	61	28	mycotb	mycotb	NOUN
ajlm-840	61	29	method	method	NOUN
ajlm-840	61	30	and	and	CCONJ
ajlm-840	61	31	apm	apm	NOUN
ajlm-840	61	32	on	on	ADP
ajlm-840	61	33	initial	initial	ADJ
ajlm-840	61	34	testing	testing	NOUN
ajlm-840	61	35	.	.	PUNCT
ajlm-840	62	1	in	in	ADP
ajlm-840	62	2	this	this	DET
ajlm-840	62	3	study	study	NOUN
ajlm-840	62	4	,	,	PUNCT
ajlm-840	62	5	for	for	ADP
ajlm-840	62	6	interpretation	interpretation	NOUN
ajlm-840	62	7	of	of	ADP
ajlm-840	62	8	the	the	DET
ajlm-840	62	9	sensititre	sensititre	NOUN
ajlm-840	62	10	data	data	PROPN
ajlm-840	62	11	,	,	PUNCT
ajlm-840	62	12	true	true	ADJ
ajlm-840	62	13	resistance	resistance	NOUN
ajlm-840	62	14	by	by	ADP
ajlm-840	62	15	sensititre	sensititre	NOUN
ajlm-840	62	16	®	®	PROPN
ajlm-840	62	17	mycotb	mycotb	NOUN
ajlm-840	62	18	was	be	AUX
ajlm-840	62	19	established	establish	VERB
ajlm-840	62	20	by	by	ADP
ajlm-840	62	21	comparing	compare	VERB
ajlm-840	62	22	the	the	DET
ajlm-840	62	23	sensititre	sensititre	NOUN
ajlm-840	62	24	mic	mic	NOUN
ajlm-840	62	25	to	to	ADP
ajlm-840	62	26	the	the	DET
ajlm-840	62	27	apm	apm	NOUN
ajlm-840	62	28	critical	critical	ADJ
ajlm-840	62	29	concentration	concentration	NOUN
ajlm-840	62	30	.	.	PUNCT
ajlm-840	63	1	this	this	PRON
ajlm-840	63	2	means	mean	VERB
ajlm-840	63	3	that	that	SCONJ
ajlm-840	63	4	an	an	DET
ajlm-840	63	5	isolate	isolate	NOUN
ajlm-840	63	6	was	be	AUX
ajlm-840	63	7	considered	consider	VERB
ajlm-840	63	8	resistant	resistant	ADJ
ajlm-840	63	9	if	if	SCONJ
ajlm-840	63	10	the	the	DET
ajlm-840	63	11	sensititre	sensititre	NOUN
ajlm-840	63	12	mic	mic	NOUN
ajlm-840	63	13	was	be	AUX
ajlm-840	63	14	greater	great	ADJ
ajlm-840	63	15	than	than	ADP
ajlm-840	63	16	the	the	DET
ajlm-840	63	17	apm	apm	NOUN
ajlm-840	63	18	critical	critical	ADJ
ajlm-840	63	19	concentration	concentration	NOUN
ajlm-840	63	20	and	and	CCONJ
ajlm-840	63	21	therefore	therefore	ADV
ajlm-840	63	22	truly	truly	ADV
ajlm-840	63	23	susceptible	susceptible	ADJ
ajlm-840	63	24	if	if	SCONJ
ajlm-840	63	25	it	it	PRON
ajlm-840	63	26	was	be	AUX
ajlm-840	63	27	less	less	ADJ
ajlm-840	63	28	than	than	ADP
ajlm-840	63	29	or	or	CCONJ
ajlm-840	63	30	equal	equal	ADJ
ajlm-840	63	31	to	to	ADP
ajlm-840	63	32	the	the	DET
ajlm-840	63	33	apm	apm	NOUN
ajlm-840	63	34	critical	critical	ADJ
ajlm-840	63	35	concentration	concentration	NOUN
ajlm-840	63	36	.	.	PUNCT
ajlm-840	64	1	for	for	ADP
ajlm-840	64	2	the	the	DET
ajlm-840	64	3	rema	rema	NOUN
ajlm-840	64	4	method	method	NOUN
ajlm-840	64	5	,	,	PUNCT
ajlm-840	64	6	resistance	resistance	NOUN
ajlm-840	64	7	to	to	ADP
ajlm-840	64	8	each	each	DET
ajlm-840	64	9	drug	drug	NOUN
ajlm-840	64	10	was	be	AUX
ajlm-840	64	11	determined	determine	VERB
ajlm-840	64	12	when	when	SCONJ
ajlm-840	64	13	there	there	PRON
ajlm-840	64	14	was	be	VERB
ajlm-840	64	15	growth	growth	NOUN
ajlm-840	64	16	in	in	ADP
ajlm-840	64	17	wells	well	NOUN
ajlm-840	64	18	above	above	ADP
ajlm-840	64	19	the	the	DET
ajlm-840	64	20	apm	apm	NOUN
ajlm-840	64	21	critical	critical	ADJ
ajlm-840	64	22	concentrations	concentration	NOUN
ajlm-840	64	23	of	of	ADP
ajlm-840	64	24	0.25	0.25	NUM
ajlm-840	64	25	µg	µg	NOUN
ajlm-840	64	26	/	/	SYM
ajlm-840	64	27	ml	ml	PROPN
ajlm-840	64	28	(	(	PUNCT
ajlm-840	64	29	isoniazid	isoniazid	NOUN
ajlm-840	64	30	)	)	PUNCT
ajlm-840	64	31	,	,	PUNCT
ajlm-840	64	32	1.0	1.0	NUM
ajlm-840	64	33	µg	µg	NOUN
ajlm-840	64	34	/	/	SYM
ajlm-840	64	35	ml	ml	PROPN
ajlm-840	64	36	(	(	PUNCT
ajlm-840	64	37	rifampicin	rifampicin	VERB
ajlm-840	64	38	)	)	PUNCT
ajlm-840	64	39	,	,	PUNCT
ajlm-840	64	40	2.0	2.0	NUM
ajlm-840	64	41	µg	µg	NOUN
ajlm-840	64	42	/	/	SYM
ajlm-840	64	43	ml	ml	PROPN
ajlm-840	64	44	(	(	PUNCT
ajlm-840	64	45	moxifloxacin	moxifloxacin	ADJ
ajlm-840	64	46	)	)	PUNCT
ajlm-840	64	47	,	,	PUNCT
ajlm-840	64	48	4.0	4.0	NUM
ajlm-840	64	49	µg	µg	NOUN
ajlm-840	64	50	/	/	SYM
ajlm-840	64	51	ml	ml	PROPN
ajlm-840	64	52	(	(	PUNCT
ajlm-840	64	53	capreomycin	capreomycin	PROPN
ajlm-840	64	54	)	)	PUNCT
ajlm-840	64	55	and	and	CCONJ
ajlm-840	64	56	5.0	5.0	NUM
ajlm-840	64	57	µg	µg	NOUN
ajlm-840	64	58	/	/	SYM
ajlm-840	64	59	ml	ml	NOUN
ajlm-840	64	60	(	(	PUNCT
ajlm-840	64	61	kanamycin).18	kanamycin).18	X
ajlm-840	64	62	rema	rema	NOUN
ajlm-840	64	63	plates	plate	NOUN
ajlm-840	64	64	were	be	AUX
ajlm-840	64	65	therefore	therefore	ADV
ajlm-840	64	66	interpreted	interpret	VERB
ajlm-840	64	67	categorically	categorically	ADV
ajlm-840	64	68	based	base	VERB
ajlm-840	64	69	on	on	ADP
ajlm-840	64	70	the	the	DET
ajlm-840	64	71	calorimetric	calorimetric	ADJ
ajlm-840	64	72	reaction	reaction	NOUN
ajlm-840	64	73	.	.	PUNCT
ajlm-840	65	1	the	the	DET
ajlm-840	65	2	rema	rema	PROPN
ajlm-840	65	3	and	and	CCONJ
ajlm-840	65	4	sensititre	sensititre	NOUN
ajlm-840	65	5	plates	plate	NOUN
ajlm-840	65	6	were	be	AUX
ajlm-840	65	7	interpreted	interpret	VERB
ajlm-840	65	8	by	by	ADP
ajlm-840	65	9	two	two	NUM
ajlm-840	65	10	readers	reader	NOUN
ajlm-840	65	11	who	who	PRON
ajlm-840	65	12	were	be	AUX
ajlm-840	65	13	blinded	blind	VERB
ajlm-840	65	14	to	to	ADP
ajlm-840	65	15	the	the	DET
ajlm-840	65	16	apm	apm	NOUN
ajlm-840	65	17	results	result	NOUN
ajlm-840	65	18	.	.	PUNCT
ajlm-840	66	1	the	the	DET
ajlm-840	66	2	two	two	NUM
ajlm-840	66	3	readers	reader	NOUN
ajlm-840	66	4	were	be	AUX
ajlm-840	66	5	in	in	ADP
ajlm-840	66	6	agreement	agreement	NOUN
ajlm-840	66	7	with	with	ADP
ajlm-840	66	8	all	all	DET
ajlm-840	66	9	plates	plate	NOUN
ajlm-840	66	10	read	read	VERB
ajlm-840	66	11	and	and	CCONJ
ajlm-840	66	12	therefore	therefore	ADV
ajlm-840	66	13	there	there	PRON
ajlm-840	66	14	was	be	VERB
ajlm-840	66	15	no	no	DET
ajlm-840	66	16	discordance	discordance	NOUN
ajlm-840	66	17	in	in	ADP
ajlm-840	66	18	interpretation	interpretation	NOUN
ajlm-840	66	19	.	.	PUNCT
ajlm-840	67	1	results	result	VERB
ajlm-840	67	2	the	the	DET
ajlm-840	67	3	134	134	NUM
ajlm-840	67	4	isolates	isolate	NOUN
ajlm-840	67	5	utilised	utilise	VERB
ajlm-840	67	6	comprised	comprise	VERB
ajlm-840	67	7	clinically	clinically	ADV
ajlm-840	67	8	derived	derive	VERB
ajlm-840	67	9	xdr	xdr	NOUN
ajlm-840	67	10	(	(	PUNCT
ajlm-840	67	11	n	n	NOUN
ajlm-840	67	12	=	=	SYM
ajlm-840	67	13	65	65	NUM
ajlm-840	67	14	)	)	PUNCT
ajlm-840	67	15	,	,	PUNCT
ajlm-840	67	16	mdr	mdr	PROPN
ajlm-840	67	17	(	(	PUNCT
ajlm-840	67	18	n	n	NOUN
ajlm-840	67	19	=	=	NUM
ajlm-840	67	20	28	28	NUM
ajlm-840	67	21	)	)	PUNCT
ajlm-840	67	22	,	,	PUNCT
ajlm-840	67	23	pre	pre	PROPN
ajlm-840	67	24	-	-	NOUN
ajlm-840	67	25	xdr	xdr	PROPN
ajlm-840	67	26	(	(	PUNCT
ajlm-840	67	27	n	n	NOUN
ajlm-840	67	28	=	=	SYM
ajlm-840	67	29	3	3	NUM
ajlm-840	67	30	)	)	PUNCT
ajlm-840	67	31	,	,	PUNCT
ajlm-840	67	32	isoniazid	isoniazid	VERB
ajlm-840	67	33	mono	mono	NOUN
ajlm-840	67	34	-	-	PUNCT
ajlm-840	67	35	resistant	resistant	ADJ
ajlm-840	67	36	(	(	PUNCT
ajlm-840	67	37	n	n	NOUN
ajlm-840	67	38	=	=	NUM
ajlm-840	67	39	15	15	NUM
ajlm-840	67	40	)	)	PUNCT
ajlm-840	67	41	,	,	PUNCT
ajlm-840	67	42	rifampicin	rifampicin	VERB
ajlm-840	67	43	mono	mono	NOUN
ajlm-840	67	44	-	-	PUNCT
ajlm-840	67	45	resistant	resistant	ADJ
ajlm-840	67	46	(	(	PUNCT
ajlm-840	67	47	n	n	NOUN
ajlm-840	67	48	=	=	SYM
ajlm-840	67	49	4	4	NUM
ajlm-840	67	50	)	)	PUNCT
ajlm-840	67	51	and	and	CCONJ
ajlm-840	67	52	susceptible	susceptible	ADJ
ajlm-840	67	53	(	(	PUNCT
ajlm-840	67	54	n	n	NOUN
ajlm-840	67	55	=	=	NUM
ajlm-840	67	56	19	19	NUM
ajlm-840	67	57	)	)	PUNCT
ajlm-840	67	58	according	accord	VERB
ajlm-840	67	59	to	to	ADP
ajlm-840	67	60	the	the	DET
ajlm-840	67	61	gold	gold	ADJ
ajlm-840	67	62	standard	standard	NOUN
ajlm-840	67	63	.	.	PUNCT
ajlm-840	68	1	the	the	DET
ajlm-840	68	2	rema	rema	PROPN
ajlm-840	68	3	and	and	CCONJ
ajlm-840	68	4	sensititre	sensititre	PROPN
ajlm-840	68	5	®	®	PROPN
ajlm-840	68	6	mycotb	mycotb	NOUN
ajlm-840	68	7	results	result	NOUN
ajlm-840	68	8	for	for	ADP
ajlm-840	68	9	all	all	DET
ajlm-840	68	10	134	134	NUM
ajlm-840	68	11	(	(	PUNCT
ajlm-840	68	12	100	100	NUM
ajlm-840	68	13	%	%	NOUN
ajlm-840	68	14	)	)	PUNCT
ajlm-840	68	15	clinical	clinical	ADJ
ajlm-840	68	16	isolates	isolate	NOUN
ajlm-840	68	17	were	be	AUX
ajlm-840	68	18	tested	test	VERB
ajlm-840	68	19	and	and	CCONJ
ajlm-840	68	20	interpreted	interpret	VERB
ajlm-840	68	21	.	.	PUNCT
ajlm-840	69	1	the	the	DET
ajlm-840	69	2	time	time	NOUN
ajlm-840	69	3	to	to	PART
ajlm-840	69	4	results	result	NOUN
ajlm-840	69	5	for	for	ADP
ajlm-840	69	6	the	the	DET
ajlm-840	69	7	sensititre	sensititre	PROPN
ajlm-840	69	8	®	®	PROPN
ajlm-840	69	9	mycotb	mycotb	NOUN
ajlm-840	69	10	method	method	NOUN
ajlm-840	69	11	was	be	AUX
ajlm-840	69	12	as	as	ADV
ajlm-840	69	13	early	early	ADJ
ajlm-840	69	14	as	as	ADP
ajlm-840	69	15	7	7	NUM
ajlm-840	69	16	days	day	NOUN
ajlm-840	69	17	,	,	PUNCT
ajlm-840	69	18	with	with	ADP
ajlm-840	69	19	more	more	ADV
ajlm-840	69	20	reliable	reliable	ADJ
ajlm-840	69	21	results	result	NOUN
ajlm-840	69	22	being	be	AUX
ajlm-840	69	23	produced	produce	VERB
ajlm-840	69	24	within	within	ADP
ajlm-840	69	25	10	10	NUM
ajlm-840	69	26	days	day	NOUN
ajlm-840	69	27	.	.	PUNCT
ajlm-840	70	1	of	of	ADP
ajlm-840	70	2	the	the	DET
ajlm-840	70	3	100	100	NUM
ajlm-840	70	4	rifampicin	rifampicin	VERB
ajlm-840	70	5	-	-	PUNCT
ajlm-840	70	6	resistant	resistant	ADJ
ajlm-840	70	7	isolates	isolate	NOUN
ajlm-840	70	8	by	by	ADP
ajlm-840	70	9	apm	apm	NOUN
ajlm-840	70	10	,	,	PUNCT
ajlm-840	70	11	98	98	NUM
ajlm-840	70	12	were	be	AUX
ajlm-840	70	13	resistant	resistant	ADJ
ajlm-840	70	14	by	by	ADP
ajlm-840	70	15	sensititre	sensititre	NOUN
ajlm-840	70	16	assay	assay	PROPN
ajlm-840	70	17	.	.	PUNCT
ajlm-840	71	1	of	of	ADP
ajlm-840	71	2	these	these	DET
ajlm-840	71	3	98	98	NUM
ajlm-840	71	4	isolates	isolate	NOUN
ajlm-840	71	5	,	,	PUNCT
ajlm-840	71	6	9	9	NUM
ajlm-840	71	7	had	have	VERB
ajlm-840	71	8	an	an	DET
ajlm-840	71	9	mic	mic	NOUN
ajlm-840	71	10	of	of	ADP
ajlm-840	71	11	1	1	NUM
ajlm-840	71	12	µg	µg	NOUN
ajlm-840	71	13	/	/	SYM
ajlm-840	71	14	ml	ml	NOUN
ajlm-840	71	15	,	,	PUNCT
ajlm-840	71	16	7	7	NUM
ajlm-840	71	17	had	have	VERB
ajlm-840	71	18	an	an	DET
ajlm-840	71	19	mic	mic	NOUN
ajlm-840	71	20	of	of	ADP
ajlm-840	71	21	2	2	NUM
ajlm-840	71	22	µg	µg	NOUN
ajlm-840	71	23	/	/	SYM
ajlm-840	71	24	ml	ml	NOUN
ajlm-840	71	25	,	,	PUNCT
ajlm-840	71	26	16	16	NUM
ajlm-840	71	27	had	have	VERB
ajlm-840	71	28	an	an	DET
ajlm-840	71	29	mic	mic	NOUN
ajlm-840	71	30	of	of	ADP
ajlm-840	71	31	4	4	NUM
ajlm-840	71	32	µg	µg	ADV
ajlm-840	71	33	/	/	SYM
ajlm-840	71	34	ml	ml	NOUN
ajlm-840	71	35	,	,	PUNCT
ajlm-840	71	36	24	24	NUM
ajlm-840	71	37	had	have	VERB
ajlm-840	71	38	an	an	DET
ajlm-840	71	39	mic	mic	NOUN
ajlm-840	71	40	of	of	ADP
ajlm-840	71	41	8	8	NUM
ajlm-840	71	42	µg	µg	ADV
ajlm-840	71	43	/	/	SYM
ajlm-840	71	44	ml	ml	NOUN
ajlm-840	71	45	,	,	PUNCT
ajlm-840	71	46	4	4	NUM
ajlm-840	71	47	had	have	VERB
ajlm-840	71	48	an	an	DET
ajlm-840	71	49	mic	mic	NOUN
ajlm-840	71	50	of	of	ADP
ajlm-840	71	51	16	16	NUM
ajlm-840	71	52	µg	µg	NOUN
ajlm-840	71	53	/	/	SYM
ajlm-840	71	54	ml	ml	NOUN
ajlm-840	71	55	and	and	CCONJ
ajlm-840	71	56	38	38	NUM
ajlm-840	71	57	had	have	VERB
ajlm-840	71	58	an	an	DET
ajlm-840	71	59	mic	mic	NOUN
ajlm-840	71	60	above	above	ADP
ajlm-840	71	61	16	16	NUM
ajlm-840	71	62	µg	µg	NOUN
ajlm-840	71	63	/	/	SYM
ajlm-840	71	64	ml	ml	NOUN
ajlm-840	71	65	.	.	PUNCT
ajlm-840	71	66	refer	refer	VERB
ajlm-840	71	67	to	to	PART
ajlm-840	71	68	figure	figure	VERB
ajlm-840	71	69	1	1	NUM
ajlm-840	71	70	for	for	ADP
ajlm-840	71	71	rifampicin	rifampicin	VERB
ajlm-840	71	72	mic	mic	ADJ
ajlm-840	71	73	distributions	distribution	NOUN
ajlm-840	71	74	using	use	VERB
ajlm-840	71	75	the	the	DET
ajlm-840	71	76	sensititre	sensititre	NOUN
ajlm-840	71	77	®	®	PROPN
ajlm-840	71	78	mycotb	mycotb	PROPN
ajlm-840	71	79	.	.	PUNCT
ajlm-840	72	1	figure	figure	NOUN
ajlm-840	72	2	1	1	NUM
ajlm-840	72	3	:	:	PUNCT
ajlm-840	72	4	distribution	distribution	NOUN
ajlm-840	72	5	of	of	ADP
ajlm-840	72	6	isolates	isolate	NOUN
ajlm-840	72	7	by	by	ADP
ajlm-840	72	8	minimum	minimum	ADJ
ajlm-840	72	9	inhibitory	inhibitory	ADJ
ajlm-840	72	10	concentration	concentration	NOUN
ajlm-840	72	11	for	for	ADP
ajlm-840	72	12	isoniazid	isoniazid	NOUN
ajlm-840	72	13	and	and	CCONJ
ajlm-840	72	14	rifampicin	rifampicin	VERB
ajlm-840	72	15	,	,	PUNCT
ajlm-840	72	16	inkosi	inkosi	PROPN
ajlm-840	72	17	albert	albert	PROPN
ajlm-840	72	18	luthuli	luthuli	PROPN
ajlm-840	72	19	central	central	PROPN
ajlm-840	72	20	hospital	hospital	NOUN
ajlm-840	72	21	,	,	PUNCT
ajlm-840	72	22	durban	durban	PROPN
ajlm-840	72	23	,	,	PUNCT
ajlm-840	72	24	south	south	PROPN
ajlm-840	72	25	africa	africa	PROPN
ajlm-840	72	26	,	,	PUNCT
ajlm-840	72	27	january	january	PROPN
ajlm-840	72	28	2014	2014	NUM
ajlm-840	72	29	–	–	PUNCT
ajlm-840	72	30	june	june	PROPN
ajlm-840	72	31	2015	2015	NUM
ajlm-840	72	32	.	.	PUNCT
ajlm-840	73	1	(	(	PUNCT
ajlm-840	73	2	a	a	X
ajlm-840	73	3	)	)	PUNCT
ajlm-840	73	4	distribution	distribution	NOUN
ajlm-840	73	5	of	of	ADP
ajlm-840	73	6	rif	rif	NOUN
ajlm-840	73	7	-	-	ADJ
ajlm-840	73	8	resistant	resistant	ADJ
ajlm-840	73	9	and	and	CCONJ
ajlm-840	73	10	-susceptible	-susceptible	ADJ
ajlm-840	73	11	isolates	isolate	NOUN
ajlm-840	73	12	as	as	SCONJ
ajlm-840	73	13	determined	determine	VERB
ajlm-840	73	14	by	by	ADP
ajlm-840	73	15	apm	apm	NOUN
ajlm-840	73	16	according	accord	VERB
ajlm-840	73	17	to	to	ADP
ajlm-840	73	18	their	their	PRON
ajlm-840	73	19	mic	mic	NOUN
ajlm-840	73	20	as	as	SCONJ
ajlm-840	73	21	determined	determine	VERB
ajlm-840	73	22	by	by	ADP
ajlm-840	73	23	the	the	DET
ajlm-840	73	24	sensititre	sensititre	PROPN
ajlm-840	73	25	®	®	PROPN
ajlm-840	73	26	mycotb	mycotb	NOUN
ajlm-840	73	27	assay	assay	PROPN
ajlm-840	73	28	.	.	PUNCT
ajlm-840	74	1	(	(	PUNCT
ajlm-840	74	2	b	b	X
ajlm-840	74	3	)	)	PUNCT
ajlm-840	74	4	distribution	distribution	NOUN
ajlm-840	74	5	of	of	ADP
ajlm-840	74	6	inh	inh	NOUN
ajlm-840	74	7	-	-	PUNCT
ajlm-840	74	8	resistant	resistant	ADJ
ajlm-840	74	9	and	and	CCONJ
ajlm-840	74	10	-susceptible	-susceptible	ADJ
ajlm-840	74	11	isolates	isolate	NOUN
ajlm-840	74	12	as	as	SCONJ
ajlm-840	74	13	determined	determine	VERB
ajlm-840	74	14	by	by	ADP
ajlm-840	74	15	apm	apm	NOUN
ajlm-840	74	16	according	accord	VERB
ajlm-840	74	17	to	to	ADP
ajlm-840	74	18	their	their	PRON
ajlm-840	74	19	mic	mic	NOUN
ajlm-840	74	20	as	as	SCONJ
ajlm-840	74	21	determined	determine	VERB
ajlm-840	74	22	by	by	ADP
ajlm-840	74	23	the	the	DET
ajlm-840	74	24	sensititre	sensititre	PROPN
ajlm-840	74	25	®	®	PROPN
ajlm-840	74	26	mycotb	mycotb	NOUN
ajlm-840	74	27	assay	assay	PROPN
ajlm-840	74	28	.	.	PUNCT
ajlm-840	75	1	of	of	ADP
ajlm-840	75	2	the	the	DET
ajlm-840	75	3	16	16	NUM
ajlm-840	75	4	isolates	isolate	NOUN
ajlm-840	75	5	that	that	PRON
ajlm-840	75	6	were	be	AUX
ajlm-840	75	7	rifampicin	rifampicin	VERB
ajlm-840	75	8	-	-	PUNCT
ajlm-840	75	9	resistant	resistant	ADJ
ajlm-840	75	10	by	by	ADP
ajlm-840	75	11	the	the	DET
ajlm-840	75	12	sensititre	sensititre	PROPN
ajlm-840	75	13	®	®	PROPN
ajlm-840	75	14	mycotb	mycotb	NOUN
ajlm-840	75	15	having	have	VERB
ajlm-840	75	16	mic	mic	NOUN
ajlm-840	75	17	of	of	ADP
ajlm-840	75	18	4	4	NUM
ajlm-840	75	19	µg	µg	ADV
ajlm-840	75	20	/	/	SYM
ajlm-840	75	21	ml	ml	NOUN
ajlm-840	75	22	,	,	PUNCT
ajlm-840	75	23	75	75	NUM
ajlm-840	75	24	%	%	NOUN
ajlm-840	75	25	(	(	PUNCT
ajlm-840	75	26	12/16	12/16	NUM
ajlm-840	75	27	)	)	PUNCT
ajlm-840	75	28	were	be	AUX
ajlm-840	75	29	xdr	xdr	PROPN
ajlm-840	75	30	,	,	PUNCT
ajlm-840	75	31	12.5	12.5	NUM
ajlm-840	75	32	%	%	NOUN
ajlm-840	75	33	(	(	PUNCT
ajlm-840	75	34	2/16	2/16	NUM
ajlm-840	75	35	)	)	PUNCT
ajlm-840	75	36	mdr	mdr	NOUN
ajlm-840	75	37	and	and	CCONJ
ajlm-840	75	38	12.5	12.5	NUM
ajlm-840	75	39	%	%	NOUN
ajlm-840	75	40	(	(	PUNCT
ajlm-840	75	41	2/16	2/16	NUM
ajlm-840	75	42	)	)	PUNCT
ajlm-840	75	43	mono	mono	NOUN
ajlm-840	75	44	-	-	PUNCT
ajlm-840	75	45	resistant	resistant	ADJ
ajlm-840	75	46	to	to	ADP
ajlm-840	75	47	rifampicin	rifampicin	VERB
ajlm-840	75	48	by	by	ADP
ajlm-840	75	49	the	the	DET
ajlm-840	75	50	apm	apm	NOUN
ajlm-840	75	51	.	.	PUNCT
ajlm-840	76	1	of	of	ADP
ajlm-840	76	2	the	the	DET
ajlm-840	76	3	24	24	NUM
ajlm-840	76	4	isolates	isolate	NOUN
ajlm-840	76	5	that	that	PRON
ajlm-840	76	6	were	be	AUX
ajlm-840	76	7	resistant	resistant	ADJ
ajlm-840	76	8	to	to	ADP
ajlm-840	76	9	rifampicin	rifampicin	VERB
ajlm-840	76	10	by	by	ADP
ajlm-840	76	11	the	the	DET
ajlm-840	76	12	sensititre	sensititre	PROPN
ajlm-840	76	13	®	®	PROPN
ajlm-840	76	14	mycotb	mycotb	NOUN
ajlm-840	76	15	with	with	ADP
ajlm-840	76	16	mic	mic	NOUN
ajlm-840	76	17	of	of	ADP
ajlm-840	76	18	8	8	NUM
ajlm-840	76	19	µg	µg	ADV
ajlm-840	76	20	/	/	SYM
ajlm-840	76	21	ml	ml	NOUN
ajlm-840	76	22	,	,	PUNCT
ajlm-840	76	23	67	67	NUM
ajlm-840	76	24	%	%	NOUN
ajlm-840	76	25	(	(	PUNCT
ajlm-840	76	26	16/24	16/24	NUM
ajlm-840	76	27	)	)	PUNCT
ajlm-840	76	28	were	be	AUX
ajlm-840	76	29	xdr	xdr	PROPN
ajlm-840	76	30	,	,	PUNCT
ajlm-840	76	31	8	8	NUM
ajlm-840	76	32	%	%	NOUN
ajlm-840	76	33	(	(	PUNCT
ajlm-840	76	34	2/24	2/24	NUM
ajlm-840	76	35	)	)	PUNCT
ajlm-840	76	36	pre	pre	NOUN
ajlm-840	76	37	-	-	NOUN
ajlm-840	76	38	xdr	xdr	NOUN
ajlm-840	76	39	and	and	CCONJ
ajlm-840	76	40	25	25	NUM
ajlm-840	76	41	%	%	NOUN
ajlm-840	76	42	(	(	PUNCT
ajlm-840	76	43	6/24	6/24	NUM
ajlm-840	76	44	)	)	PUNCT
ajlm-840	76	45	were	be	AUX
ajlm-840	76	46	mdr	mdr	PROPN
ajlm-840	76	47	by	by	ADP
ajlm-840	76	48	the	the	DET
ajlm-840	76	49	apm	apm	NOUN
ajlm-840	76	50	.	.	PUNCT
ajlm-840	77	1	the	the	DET
ajlm-840	77	2	rema	rema	NOUN
ajlm-840	77	3	correctly	correctly	ADV
ajlm-840	77	4	detected	detect	VERB
ajlm-840	77	5	rifampicin	rifampicin	VERB
ajlm-840	77	6	resistance	resistance	NOUN
ajlm-840	77	7	in	in	ADP
ajlm-840	77	8	all	all	DET
ajlm-840	77	9	seven	seven	NUM
ajlm-840	77	10	isolates	isolate	NOUN
ajlm-840	77	11	with	with	ADP
ajlm-840	77	12	an	an	DET
ajlm-840	77	13	mic	mic	NOUN
ajlm-840	77	14	of	of	ADP
ajlm-840	77	15	2	2	NUM
ajlm-840	77	16	µg	µg	NOUN
ajlm-840	77	17	/	/	SYM
ajlm-840	77	18	ml	ml	NOUN
ajlm-840	77	19	by	by	ADP
ajlm-840	77	20	the	the	DET
ajlm-840	77	21	sensititre	sensititre	PROPN
ajlm-840	77	22	®	®	PROPN
ajlm-840	77	23	mycotb	mycotb	NOUN
ajlm-840	77	24	(	(	PUNCT
ajlm-840	77	25	43	43	NUM
ajlm-840	77	26	%	%	NOUN
ajlm-840	77	27	[	[	X
ajlm-840	77	28	3/7	3/7	NUM
ajlm-840	77	29	]	]	X
ajlm-840	77	30	xdr	xdr	PROPN
ajlm-840	77	31	,	,	PUNCT
ajlm-840	77	32	43	43	NUM
ajlm-840	77	33	%	%	NOUN
ajlm-840	77	34	[	[	X
ajlm-840	77	35	3/7	3/7	NUM
ajlm-840	77	36	]	]	X
ajlm-840	77	37	mdr	mdr	PROPN
ajlm-840	77	38	and	and	CCONJ
ajlm-840	77	39	14	14	NUM
ajlm-840	77	40	%	%	NOUN
ajlm-840	78	1	[	[	X
ajlm-840	78	2	1/7	1/7	X
ajlm-840	78	3	]	]	X
ajlm-840	78	4	mono	mono	NOUN
ajlm-840	78	5	-	-	PUNCT
ajlm-840	78	6	resistant	resistant	ADJ
ajlm-840	78	7	to	to	ADP
ajlm-840	78	8	rifampicin	rifampicin	VERB
ajlm-840	78	9	by	by	ADP
ajlm-840	78	10	apm	apm	NOUN
ajlm-840	78	11	)	)	PUNCT
ajlm-840	78	12	with	with	ADP
ajlm-840	78	13	an	an	DET
ajlm-840	78	14	mic	mic	NOUN
ajlm-840	78	15	of	of	ADP
ajlm-840	78	16	2	2	NUM
ajlm-840	78	17	µg	µg	NOUN
ajlm-840	78	18	/	/	SYM
ajlm-840	78	19	ml	ml	NOUN
ajlm-840	78	20	by	by	ADP
ajlm-840	78	21	the	the	DET
ajlm-840	78	22	sensititre	sensititre	PROPN
ajlm-840	78	23	®	®	PROPN
ajlm-840	78	24	mycotb	mycotb	PROPN
ajlm-840	78	25	.	.	PUNCT
ajlm-840	79	1	the	the	DET
ajlm-840	79	2	rema	rema	NOUN
ajlm-840	79	3	confirmed	confirm	VERB
ajlm-840	79	4	rifampicin	rifampicin	VERB
ajlm-840	79	5	resistance	resistance	NOUN
ajlm-840	79	6	in	in	ADP
ajlm-840	79	7	all	all	PRON
ajlm-840	79	8	of	of	ADP
ajlm-840	79	9	the	the	DET
ajlm-840	79	10	38	38	NUM
ajlm-840	79	11	isolates	isolate	NOUN
ajlm-840	79	12	with	with	ADP
ajlm-840	79	13	an	an	DET
ajlm-840	79	14	mic	mic	NOUN
ajlm-840	79	15	above	above	ADP
ajlm-840	79	16	16	16	NUM
ajlm-840	79	17	μg	μg	NOUN
ajlm-840	79	18	/	/	SYM
ajlm-840	79	19	ml	ml	NOUN
ajlm-840	79	20	by	by	ADP
ajlm-840	79	21	the	the	DET
ajlm-840	79	22	sensititre	sensititre	PROPN
ajlm-840	79	23	®	®	PROPN
ajlm-840	79	24	mycotb	mycotb	NOUN
ajlm-840	79	25	(	(	PUNCT
ajlm-840	79	26	68	68	NUM
ajlm-840	79	27	%	%	NOUN
ajlm-840	80	1	[	[	X
ajlm-840	80	2	26/38	26/38	X
ajlm-840	80	3	]	]	X
ajlm-840	80	4	xdr	xdr	PROPN
ajlm-840	80	5	and	and	CCONJ
ajlm-840	80	6	32	32	NUM
ajlm-840	80	7	%	%	NOUN
ajlm-840	80	8	[	[	X
ajlm-840	80	9	12/38	12/38	X
ajlm-840	80	10	]	]	X
ajlm-840	80	11	mdr	mdr	PROPN
ajlm-840	80	12	)	)	PUNCT
ajlm-840	80	13	by	by	ADP
ajlm-840	80	14	apm	apm	PROPN
ajlm-840	80	15	.	.	PUNCT
ajlm-840	81	1	the	the	DET
ajlm-840	81	2	overall	overall	ADJ
ajlm-840	81	3	sensitivity	sensitivity	NOUN
ajlm-840	81	4	,	,	PUNCT
ajlm-840	81	5	specificity	specificity	NOUN
ajlm-840	81	6	,	,	PUNCT
ajlm-840	81	7	positive	positive	ADJ
ajlm-840	81	8	and	and	CCONJ
ajlm-840	81	9	negative	negative	ADJ
ajlm-840	81	10	predictive	predictive	ADJ
ajlm-840	81	11	values	value	NOUN
ajlm-840	81	12	of	of	ADP
ajlm-840	81	13	the	the	DET
ajlm-840	81	14	sensititre	sensititre	NOUN
ajlm-840	81	15	®	®	PROPN
ajlm-840	81	16	mycotb	mycotb	ADJ
ajlm-840	81	17	plate	plate	NOUN
ajlm-840	81	18	for	for	ADP
ajlm-840	81	19	rifampicin	rifampicin	VERB
ajlm-840	81	20	-	-	PUNCT
ajlm-840	81	21	resistance	resistance	NOUN
ajlm-840	81	22	detection	detection	NOUN
ajlm-840	81	23	were	be	AUX
ajlm-840	81	24	found	find	VERB
ajlm-840	81	25	to	to	PART
ajlm-840	81	26	be	be	AUX
ajlm-840	81	27	98	98	NUM
ajlm-840	81	28	%	%	NOUN
ajlm-840	81	29	,	,	PUNCT
ajlm-840	81	30	82	82	NUM
ajlm-840	81	31	%	%	NOUN
ajlm-840	81	32	,	,	PUNCT
ajlm-840	81	33	94	94	NUM
ajlm-840	81	34	%	%	NOUN
ajlm-840	81	35	and	and	CCONJ
ajlm-840	81	36	93	93	NUM
ajlm-840	81	37	%	%	NOUN
ajlm-840	81	38	(	(	PUNCT
ajlm-840	81	39	table	table	NOUN
ajlm-840	81	40	1	1	NUM
ajlm-840	81	41	)	)	PUNCT
ajlm-840	81	42	.	.	PUNCT
ajlm-840	82	1	the	the	DET
ajlm-840	82	2	rema	rema	NOUN
ajlm-840	82	3	displayed	display	VERB
ajlm-840	82	4	a	a	DET
ajlm-840	82	5	sensitivity	sensitivity	NOUN
ajlm-840	82	6	,	,	PUNCT
ajlm-840	82	7	specificity	specificity	NOUN
ajlm-840	82	8	,	,	PUNCT
ajlm-840	82	9	positive	positive	ADJ
ajlm-840	82	10	and	and	CCONJ
ajlm-840	82	11	negative	negative	ADJ
ajlm-840	82	12	predictive	predictive	ADJ
ajlm-840	82	13	values	value	NOUN
ajlm-840	82	14	of	of	ADP
ajlm-840	82	15	89	89	NUM
ajlm-840	82	16	%	%	NOUN
ajlm-840	82	17	,	,	PUNCT
ajlm-840	82	18	68	68	NUM
ajlm-840	82	19	%	%	NOUN
ajlm-840	82	20	,	,	PUNCT
ajlm-840	82	21	89	89	NUM
ajlm-840	82	22	%	%	NOUN
ajlm-840	82	23	and	and	CCONJ
ajlm-840	82	24	68	68	NUM
ajlm-840	82	25	%	%	NOUN
ajlm-840	82	26	for	for	ADP
ajlm-840	82	27	the	the	DET
ajlm-840	82	28	detection	detection	NOUN
ajlm-840	82	29	of	of	ADP
ajlm-840	82	30	rifampicin	rifampicin	VERB
ajlm-840	82	31	resistance	resistance	NOUN
ajlm-840	82	32	(	(	PUNCT
ajlm-840	82	33	table	table	NOUN
ajlm-840	82	34	2	2	NUM
ajlm-840	82	35	)	)	PUNCT
ajlm-840	82	36	.	.	PUNCT
ajlm-840	83	1	table	table	NOUN
ajlm-840	83	2	1	1	NUM
ajlm-840	83	3	:	:	PUNCT
ajlm-840	83	4	 	 	SPACE
ajlm-840	83	5	comparative	comparative	ADJ
ajlm-840	83	6	performance	performance	NOUN
ajlm-840	83	7	of	of	ADP
ajlm-840	83	8	the	the	DET
ajlm-840	83	9	sensititre	sensititre	PROPN
ajlm-840	83	10	®	®	PROPN
ajlm-840	83	11	mycotb	mycotb	NOUN
ajlm-840	83	12	assay	assay	PROPN
ajlm-840	83	13	and	and	CCONJ
ajlm-840	83	14	agar	agar	NOUN
ajlm-840	83	15	proportion	proportion	NOUN
ajlm-840	83	16	method	method	NOUN
ajlm-840	83	17	on	on	ADP
ajlm-840	83	18	multidrug	multidrug	NOUN
ajlm-840	83	19	-	-	PUNCT
ajlm-840	83	20	resistant	resistant	ADJ
ajlm-840	83	21	and	and	CCONJ
ajlm-840	83	22	extensively	extensively	ADV
ajlm-840	83	23	drug	drug	NOUN
ajlm-840	83	24	-	-	PUNCT
ajlm-840	83	25	resistant	resistant	ADJ
ajlm-840	83	26	tuberculosis	tuberculosis	NOUN
ajlm-840	83	27	isolates	isolate	NOUN
ajlm-840	83	28	,	,	PUNCT
ajlm-840	83	29	inkosi	inkosi	PROPN
ajlm-840	83	30	albert	albert	PROPN
ajlm-840	83	31	luthuli	luthuli	PROPN
ajlm-840	83	32	central	central	PROPN
ajlm-840	83	33	hospital	hospital	NOUN
ajlm-840	83	34	,	,	PUNCT
ajlm-840	83	35	durban	durban	PROPN
ajlm-840	83	36	,	,	PUNCT
ajlm-840	83	37	south	south	PROPN
ajlm-840	83	38	africa	africa	PROPN
ajlm-840	83	39	,	,	PUNCT
ajlm-840	83	40	january	january	PROPN
ajlm-840	83	41	2014	2014	NUM
ajlm-840	83	42	–	–	PUNCT
ajlm-840	83	43	june	june	PROPN
ajlm-840	83	44	2015	2015	NUM
ajlm-840	83	45	.	.	PUNCT
ajlm-840	84	1	table	table	NOUN
ajlm-840	84	2	2	2	NUM
ajlm-840	84	3	:	:	PUNCT
ajlm-840	84	4	 	 	SPACE
ajlm-840	84	5	comparative	comparative	ADJ
ajlm-840	84	6	performance	performance	NOUN
ajlm-840	84	7	of	of	ADP
ajlm-840	84	8	the	the	DET
ajlm-840	84	9	resazurin	resazurin	NOUN
ajlm-840	84	10	microtitre	microtitre	PROPN
ajlm-840	84	11	plate	plate	NOUN
ajlm-840	84	12	assay	assay	VERB
ajlm-840	84	13	and	and	CCONJ
ajlm-840	84	14	agar	agar	NOUN
ajlm-840	84	15	proportion	proportion	NOUN
ajlm-840	84	16	method	method	NOUN
ajlm-840	84	17	on	on	ADP
ajlm-840	84	18	multidrug	multidrug	NOUN
ajlm-840	84	19	-	-	PUNCT
ajlm-840	84	20	resistant	resistant	ADJ
ajlm-840	84	21	and	and	CCONJ
ajlm-840	84	22	extensively	extensively	ADV
ajlm-840	84	23	drug	drug	NOUN
ajlm-840	84	24	-	-	PUNCT
ajlm-840	84	25	resistant	resistant	ADJ
ajlm-840	84	26	tuberculosis	tuberculosis	NOUN
ajlm-840	84	27	isolates	isolate	NOUN
ajlm-840	84	28	,	,	PUNCT
ajlm-840	84	29	inkosi	inkosi	PROPN
ajlm-840	84	30	albert	albert	PROPN
ajlm-840	84	31	luthuli	luthuli	PROPN
ajlm-840	84	32	central	central	PROPN
ajlm-840	84	33	hospital	hospital	NOUN
ajlm-840	84	34	,	,	PUNCT
ajlm-840	84	35	durban	durban	PROPN
ajlm-840	84	36	,	,	PUNCT
ajlm-840	84	37	south	south	PROPN
ajlm-840	84	38	africa	africa	PROPN
ajlm-840	84	39	,	,	PUNCT
ajlm-840	84	40	january	january	PROPN
ajlm-840	84	41	2014	2014	NUM
ajlm-840	84	42	–	–	PUNCT
ajlm-840	84	43	june	june	PROPN
ajlm-840	84	44	2015	2015	NUM
ajlm-840	84	45	.	.	PUNCT
ajlm-840	85	1	of	of	ADP
ajlm-840	85	2	the	the	DET
ajlm-840	85	3	111	111	NUM
ajlm-840	85	4	isoniazid	isoniazid	NOUN
ajlm-840	85	5	-	-	PUNCT
ajlm-840	85	6	resistant	resistant	ADJ
ajlm-840	85	7	isolates	isolate	NOUN
ajlm-840	85	8	by	by	ADP
ajlm-840	85	9	apm	apm	NOUN
ajlm-840	85	10	,	,	PUNCT
ajlm-840	85	11	108	108	NUM
ajlm-840	85	12	were	be	AUX
ajlm-840	85	13	resistant	resistant	ADJ
ajlm-840	85	14	by	by	ADP
ajlm-840	85	15	the	the	DET
ajlm-840	85	16	sensititre	sensititre	NOUN
ajlm-840	85	17	assay	assay	VERB
ajlm-840	85	18	.	.	PUNCT
ajlm-840	86	1	of	of	ADP
ajlm-840	86	2	these	these	DET
ajlm-840	86	3	108	108	NUM
ajlm-840	86	4	isolates	isolate	NOUN
ajlm-840	86	5	,	,	PUNCT
ajlm-840	86	6	7	7	NUM
ajlm-840	86	7	had	have	VERB
ajlm-840	86	8	an	an	DET
ajlm-840	86	9	mic	mic	NOUN
ajlm-840	86	10	of	of	ADP
ajlm-840	86	11	1	1	NUM
ajlm-840	86	12	µg	µg	NOUN
ajlm-840	86	13	/	/	SYM
ajlm-840	86	14	ml	ml	NOUN
ajlm-840	86	15	,	,	PUNCT
ajlm-840	86	16	9	9	NUM
ajlm-840	86	17	had	have	VERB
ajlm-840	86	18	an	an	DET
ajlm-840	86	19	mic	mic	NOUN
ajlm-840	86	20	of	of	ADP
ajlm-840	86	21	2	2	NUM
ajlm-840	86	22	µg	µg	NOUN
ajlm-840	86	23	/	/	SYM
ajlm-840	86	24	ml	ml	NOUN
ajlm-840	86	25	,	,	PUNCT
ajlm-840	86	26	39	39	NUM
ajlm-840	86	27	had	have	VERB
ajlm-840	86	28	an	an	DET
ajlm-840	86	29	mic	mic	NOUN
ajlm-840	86	30	of	of	ADP
ajlm-840	86	31	4	4	NUM
ajlm-840	86	32	µg	µg	ADV
ajlm-840	86	33	/	/	SYM
ajlm-840	86	34	ml	ml	NOUN
ajlm-840	86	35	,	,	PUNCT
ajlm-840	86	36	52	52	NUM
ajlm-840	86	37	had	have	VERB
ajlm-840	86	38	an	an	DET
ajlm-840	86	39	mic	mic	NOUN
ajlm-840	86	40	of	of	ADP
ajlm-840	86	41	greater	great	ADJ
ajlm-840	86	42	than	than	ADP
ajlm-840	86	43	4	4	NUM
ajlm-840	86	44	µg	µg	ADV
ajlm-840	86	45	/	/	SYM
ajlm-840	86	46	ml	ml	NOUN
ajlm-840	86	47	and	and	CCONJ
ajlm-840	86	48	1	1	NUM
ajlm-840	86	49	had	have	VERB
ajlm-840	86	50	an	an	DET
ajlm-840	86	51	mic	mic	NOUN
ajlm-840	86	52	above	above	ADP
ajlm-840	86	53	8	8	NUM
ajlm-840	86	54	µg	µg	NOUN
ajlm-840	86	55	/	/	SYM
ajlm-840	86	56	ml	ml	NOUN
ajlm-840	86	57	.	.	PUNCT
ajlm-840	87	1	the	the	DET
ajlm-840	87	2	seven	seven	NUM
ajlm-840	87	3	isolates	isolate	NOUN
ajlm-840	87	4	that	that	PRON
ajlm-840	87	5	were	be	AUX
ajlm-840	87	6	isoniazid	isoniazid	NOUN
ajlm-840	87	7	-	-	PUNCT
ajlm-840	87	8	resistant	resistant	ADJ
ajlm-840	87	9	by	by	ADP
ajlm-840	87	10	the	the	DET
ajlm-840	87	11	sensititre	sensititre	PROPN
ajlm-840	87	12	®	®	PROPN
ajlm-840	87	13	mycotb	mycotb	ADJ
ajlm-840	87	14	with	with	ADP
ajlm-840	87	15	an	an	DET
ajlm-840	87	16	mic	mic	NOUN
ajlm-840	87	17	of	of	ADP
ajlm-840	87	18	1	1	NUM
ajlm-840	87	19	µg	µg	NOUN
ajlm-840	87	20	/	/	SYM
ajlm-840	87	21	ml	ml	NOUN
ajlm-840	87	22	(	(	PUNCT
ajlm-840	87	23	72	72	NUM
ajlm-840	87	24	%	%	NOUN
ajlm-840	87	25	mdr	mdr	NOUN
ajlm-840	87	26	and	and	CCONJ
ajlm-840	87	27	28	28	NUM
ajlm-840	87	28	%	%	NOUN
ajlm-840	87	29	mono	mono	NOUN
ajlm-840	87	30	-	-	PUNCT
ajlm-840	87	31	resistant	resistant	ADJ
ajlm-840	87	32	to	to	ADP
ajlm-840	87	33	isoniazid	isoniazid	NOUN
ajlm-840	87	34	by	by	ADP
ajlm-840	87	35	apm	apm	NOUN
ajlm-840	87	36	)	)	PUNCT
ajlm-840	87	37	were	be	AUX
ajlm-840	87	38	also	also	ADV
ajlm-840	87	39	confirmed	confirm	VERB
ajlm-840	87	40	resistant	resistant	ADJ
ajlm-840	87	41	by	by	ADP
ajlm-840	87	42	the	the	DET
ajlm-840	87	43	rema	rema	NOUN
ajlm-840	87	44	assay	assay	VERB
ajlm-840	87	45	.	.	PUNCT
ajlm-840	88	1	nine	nine	NUM
ajlm-840	88	2	isolates	isolate	NOUN
ajlm-840	88	3	resistant	resistant	ADJ
ajlm-840	88	4	to	to	ADP
ajlm-840	88	5	isoniazid	isoniazid	NOUN
ajlm-840	88	6	by	by	ADP
ajlm-840	88	7	the	the	DET
ajlm-840	88	8	sensititre	sensititre	PROPN
ajlm-840	88	9	®	®	PROPN
ajlm-840	88	10	mycotb	mycotb	ADJ
ajlm-840	88	11	with	with	ADP
ajlm-840	88	12	an	an	DET
ajlm-840	88	13	mic	mic	NOUN
ajlm-840	88	14	of	of	ADP
ajlm-840	88	15	2	2	NUM
ajlm-840	88	16	µg	µg	NOUN
ajlm-840	88	17	/	/	SYM
ajlm-840	88	18	ml	ml	VERB
ajlm-840	88	19	comprised	comprise	VERB
ajlm-840	88	20	clinically	clinically	ADV
ajlm-840	88	21	-	-	PUNCT
ajlm-840	88	22	derived	derive	VERB
ajlm-840	88	23	xdr	xdr	NOUN
ajlm-840	88	24	(	(	PUNCT
ajlm-840	88	25	n	n	NOUN
ajlm-840	88	26	=	=	SYM
ajlm-840	88	27	6	6	NUM
ajlm-840	88	28	)	)	PUNCT
ajlm-840	88	29	,	,	PUNCT
ajlm-840	88	30	mdr	mdr	PROPN
ajlm-840	88	31	(	(	PUNCT
ajlm-840	88	32	n	n	NOUN
ajlm-840	88	33	=	=	SYM
ajlm-840	88	34	2	2	NUM
ajlm-840	88	35	)	)	PUNCT
ajlm-840	88	36	and	and	CCONJ
ajlm-840	88	37	pre	pre	PROPN
ajlm-840	88	38	-	-	PROPN
ajlm-840	88	39	xdr	xdr	PROPN
ajlm-840	88	40	(	(	PUNCT
ajlm-840	88	41	n	n	NOUN
ajlm-840	88	42	=	=	SYM
ajlm-840	88	43	1	1	NUM
ajlm-840	88	44	)	)	PUNCT
ajlm-840	88	45	.	.	PUNCT
ajlm-840	89	1	resistance	resistance	NOUN
ajlm-840	89	2	to	to	ADP
ajlm-840	89	3	isoniazid	isoniazid	NOUN
ajlm-840	89	4	by	by	ADP
ajlm-840	89	5	the	the	DET
ajlm-840	89	6	rema	rema	NOUN
ajlm-840	89	7	method	method	NOUN
ajlm-840	89	8	was	be	AUX
ajlm-840	89	9	noted	note	VERB
ajlm-840	89	10	in	in	ADP
ajlm-840	89	11	all	all	DET
ajlm-840	89	12	9	9	NUM
ajlm-840	89	13	isolates	isolate	NOUN
ajlm-840	89	14	.	.	PUNCT
ajlm-840	90	1	of	of	ADP
ajlm-840	90	2	the	the	DET
ajlm-840	90	3	52	52	NUM
ajlm-840	90	4	isoniazid	isoniazid	NOUN
ajlm-840	90	5	-	-	PUNCT
ajlm-840	90	6	resistant	resistant	ADJ
ajlm-840	90	7	isolates	isolate	NOUN
ajlm-840	90	8	with	with	ADP
ajlm-840	90	9	an	an	DET
ajlm-840	90	10	mic	mic	NOUN
ajlm-840	90	11	of	of	ADP
ajlm-840	90	12	over	over	ADP
ajlm-840	90	13	4	4	NUM
ajlm-840	90	14	µg	µg	ADV
ajlm-840	90	15	/	/	SYM
ajlm-840	90	16	ml	ml	NOUN
ajlm-840	90	17	by	by	ADP
ajlm-840	90	18	the	the	DET
ajlm-840	90	19	sensititre	sensititre	PROPN
ajlm-840	90	20	®	®	PROPN
ajlm-840	90	21	mycotb	mycotb	NOUN
ajlm-840	90	22	(	(	PUNCT
ajlm-840	90	23	figure	figure	NOUN
ajlm-840	90	24	1	1	NUM
ajlm-840	90	25	)	)	PUNCT
ajlm-840	90	26	,	,	PUNCT
ajlm-840	90	27	25	25	NUM
ajlm-840	90	28	were	be	AUX
ajlm-840	90	29	xdr	xdr	PROPN
ajlm-840	90	30	,	,	PUNCT
ajlm-840	90	31	23	23	NUM
ajlm-840	90	32	mdr	mdr	NOUN
ajlm-840	90	33	and	and	CCONJ
ajlm-840	90	34	4	4	NUM
ajlm-840	90	35	were	be	AUX
ajlm-840	90	36	mono	mono	NOUN
ajlm-840	90	37	-	-	PUNCT
ajlm-840	90	38	resistant	resistant	ADJ
ajlm-840	90	39	to	to	ADP
ajlm-840	90	40	isoniazid	isoniazid	NOUN
ajlm-840	90	41	by	by	ADP
ajlm-840	90	42	the	the	DET
ajlm-840	90	43	apm	apm	NOUN
ajlm-840	90	44	.	.	PUNCT
ajlm-840	91	1	the	the	DET
ajlm-840	91	2	rema	rema	PROPN
ajlm-840	91	3	assay	assay	PROPN
ajlm-840	91	4	confirmed	confirm	VERB
ajlm-840	91	5	isoniazid	isoniazid	PROPN
ajlm-840	91	6	resistance	resistance	NOUN
ajlm-840	91	7	in	in	ADP
ajlm-840	91	8	51	51	NUM
ajlm-840	91	9	of	of	ADP
ajlm-840	91	10	the	the	DET
ajlm-840	91	11	52	52	NUM
ajlm-840	91	12	(	(	PUNCT
ajlm-840	91	13	98	98	NUM
ajlm-840	91	14	%	%	NOUN
ajlm-840	91	15	)	)	PUNCT
ajlm-840	91	16	isolates	isolate	NOUN
ajlm-840	91	17	.	.	PUNCT
ajlm-840	92	1	refer	refer	VERB
ajlm-840	92	2	to	to	PART
ajlm-840	92	3	figure	figure	VERB
ajlm-840	92	4	1	1	NUM
ajlm-840	92	5	for	for	ADP
ajlm-840	92	6	isoniazid	isoniazid	NOUN
ajlm-840	92	7	mic	mic	ADJ
ajlm-840	92	8	distributions	distribution	NOUN
ajlm-840	92	9	using	use	VERB
ajlm-840	92	10	the	the	DET
ajlm-840	92	11	sensititre	sensititre	NOUN
ajlm-840	92	12	®	®	PROPN
ajlm-840	92	13	mycotb	mycotb	PROPN
ajlm-840	92	14	.	.	PUNCT
ajlm-840	93	1	the	the	DET
ajlm-840	93	2	sensititre	sensititre	PROPN
ajlm-840	93	3	®	®	PROPN
ajlm-840	93	4	mycotb	mycotb	ADJ
ajlm-840	93	5	assay	assay	PROPN
ajlm-840	93	6	sensitivity	sensitivity	NOUN
ajlm-840	93	7	,	,	PUNCT
ajlm-840	93	8	specificity	specificity	NOUN
ajlm-840	93	9	,	,	PUNCT
ajlm-840	93	10	positive	positive	ADJ
ajlm-840	93	11	and	and	CCONJ
ajlm-840	93	12	negative	negative	ADJ
ajlm-840	93	13	predictive	predictive	ADJ
ajlm-840	93	14	values	value	NOUN
ajlm-840	93	15	for	for	ADP
ajlm-840	93	16	the	the	DET
ajlm-840	93	17	detection	detection	NOUN
ajlm-840	93	18	of	of	ADP
ajlm-840	93	19	isoniazid	isoniazid	NOUN
ajlm-840	93	20	resistance	resistance	NOUN
ajlm-840	93	21	were	be	AUX
ajlm-840	93	22	found	find	VERB
ajlm-840	93	23	to	to	PART
ajlm-840	93	24	be	be	AUX
ajlm-840	93	25	97	97	NUM
ajlm-840	93	26	%	%	NOUN
ajlm-840	93	27	,	,	PUNCT
ajlm-840	93	28	96	96	NUM
ajlm-840	93	29	%	%	NOUN
ajlm-840	93	30	,	,	PUNCT
ajlm-840	93	31	99	99	NUM
ajlm-840	93	32	%	%	NOUN
ajlm-840	93	33	and	and	CCONJ
ajlm-840	93	34	88	88	NUM
ajlm-840	93	35	%	%	NOUN
ajlm-840	93	36	(	(	PUNCT
ajlm-840	93	37	table	table	NOUN
ajlm-840	93	38	1	1	NUM
ajlm-840	93	39	)	)	PUNCT
ajlm-840	93	40	.	.	PUNCT
ajlm-840	94	1	the	the	DET
ajlm-840	94	2	rema	rema	NOUN
ajlm-840	94	3	showed	show	VERB
ajlm-840	94	4	sensitivity	sensitivity	NOUN
ajlm-840	94	5	,	,	PUNCT
ajlm-840	94	6	specificity	specificity	NOUN
ajlm-840	94	7	,	,	PUNCT
ajlm-840	94	8	positive	positive	ADJ
ajlm-840	94	9	and	and	CCONJ
ajlm-840	94	10	negative	negative	ADJ
ajlm-840	94	11	predictive	predictive	ADJ
ajlm-840	94	12	values	value	NOUN
ajlm-840	94	13	of	of	ADP
ajlm-840	94	14	95	95	NUM
ajlm-840	94	15	%	%	NOUN
ajlm-840	94	16	,	,	PUNCT
ajlm-840	94	17	96	96	NUM
ajlm-840	94	18	%	%	NOUN
ajlm-840	94	19	,	,	PUNCT
ajlm-840	94	20	99	99	NUM
ajlm-840	94	21	%	%	NOUN
ajlm-840	94	22	and	and	CCONJ
ajlm-840	94	23	81	81	NUM
ajlm-840	94	24	%	%	NOUN
ajlm-840	94	25	for	for	ADP
ajlm-840	94	26	the	the	DET
ajlm-840	94	27	detection	detection	NOUN
ajlm-840	94	28	of	of	ADP
ajlm-840	94	29	isoniazid	isoniazid	NOUN
ajlm-840	94	30	resistance	resistance	NOUN
ajlm-840	94	31	(	(	PUNCT
ajlm-840	94	32	table	table	NOUN
ajlm-840	94	33	2	2	NUM
ajlm-840	94	34	)	)	PUNCT
ajlm-840	94	35	.	.	PUNCT
ajlm-840	95	1	sensititre	sensititre	PROPN
ajlm-840	95	2	®	®	PROPN
ajlm-840	95	3	mycotb	mycotb	PROPN
ajlm-840	95	4	testing	testing	NOUN
ajlm-840	95	5	for	for	ADP
ajlm-840	95	6	the	the	DET
ajlm-840	95	7	detection	detection	NOUN
ajlm-840	95	8	of	of	ADP
ajlm-840	95	9	resistance	resistance	NOUN
ajlm-840	95	10	among	among	ADP
ajlm-840	95	11	the	the	DET
ajlm-840	95	12	mdr	mdr	PROPN
ajlm-840	95	13	and	and	CCONJ
ajlm-840	95	14	xdr	xdr	PROPN
ajlm-840	95	15	isolates	isolate	NOUN
ajlm-840	95	16	for	for	ADP
ajlm-840	95	17	rifampicin	rifampicin	NOUN
ajlm-840	95	18	,	,	PUNCT
ajlm-840	95	19	isoniazid	isoniazid	NOUN
ajlm-840	95	20	,	,	PUNCT
ajlm-840	95	21	ofloxacin	ofloxacin	PRON
ajlm-840	95	22	and	and	CCONJ
ajlm-840	95	23	kanamycin	kanamycin	NOUN
ajlm-840	95	24	correlated	correlate	VERB
ajlm-840	95	25	well	well	ADV
ajlm-840	95	26	with	with	ADP
ajlm-840	95	27	the	the	DET
ajlm-840	95	28	apm	apm	NOUN
ajlm-840	95	29	(	(	PUNCT
ajlm-840	95	30	table	table	NOUN
ajlm-840	95	31	1	1	NUM
ajlm-840	95	32	)	)	PUNCT
ajlm-840	95	33	.	.	PUNCT
ajlm-840	96	1	discrepancies	discrepancy	NOUN
ajlm-840	96	2	between	between	ADP
ajlm-840	96	3	apm	apm	PROPN
ajlm-840	96	4	and	and	CCONJ
ajlm-840	96	5	rema	rema	NOUN
ajlm-840	96	6	were	be	AUX
ajlm-840	96	7	observed	observe	VERB
ajlm-840	96	8	with	with	ADP
ajlm-840	96	9	moxifloxacin	moxifloxacin	NOUN
ajlm-840	96	10	susceptible	susceptible	ADJ
ajlm-840	96	11	isolates	isolate	NOUN
ajlm-840	96	12	(	(	PUNCT
ajlm-840	96	13	apm	apm	NOUN
ajlm-840	96	14	)	)	PUNCT
ajlm-840	96	15	where	where	SCONJ
ajlm-840	96	16	12	12	NUM
ajlm-840	96	17	isolates	isolate	NOUN
ajlm-840	96	18	were	be	AUX
ajlm-840	96	19	falsely	falsely	ADV
ajlm-840	96	20	designated	designate	VERB
ajlm-840	96	21	as	as	ADP
ajlm-840	96	22	resistant	resistant	ADJ
ajlm-840	96	23	by	by	ADP
ajlm-840	96	24	rema	rema	NOUN
ajlm-840	96	25	(	(	PUNCT
ajlm-840	96	26	table	table	NOUN
ajlm-840	96	27	2	2	NUM
ajlm-840	96	28	)	)	PUNCT
ajlm-840	96	29	.	.	PUNCT
ajlm-840	97	1	the	the	DET
ajlm-840	97	2	overall	overall	ADJ
ajlm-840	97	3	sensitivity	sensitivity	NOUN
ajlm-840	97	4	,	,	PUNCT
ajlm-840	97	5	specificity	specificity	NOUN
ajlm-840	97	6	,	,	PUNCT
ajlm-840	97	7	positive	positive	ADJ
ajlm-840	97	8	and	and	CCONJ
ajlm-840	97	9	negative	negative	ADJ
ajlm-840	97	10	predictive	predictive	ADJ
ajlm-840	97	11	values	value	NOUN
ajlm-840	97	12	of	of	ADP
ajlm-840	97	13	the	the	DET
ajlm-840	97	14	sensititre	sensititre	NOUN
ajlm-840	97	15	®	®	PROPN
ajlm-840	97	16	mycotb	mycotb	ADJ
ajlm-840	97	17	plate	plate	NOUN
ajlm-840	97	18	for	for	ADP
ajlm-840	97	19	moxifloxacin	moxifloxacin	ADJ
ajlm-840	97	20	-	-	PUNCT
ajlm-840	97	21	resistance	resistance	NOUN
ajlm-840	97	22	detection	detection	NOUN
ajlm-840	97	23	were	be	AUX
ajlm-840	97	24	found	find	VERB
ajlm-840	97	25	to	to	PART
ajlm-840	97	26	be	be	AUX
ajlm-840	97	27	91	91	NUM
ajlm-840	97	28	%	%	NOUN
ajlm-840	97	29	,	,	PUNCT
ajlm-840	97	30	98	98	NUM
ajlm-840	97	31	%	%	NOUN
ajlm-840	97	32	,	,	PUNCT
ajlm-840	97	33	91	91	NUM
ajlm-840	97	34	%	%	NOUN
ajlm-840	97	35	and	and	CCONJ
ajlm-840	97	36	96	96	NUM
ajlm-840	97	37	%	%	NOUN
ajlm-840	97	38	(	(	PUNCT
ajlm-840	97	39	table	table	NOUN
ajlm-840	97	40	1	1	NUM
ajlm-840	97	41	)	)	PUNCT
ajlm-840	97	42	.	.	PUNCT
ajlm-840	98	1	the	the	DET
ajlm-840	98	2	rema	rema	PROPN
ajlm-840	98	3	assay	assay	PROPN
ajlm-840	98	4	showed	show	VERB
ajlm-840	98	5	sensitivity	sensitivity	NOUN
ajlm-840	98	6	,	,	PUNCT
ajlm-840	98	7	specificity	specificity	NOUN
ajlm-840	98	8	,	,	PUNCT
ajlm-840	98	9	positive	positive	ADJ
ajlm-840	98	10	and	and	CCONJ
ajlm-840	98	11	negative	negative	ADJ
ajlm-840	98	12	predictive	predictive	ADJ
ajlm-840	98	13	values	value	NOUN
ajlm-840	98	14	of	of	ADP
ajlm-840	98	15	91	91	NUM
ajlm-840	98	16	%	%	NOUN
ajlm-840	98	17	,	,	PUNCT
ajlm-840	98	18	78	78	NUM
ajlm-840	98	19	%	%	NOUN
ajlm-840	98	20	,	,	PUNCT
ajlm-840	98	21	64	64	NUM
ajlm-840	98	22	%	%	NOUN
ajlm-840	98	23	and	and	CCONJ
ajlm-840	98	24	96	96	NUM
ajlm-840	98	25	%	%	NOUN
ajlm-840	98	26	for	for	ADP
ajlm-840	98	27	the	the	DET
ajlm-840	98	28	detection	detection	NOUN
ajlm-840	98	29	of	of	ADP
ajlm-840	98	30	moxifloxacin	moxifloxacin	ADJ
ajlm-840	98	31	resistance	resistance	NOUN
ajlm-840	98	32	(	(	PUNCT
ajlm-840	98	33	table	table	NOUN
ajlm-840	98	34	2	2	NUM
ajlm-840	98	35	)	)	PUNCT
ajlm-840	98	36	.	.	PUNCT
ajlm-840	99	1	the	the	DET
ajlm-840	99	2	overall	overall	ADJ
ajlm-840	99	3	sensitivity	sensitivity	NOUN
ajlm-840	99	4	,	,	PUNCT
ajlm-840	99	5	specificity	specificity	NOUN
ajlm-840	99	6	,	,	PUNCT
ajlm-840	99	7	positive	positive	ADJ
ajlm-840	99	8	and	and	CCONJ
ajlm-840	99	9	negative	negative	ADJ
ajlm-840	99	10	predictive	predictive	ADJ
ajlm-840	99	11	values	value	NOUN
ajlm-840	99	12	of	of	ADP
ajlm-840	99	13	the	the	DET
ajlm-840	99	14	sensititre	sensititre	PROPN
ajlm-840	99	15	®	®	PROPN
ajlm-840	99	16	mycotb	mycotb	NOUN
ajlm-840	99	17	assay	assay	PROPN
ajlm-840	99	18	for	for	ADP
ajlm-840	99	19	ofloxacin	ofloxacin	PROPN
ajlm-840	99	20	resistance	resistance	NOUN
ajlm-840	99	21	detection	detection	NOUN
ajlm-840	99	22	were	be	AUX
ajlm-840	99	23	found	find	VERB
ajlm-840	99	24	to	to	PART
ajlm-840	99	25	be	be	AUX
ajlm-840	99	26	100	100	NUM
ajlm-840	99	27	%	%	NOUN
ajlm-840	99	28	,	,	PUNCT
ajlm-840	99	29	97	97	NUM
ajlm-840	99	30	%	%	NOUN
ajlm-840	99	31	,	,	PUNCT
ajlm-840	99	32	97	97	NUM
ajlm-840	99	33	%	%	NOUN
ajlm-840	99	34	and	and	CCONJ
ajlm-840	99	35	100	100	NUM
ajlm-840	99	36	%	%	NOUN
ajlm-840	99	37	(	(	PUNCT
ajlm-840	99	38	table	table	NOUN
ajlm-840	99	39	1	1	NUM
ajlm-840	99	40	)	)	PUNCT
ajlm-840	99	41	.	.	PUNCT
ajlm-840	100	1	the	the	DET
ajlm-840	100	2	sensitivity	sensitivity	NOUN
ajlm-840	100	3	of	of	ADP
ajlm-840	100	4	detection	detection	NOUN
ajlm-840	100	5	for	for	ADP
ajlm-840	100	6	ofloxacin	ofloxacin	ADJ
ajlm-840	100	7	resistance	resistance	NOUN
ajlm-840	100	8	was	be	AUX
ajlm-840	100	9	not	not	PART
ajlm-840	100	10	assessed	assess	VERB
ajlm-840	100	11	by	by	ADP
ajlm-840	100	12	the	the	DET
ajlm-840	100	13	rema	rema	NOUN
ajlm-840	100	14	as	as	SCONJ
ajlm-840	100	15	the	the	DET
ajlm-840	100	16	drug	drug	NOUN
ajlm-840	100	17	could	could	AUX
ajlm-840	100	18	not	not	PART
ajlm-840	100	19	be	be	AUX
ajlm-840	100	20	procured	procure	VERB
ajlm-840	100	21	due	due	ADP
ajlm-840	100	22	to	to	ADP
ajlm-840	100	23	limited	limited	ADJ
ajlm-840	100	24	funds	fund	NOUN
ajlm-840	100	25	.	.	PUNCT
ajlm-840	101	1	the	the	DET
ajlm-840	101	2	overall	overall	ADJ
ajlm-840	101	3	sensitivity	sensitivity	NOUN
ajlm-840	101	4	,	,	PUNCT
ajlm-840	101	5	specificity	specificity	NOUN
ajlm-840	101	6	,	,	PUNCT
ajlm-840	101	7	positive	positive	ADJ
ajlm-840	101	8	and	and	CCONJ
ajlm-840	101	9	negative	negative	ADJ
ajlm-840	101	10	predictive	predictive	ADJ
ajlm-840	101	11	values	value	NOUN
ajlm-840	101	12	of	of	ADP
ajlm-840	101	13	the	the	DET
ajlm-840	101	14	sensititre	sensititre	NOUN
ajlm-840	101	15	®	®	PROPN
ajlm-840	101	16	mycotb	mycotb	ADJ
ajlm-840	101	17	plate	plate	NOUN
ajlm-840	101	18	for	for	ADP
ajlm-840	101	19	kanamycin	kanamycin	PROPN
ajlm-840	101	20	resistance	resistance	NOUN
ajlm-840	101	21	detection	detection	NOUN
ajlm-840	101	22	were	be	AUX
ajlm-840	101	23	found	find	VERB
ajlm-840	101	24	to	to	PART
ajlm-840	101	25	be	be	AUX
ajlm-840	101	26	92	92	NUM
ajlm-840	101	27	%	%	NOUN
ajlm-840	101	28	,	,	PUNCT
ajlm-840	101	29	85	85	NUM
ajlm-840	101	30	%	%	NOUN
ajlm-840	101	31	,	,	PUNCT
ajlm-840	101	32	86	86	NUM
ajlm-840	101	33	%	%	NOUN
ajlm-840	101	34	and	and	CCONJ
ajlm-840	101	35	92	92	NUM
ajlm-840	101	36	%	%	NOUN
ajlm-840	101	37	(	(	PUNCT
ajlm-840	101	38	table	table	NOUN
ajlm-840	101	39	1	1	NUM
ajlm-840	101	40	)	)	PUNCT
ajlm-840	101	41	.	.	PUNCT
ajlm-840	102	1	the	the	DET
ajlm-840	102	2	rema	rema	PROPN
ajlm-840	102	3	assay	assay	PROPN
ajlm-840	102	4	showed	show	VERB
ajlm-840	102	5	sensitivity	sensitivity	NOUN
ajlm-840	102	6	,	,	PUNCT
ajlm-840	102	7	specificity	specificity	NOUN
ajlm-840	102	8	,	,	PUNCT
ajlm-840	102	9	positive	positive	ADJ
ajlm-840	102	10	and	and	CCONJ
ajlm-840	102	11	negative	negative	ADJ
ajlm-840	102	12	predictive	predictive	ADJ
ajlm-840	102	13	values	value	NOUN
ajlm-840	102	14	of	of	ADP
ajlm-840	102	15	83	83	NUM
ajlm-840	102	16	%	%	NOUN
ajlm-840	102	17	,	,	PUNCT
ajlm-840	102	18	94	94	NUM
ajlm-840	102	19	%	%	NOUN
ajlm-840	102	20	,	,	PUNCT
ajlm-840	102	21	93	93	NUM
ajlm-840	102	22	%	%	NOUN
ajlm-840	102	23	and	and	CCONJ
ajlm-840	102	24	85	85	NUM
ajlm-840	102	25	%	%	NOUN
ajlm-840	102	26	for	for	ADP
ajlm-840	102	27	kanamycin	kanamycin	PROPN
ajlm-840	102	28	resistance	resistance	NOUN
ajlm-840	102	29	detection	detection	NOUN
ajlm-840	102	30	(	(	PUNCT
ajlm-840	102	31	table	table	NOUN
ajlm-840	102	32	2	2	NUM
ajlm-840	102	33	)	)	PUNCT
ajlm-840	102	34	.	.	PUNCT
ajlm-840	103	1	refer	refer	VERB
ajlm-840	103	2	to	to	PART
ajlm-840	103	3	figure	figure	VERB
ajlm-840	103	4	3	3	NUM
ajlm-840	103	5	for	for	ADP
ajlm-840	103	6	kanamycin	kanamycin	PROPN
ajlm-840	103	7	mic	mic	ADJ
ajlm-840	103	8	distributions	distribution	NOUN
ajlm-840	103	9	using	use	VERB
ajlm-840	103	10	the	the	DET
ajlm-840	103	11	sensititre	sensititre	NOUN
ajlm-840	103	12	®	®	PROPN
ajlm-840	103	13	mycotb	mycotb	PROPN
ajlm-840	103	14	.	.	PUNCT
ajlm-840	104	1	good	good	ADJ
ajlm-840	104	2	accuracy	accuracy	NOUN
ajlm-840	104	3	with	with	ADP
ajlm-840	104	4	regard	regard	NOUN
ajlm-840	104	5	to	to	ADP
ajlm-840	104	6	resistance	resistance	NOUN
ajlm-840	104	7	to	to	ADP
ajlm-840	104	8	the	the	DET
ajlm-840	104	9	first	first	ADJ
ajlm-840	104	10	-	-	PUNCT
ajlm-840	104	11	line	line	NOUN
ajlm-840	104	12	anti	anti	ADJ
ajlm-840	104	13	-	-	ADJ
ajlm-840	104	14	tuberculosis	tuberculosis	ADJ
ajlm-840	104	15	drugs	drug	NOUN
ajlm-840	104	16	was	be	AUX
ajlm-840	104	17	observed	observe	VERB
ajlm-840	104	18	with	with	ADP
ajlm-840	104	19	the	the	DET
ajlm-840	104	20	sensititre	sensititre	NOUN
ajlm-840	104	21	method	method	NOUN
ajlm-840	104	22	as	as	SCONJ
ajlm-840	104	23	compared	compare	VERB
ajlm-840	104	24	to	to	ADP
ajlm-840	104	25	the	the	DET
ajlm-840	104	26	rema	rema	NOUN
ajlm-840	104	27	(	(	PUNCT
ajlm-840	104	28	tables	table	NOUN
ajlm-840	104	29	1	1	NUM
ajlm-840	104	30	and	and	CCONJ
ajlm-840	104	31	2	2	NUM
ajlm-840	104	32	)	)	PUNCT
ajlm-840	104	33	.	.	PUNCT
ajlm-840	105	1	figure	figure	VERB
ajlm-840	105	2	2	2	NUM
ajlm-840	105	3	:	:	PUNCT
ajlm-840	105	4	distribution	distribution	NOUN
ajlm-840	105	5	of	of	ADP
ajlm-840	105	6	isolates	isolate	NOUN
ajlm-840	105	7	by	by	ADP
ajlm-840	105	8	minimum	minimum	ADJ
ajlm-840	105	9	inhibitory	inhibitory	ADJ
ajlm-840	105	10	concentration	concentration	NOUN
ajlm-840	105	11	for	for	ADP
ajlm-840	105	12	ofloxacin	ofloxacin	NOUN
ajlm-840	105	13	and	and	CCONJ
ajlm-840	105	14	moxifloxacin	moxifloxacin	NOUN
ajlm-840	105	15	,	,	PUNCT
ajlm-840	105	16	inkosi	inkosi	PROPN
ajlm-840	105	17	albert	albert	PROPN
ajlm-840	105	18	luthuli	luthuli	PROPN
ajlm-840	105	19	central	central	PROPN
ajlm-840	105	20	hospital	hospital	NOUN
ajlm-840	105	21	,	,	PUNCT
ajlm-840	105	22	durban	durban	PROPN
ajlm-840	105	23	,	,	PUNCT
ajlm-840	105	24	south	south	PROPN
ajlm-840	105	25	africa	africa	PROPN
ajlm-840	105	26	,	,	PUNCT
ajlm-840	105	27	january	january	PROPN
ajlm-840	105	28	2014	2014	NUM
ajlm-840	105	29	–	–	PUNCT
ajlm-840	105	30	june	june	PROPN
ajlm-840	105	31	2015	2015	NUM
ajlm-840	105	32	.	.	PUNCT
ajlm-840	106	1	(	(	PUNCT
ajlm-840	106	2	a	a	X
ajlm-840	106	3	)	)	PUNCT
ajlm-840	106	4	distribution	distribution	NOUN
ajlm-840	106	5	of	of	ADP
ajlm-840	106	6	oflox	oflox	NOUN
ajlm-840	106	7	-	-	PUNCT
ajlm-840	106	8	resistant	resistant	ADJ
ajlm-840	106	9	and	and	CCONJ
ajlm-840	106	10	-susceptible	-susceptible	ADJ
ajlm-840	106	11	isolates	isolate	NOUN
ajlm-840	106	12	as	as	SCONJ
ajlm-840	106	13	determined	determine	VERB
ajlm-840	106	14	by	by	ADP
ajlm-840	106	15	apm	apm	NOUN
ajlm-840	106	16	according	accord	VERB
ajlm-840	106	17	to	to	ADP
ajlm-840	106	18	their	their	PRON
ajlm-840	106	19	mic	mic	NOUN
ajlm-840	106	20	as	as	SCONJ
ajlm-840	106	21	determined	determine	VERB
ajlm-840	106	22	by	by	ADP
ajlm-840	106	23	the	the	DET
ajlm-840	106	24	sensititre	sensititre	PROPN
ajlm-840	106	25	®	®	PROPN
ajlm-840	106	26	mycotb	mycotb	NOUN
ajlm-840	106	27	assay	assay	PROPN
ajlm-840	106	28	.	.	PUNCT
ajlm-840	107	1	(	(	PUNCT
ajlm-840	107	2	b	b	X
ajlm-840	107	3	)	)	PUNCT
ajlm-840	107	4	distribution	distribution	NOUN
ajlm-840	107	5	of	of	ADP
ajlm-840	107	6	mox	mox	NOUN
ajlm-840	107	7	-	-	PUNCT
ajlm-840	107	8	resistant	resistant	ADJ
ajlm-840	107	9	and	and	CCONJ
ajlm-840	107	10	susceptible	susceptible	ADJ
ajlm-840	107	11	isolates	isolate	NOUN
ajlm-840	107	12	as	as	SCONJ
ajlm-840	107	13	determined	determine	VERB
ajlm-840	107	14	by	by	ADP
ajlm-840	107	15	apm	apm	NOUN
ajlm-840	107	16	according	accord	VERB
ajlm-840	107	17	to	to	ADP
ajlm-840	107	18	their	their	PRON
ajlm-840	107	19	mic	mic	NOUN
ajlm-840	107	20	as	as	SCONJ
ajlm-840	107	21	determined	determine	VERB
ajlm-840	107	22	by	by	ADP
ajlm-840	107	23	the	the	DET
ajlm-840	107	24	sensititre	sensititre	PROPN
ajlm-840	107	25	®	®	PROPN
ajlm-840	107	26	mycotb	mycotb	PROPN
ajlm-840	107	27	assay	assay	PROPN
ajlm-840	107	28	.	.	PUNCT
ajlm-840	108	1	figure	figure	VERB
ajlm-840	108	2	3	3	NUM
ajlm-840	108	3	:	:	PUNCT
ajlm-840	108	4	distribution	distribution	NOUN
ajlm-840	108	5	of	of	ADP
ajlm-840	108	6	isolates	isolate	NOUN
ajlm-840	108	7	by	by	ADP
ajlm-840	108	8	minimum	minimum	ADJ
ajlm-840	108	9	inhibitory	inhibitory	ADJ
ajlm-840	108	10	concentration	concentration	NOUN
ajlm-840	108	11	for	for	ADP
ajlm-840	108	12	kanamycin	kanamycin	PROPN
ajlm-840	108	13	,	,	PUNCT
ajlm-840	108	14	inkosi	inkosi	PROPN
ajlm-840	108	15	albert	albert	PROPN
ajlm-840	108	16	luthuli	luthuli	PROPN
ajlm-840	108	17	central	central	PROPN
ajlm-840	108	18	hospital	hospital	NOUN
ajlm-840	108	19	,	,	PUNCT
ajlm-840	108	20	durban	durban	PROPN
ajlm-840	108	21	,	,	PUNCT
ajlm-840	108	22	south	south	PROPN
ajlm-840	108	23	africa	africa	PROPN
ajlm-840	108	24	,	,	PUNCT
ajlm-840	108	25	january	january	PROPN
ajlm-840	108	26	2014	2014	NUM
ajlm-840	108	27	–	–	PUNCT
ajlm-840	108	28	june	june	PROPN
ajlm-840	108	29	2015	2015	NUM
ajlm-840	108	30	.	.	PUNCT
ajlm-840	109	1	distribution	distribution	NOUN
ajlm-840	109	2	of	of	ADP
ajlm-840	109	3	kana	kana	PROPN
ajlm-840	109	4	-	-	PUNCT
ajlm-840	109	5	resistant	resistant	ADJ
ajlm-840	109	6	and	and	CCONJ
ajlm-840	109	7	-susceptible	-susceptible	ADJ
ajlm-840	109	8	isolates	isolate	NOUN
ajlm-840	109	9	as	as	SCONJ
ajlm-840	109	10	determined	determine	VERB
ajlm-840	109	11	by	by	ADP
ajlm-840	109	12	apm	apm	NOUN
ajlm-840	109	13	according	accord	VERB
ajlm-840	109	14	to	to	ADP
ajlm-840	109	15	their	their	PRON
ajlm-840	109	16	mic	mic	NOUN
ajlm-840	109	17	as	as	SCONJ
ajlm-840	109	18	determined	determine	VERB
ajlm-840	109	19	by	by	ADP
ajlm-840	109	20	the	the	DET
ajlm-840	109	21	sensititre	sensititre	PROPN
ajlm-840	109	22	®	®	PROPN
ajlm-840	109	23	mycotb	mycotb	NOUN
ajlm-840	109	24	assay	assay	PROPN
ajlm-840	109	25	.	.	PUNCT
ajlm-840	110	1	the	the	DET
ajlm-840	110	2	performance	performance	NOUN
ajlm-840	110	3	of	of	ADP
ajlm-840	110	4	the	the	DET
ajlm-840	110	5	rema	rema	NOUN
ajlm-840	110	6	for	for	ADP
ajlm-840	110	7	the	the	DET
ajlm-840	110	8	detection	detection	NOUN
ajlm-840	110	9	of	of	ADP
ajlm-840	110	10	capreomycin	capreomycin	ADJ
ajlm-840	110	11	resistance	resistance	NOUN
ajlm-840	110	12	was	be	AUX
ajlm-840	110	13	determined	determine	VERB
ajlm-840	110	14	.	.	PUNCT
ajlm-840	111	1	all	all	PRON
ajlm-840	111	2	of	of	ADP
ajlm-840	111	3	the	the	DET
ajlm-840	111	4	62	62	NUM
ajlm-840	111	5	capreomycin	capreomycin	ADV
ajlm-840	111	6	-	-	PUNCT
ajlm-840	111	7	resistant	resistant	ADJ
ajlm-840	111	8	isolates	isolate	NOUN
ajlm-840	111	9	by	by	ADP
ajlm-840	111	10	the	the	DET
ajlm-840	111	11	rema	rema	NOUN
ajlm-840	111	12	were	be	AUX
ajlm-840	111	13	confirmed	confirm	VERB
ajlm-840	111	14	to	to	PART
ajlm-840	111	15	be	be	AUX
ajlm-840	111	16	xdr	xdr	PROPN
ajlm-840	111	17	tuberculosis	tuberculosis	NOUN
ajlm-840	111	18	by	by	ADP
ajlm-840	111	19	the	the	DET
ajlm-840	111	20	apm	apm	NOUN
ajlm-840	111	21	(	(	PUNCT
ajlm-840	111	22	table	table	NOUN
ajlm-840	111	23	2	2	NUM
ajlm-840	111	24	)	)	PUNCT
ajlm-840	111	25	.	.	PUNCT
ajlm-840	112	1	capreomycin	capreomycin	PROPN
ajlm-840	112	2	was	be	AUX
ajlm-840	112	3	not	not	PART
ajlm-840	112	4	part	part	NOUN
ajlm-840	112	5	of	of	ADP
ajlm-840	112	6	the	the	DET
ajlm-840	112	7	drug	drug	NOUN
ajlm-840	112	8	panel	panel	NOUN
ajlm-840	112	9	included	include	VERB
ajlm-840	112	10	in	in	ADP
ajlm-840	112	11	the	the	DET
ajlm-840	112	12	sensititre	sensititre	NOUN
ajlm-840	112	13	®	®	PROPN
ajlm-840	112	14	mycotb	mycotb	PROPN
ajlm-840	112	15	assay	assay	PROPN
ajlm-840	112	16	,	,	PUNCT
ajlm-840	112	17	therefore	therefore	ADV
ajlm-840	112	18	its	its	PRON
ajlm-840	112	19	performance	performance	NOUN
ajlm-840	112	20	could	could	AUX
ajlm-840	112	21	not	not	PART
ajlm-840	112	22	be	be	AUX
ajlm-840	112	23	assessed	assess	VERB
ajlm-840	112	24	.	.	PUNCT
ajlm-840	113	1	the	the	DET
ajlm-840	113	2	levels	level	NOUN
ajlm-840	113	3	of	of	ADP
ajlm-840	113	4	resistance	resistance	NOUN
ajlm-840	113	5	among	among	ADP
ajlm-840	113	6	the	the	DET
ajlm-840	113	7	mdr	mdr	PROPN
ajlm-840	113	8	and	and	CCONJ
ajlm-840	113	9	xdr	xdr	PROPN
ajlm-840	113	10	tuberculosis	tuberculosis	NOUN
ajlm-840	113	11	isolates	isolate	NOUN
ajlm-840	113	12	to	to	ADP
ajlm-840	113	13	the	the	DET
ajlm-840	113	14	additional	additional	ADJ
ajlm-840	113	15	firstand	firstand	ADJ
ajlm-840	113	16	second	second	ADJ
ajlm-840	113	17	-	-	PUNCT
ajlm-840	113	18	line	line	NOUN
ajlm-840	113	19	antibiotics	antibiotic	NOUN
ajlm-840	113	20	were	be	AUX
ajlm-840	113	21	further	far	ADV
ajlm-840	113	22	assessed	assess	VERB
ajlm-840	113	23	using	use	VERB
ajlm-840	113	24	the	the	DET
ajlm-840	113	25	sensititre	sensititre	NOUN
ajlm-840	113	26	®	®	PROPN
ajlm-840	113	27	mycotb	mycotb	NOUN
ajlm-840	113	28	assay	assay	PROPN
ajlm-840	113	29	using	use	VERB
ajlm-840	113	30	established	establish	VERB
ajlm-840	113	31	critical	critical	ADJ
ajlm-840	113	32	concentrations	concentration	NOUN
ajlm-840	113	33	(	(	PUNCT
ajlm-840	113	34	figures	figure	NOUN
ajlm-840	113	35	4	4	NUM
ajlm-840	113	36	and	and	CCONJ
ajlm-840	113	37	5	5	NUM
ajlm-840	113	38	)	)	PUNCT
ajlm-840	113	39	.	.	PUNCT
ajlm-840	114	1	resistance	resistance	NOUN
ajlm-840	114	2	to	to	ADP
ajlm-840	114	3	rifabutin	rifabutin	NOUN
ajlm-840	114	4	was	be	AUX
ajlm-840	114	5	observed	observe	VERB
ajlm-840	114	6	in	in	ADP
ajlm-840	114	7	93.5	93.5	NUM
ajlm-840	114	8	%	%	NOUN
ajlm-840	114	9	(	(	PUNCT
ajlm-840	114	10	58/62	58/62	NUM
ajlm-840	114	11	)	)	PUNCT
ajlm-840	114	12	of	of	ADP
ajlm-840	114	13	xdr	xdr	PROPN
ajlm-840	114	14	tuberculosis	tuberculosis	NOUN
ajlm-840	114	15	isolates	isolate	NOUN
ajlm-840	114	16	with	with	ADP
ajlm-840	114	17	the	the	DET
ajlm-840	114	18	majority	majority	NOUN
ajlm-840	114	19	27	27	NUM
ajlm-840	114	20	%	%	NOUN
ajlm-840	114	21	(	(	PUNCT
ajlm-840	114	22	17/62	17/62	NUM
ajlm-840	114	23	)	)	PUNCT
ajlm-840	114	24	showing	show	VERB
ajlm-840	114	25	an	an	DET
ajlm-840	114	26	mic	mic	NOUN
ajlm-840	114	27	of	of	ADP
ajlm-840	114	28	16	16	NUM
ajlm-840	114	29	µg	µg	NOUN
ajlm-840	114	30	/	/	SYM
ajlm-840	114	31	ml	ml	PROPN
ajlm-840	114	32	(	(	PUNCT
ajlm-840	114	33	figure	figure	NOUN
ajlm-840	114	34	4	4	NUM
ajlm-840	114	35	)	)	PUNCT
ajlm-840	114	36	at	at	ADP
ajlm-840	114	37	a	a	DET
ajlm-840	114	38	critical	critical	ADJ
ajlm-840	114	39	concentration	concentration	NOUN
ajlm-840	114	40	of	of	ADP
ajlm-840	114	41	0.5	0.5	NUM
ajlm-840	114	42	µg	µg	NOUN
ajlm-840	114	43	/	/	SYM
ajlm-840	114	44	ml	ml	NOUN
ajlm-840	114	45	.	.	PUNCT
ajlm-840	115	1	in	in	ADP
ajlm-840	115	2	contrast	contrast	NOUN
ajlm-840	115	3	to	to	ADP
ajlm-840	115	4	this	this	PRON
ajlm-840	115	5	,	,	PUNCT
ajlm-840	115	6	80	80	NUM
ajlm-840	115	7	%	%	NOUN
ajlm-840	115	8	(	(	PUNCT
ajlm-840	115	9	20/25	20/25	NUM
ajlm-840	115	10	)	)	PUNCT
ajlm-840	115	11	of	of	ADP
ajlm-840	115	12	mdr	mdr	PROPN
ajlm-840	115	13	isolates	isolate	NOUN
ajlm-840	115	14	were	be	AUX
ajlm-840	115	15	confirmed	confirm	VERB
ajlm-840	115	16	to	to	PART
ajlm-840	115	17	be	be	AUX
ajlm-840	115	18	susceptible	susceptible	ADJ
ajlm-840	115	19	to	to	ADP
ajlm-840	115	20	rifabutin	rifabutin	VERB
ajlm-840	115	21	with	with	ADP
ajlm-840	115	22	an	an	DET
ajlm-840	115	23	mic	mic	NOUN
ajlm-840	115	24	of	of	ADP
ajlm-840	115	25	0.5	0.5	NUM
ajlm-840	115	26	µg	µg	NOUN
ajlm-840	115	27	/	/	SYM
ajlm-840	115	28	ml	ml	NOUN
ajlm-840	115	29	(	(	PUNCT
ajlm-840	115	30	figure	figure	NOUN
ajlm-840	115	31	5	5	NUM
ajlm-840	115	32	)	)	PUNCT
ajlm-840	115	33	.	.	PUNCT
ajlm-840	116	1	figure	figure	VERB
ajlm-840	116	2	4	4	NUM
ajlm-840	116	3	:	:	PUNCT
ajlm-840	116	4	distribution	distribution	NOUN
ajlm-840	116	5	of	of	ADP
ajlm-840	116	6	minimum	minimum	ADJ
ajlm-840	116	7	inhibitory	inhibitory	ADJ
ajlm-840	116	8	concentrations	concentration	NOUN
ajlm-840	116	9	(	(	PUNCT
ajlm-840	116	10	µg	µg	NOUN
ajlm-840	116	11	/	/	SYM
ajlm-840	116	12	ml	ml	NOUN
ajlm-840	116	13	)	)	PUNCT
ajlm-840	116	14	for	for	ADP
ajlm-840	116	15	additional	additional	ADJ
ajlm-840	116	16	firstand	firstand	ADJ
ajlm-840	116	17	second	second	ADJ
ajlm-840	116	18	-	-	PUNCT
ajlm-840	116	19	line	line	NOUN
ajlm-840	116	20	antibiotics	antibiotic	NOUN
ajlm-840	116	21	using	use	VERB
ajlm-840	116	22	the	the	DET
ajlm-840	116	23	sensititre	sensititre	NOUN
ajlm-840	116	24	plate	plate	NOUN
ajlm-840	116	25	method	method	NOUN
ajlm-840	116	26	for	for	ADP
ajlm-840	116	27	clinical	clinical	ADJ
ajlm-840	116	28	,	,	PUNCT
ajlm-840	116	29	extensively	extensively	ADV
ajlm-840	116	30	drug	drug	NOUN
ajlm-840	116	31	-	-	PUNCT
ajlm-840	116	32	resistant	resistant	ADJ
ajlm-840	116	33	tuberculosis	tuberculosis	NOUN
ajlm-840	116	34	isolates	isolate	NOUN
ajlm-840	116	35	,	,	PUNCT
ajlm-840	116	36	inkosi	inkosi	PROPN
ajlm-840	116	37	albert	albert	PROPN
ajlm-840	116	38	luthuli	luthuli	PROPN
ajlm-840	116	39	central	central	PROPN
ajlm-840	116	40	hospital	hospital	NOUN
ajlm-840	116	41	,	,	PUNCT
ajlm-840	116	42	durban	durban	PROPN
ajlm-840	116	43	,	,	PUNCT
ajlm-840	116	44	south	south	PROPN
ajlm-840	116	45	africa	africa	PROPN
ajlm-840	116	46	,	,	PUNCT
ajlm-840	116	47	january	january	PROPN
ajlm-840	116	48	2014	2014	NUM
ajlm-840	116	49	–	–	PUNCT
ajlm-840	116	50	june	june	PROPN
ajlm-840	116	51	2015	2015	NUM
ajlm-840	116	52	.	.	PUNCT
ajlm-840	117	1	(	(	PUNCT
ajlm-840	117	2	a	a	X
ajlm-840	117	3	)	)	PUNCT
ajlm-840	117	4	str	str	NOUN
ajlm-840	117	5	(	(	PUNCT
ajlm-840	117	6	60	60	NUM
ajlm-840	117	7	isolates	isolate	NOUN
ajlm-840	117	8	)	)	PUNCT
ajlm-840	117	9	,	,	PUNCT
ajlm-840	117	10	(	(	PUNCT
ajlm-840	117	11	b	b	X
ajlm-840	117	12	)	)	PUNCT
ajlm-840	117	13	rfb	rfb	PROPN
ajlm-840	117	14	(	(	PUNCT
ajlm-840	117	15	62	62	NUM
ajlm-840	117	16	isolates	isolate	NOUN
ajlm-840	117	17	)	)	PUNCT
ajlm-840	117	18	,	,	PUNCT
ajlm-840	117	19	(	(	PUNCT
ajlm-840	117	20	c	c	X
ajlm-840	117	21	)	)	PUNCT
ajlm-840	117	22	pas	pas	NOUN
ajlm-840	117	23	(	(	PUNCT
ajlm-840	117	24	61	61	NUM
ajlm-840	117	25	isolates	isolate	NOUN
ajlm-840	117	26	)	)	PUNCT
ajlm-840	117	27	,	,	PUNCT
ajlm-840	117	28	(	(	PUNCT
ajlm-840	117	29	d	d	X
ajlm-840	117	30	)	)	PUNCT
ajlm-840	117	31	cyc	cyc	NOUN
ajlm-840	117	32	(	(	PUNCT
ajlm-840	117	33	61	61	NUM
ajlm-840	117	34	isolates	isolate	NOUN
ajlm-840	117	35	)	)	PUNCT
ajlm-840	117	36	,	,	PUNCT
ajlm-840	117	37	(	(	PUNCT
ajlm-840	117	38	e	e	NOUN
ajlm-840	117	39	)	)	PUNCT
ajlm-840	117	40	ami	ami	NOUN
ajlm-840	117	41	(	(	PUNCT
ajlm-840	117	42	62	62	NUM
ajlm-840	117	43	isolates	isolate	NOUN
ajlm-840	117	44	)	)	PUNCT
ajlm-840	117	45	,	,	PUNCT
ajlm-840	117	46	(	(	PUNCT
ajlm-840	117	47	f	f	X
ajlm-840	117	48	)	)	PUNCT
ajlm-840	117	49	eth	eth	NOUN
ajlm-840	117	50	(	(	PUNCT
ajlm-840	117	51	62	62	NUM
ajlm-840	117	52	isolates	isolate	NOUN
ajlm-840	117	53	)	)	PUNCT
ajlm-840	117	54	and	and	CCONJ
ajlm-840	117	55	(	(	PUNCT
ajlm-840	117	56	g	g	NOUN
ajlm-840	117	57	)	)	PUNCT
ajlm-840	117	58	emb	emb	NOUN
ajlm-840	117	59	(	(	PUNCT
ajlm-840	117	60	62	62	NUM
ajlm-840	117	61	isolates	isolate	NOUN
ajlm-840	117	62	)	)	PUNCT
ajlm-840	117	63	.	.	PUNCT
ajlm-840	118	1	figure	figure	VERB
ajlm-840	118	2	5	5	NUM
ajlm-840	118	3	:	:	PUNCT
ajlm-840	118	4	distribution	distribution	NOUN
ajlm-840	118	5	of	of	ADP
ajlm-840	118	6	minimum	minimum	ADJ
ajlm-840	118	7	inhibitory	inhibitory	ADJ
ajlm-840	118	8	concentrations	concentration	NOUN
ajlm-840	118	9	(	(	PUNCT
ajlm-840	118	10	µg	µg	NOUN
ajlm-840	118	11	/	/	SYM
ajlm-840	118	12	ml	ml	NOUN
ajlm-840	118	13	)	)	PUNCT
ajlm-840	118	14	for	for	ADP
ajlm-840	118	15	additional	additional	ADJ
ajlm-840	118	16	firstand	firstand	ADJ
ajlm-840	118	17	second	second	ADJ
ajlm-840	118	18	-	-	PUNCT
ajlm-840	118	19	line	line	NOUN
ajlm-840	118	20	antibiotics	antibiotic	NOUN
ajlm-840	118	21	using	use	VERB
ajlm-840	118	22	the	the	DET
ajlm-840	118	23	sensititre	sensititre	NOUN
ajlm-840	118	24	plate	plate	NOUN
ajlm-840	118	25	method	method	NOUN
ajlm-840	118	26	for	for	ADP
ajlm-840	118	27	clinical	clinical	ADJ
ajlm-840	118	28	multidrug	multidrug	NOUN
ajlm-840	118	29	-	-	PUNCT
ajlm-840	118	30	resistant	resistant	ADJ
ajlm-840	118	31	tuberculosis	tuberculosis	NOUN
ajlm-840	118	32	isolates	isolate	NOUN
ajlm-840	118	33	.	.	PUNCT
ajlm-840	119	1	(	(	PUNCT
ajlm-840	119	2	a	a	X
ajlm-840	119	3	)	)	PUNCT
ajlm-840	119	4	str	str	NOUN
ajlm-840	119	5	(	(	PUNCT
ajlm-840	119	6	25	25	NUM
ajlm-840	119	7	isolates	isolate	NOUN
ajlm-840	119	8	)	)	PUNCT
ajlm-840	119	9	,	,	PUNCT
ajlm-840	119	10	(	(	PUNCT
ajlm-840	119	11	b	b	X
ajlm-840	119	12	)	)	PUNCT
ajlm-840	119	13	rfb	rfb	PROPN
ajlm-840	119	14	(	(	PUNCT
ajlm-840	119	15	25	25	NUM
ajlm-840	119	16	isolates	isolate	NOUN
ajlm-840	119	17	)	)	PUNCT
ajlm-840	119	18	,	,	PUNCT
ajlm-840	119	19	(	(	PUNCT
ajlm-840	119	20	c	c	X
ajlm-840	119	21	)	)	PUNCT
ajlm-840	119	22	pas	pas	NOUN
ajlm-840	119	23	(	(	PUNCT
ajlm-840	119	24	25	25	NUM
ajlm-840	119	25	isolates	isolate	NOUN
ajlm-840	119	26	)	)	PUNCT
ajlm-840	119	27	,	,	PUNCT
ajlm-840	119	28	(	(	PUNCT
ajlm-840	119	29	d	d	X
ajlm-840	119	30	)	)	PUNCT
ajlm-840	119	31	cyc	cyc	NOUN
ajlm-840	119	32	(	(	PUNCT
ajlm-840	119	33	25	25	NUM
ajlm-840	119	34	isolates	isolate	NOUN
ajlm-840	119	35	)	)	PUNCT
ajlm-840	119	36	,	,	PUNCT
ajlm-840	119	37	(	(	PUNCT
ajlm-840	119	38	e	e	NOUN
ajlm-840	119	39	)	)	PUNCT
ajlm-840	119	40	ami	ami	NOUN
ajlm-840	119	41	(	(	PUNCT
ajlm-840	119	42	25	25	NUM
ajlm-840	119	43	isolates	isolate	NOUN
ajlm-840	119	44	)	)	PUNCT
ajlm-840	119	45	,	,	PUNCT
ajlm-840	119	46	(	(	PUNCT
ajlm-840	119	47	f	f	X
ajlm-840	119	48	)	)	PUNCT
ajlm-840	119	49	eth	eth	NOUN
ajlm-840	119	50	(	(	PUNCT
ajlm-840	119	51	25	25	NUM
ajlm-840	119	52	isolates	isolate	NOUN
ajlm-840	119	53	)	)	PUNCT
ajlm-840	119	54	and	and	CCONJ
ajlm-840	119	55	(	(	PUNCT
ajlm-840	119	56	g	g	NOUN
ajlm-840	119	57	)	)	PUNCT
ajlm-840	119	58	emb	emb	NOUN
ajlm-840	119	59	(	(	PUNCT
ajlm-840	119	60	25	25	NUM
ajlm-840	119	61	isolates	isolate	NOUN
ajlm-840	119	62	)	)	PUNCT
ajlm-840	119	63	,	,	PUNCT
ajlm-840	119	64	inkosi	inkosi	PROPN
ajlm-840	119	65	albert	albert	PROPN
ajlm-840	119	66	luthuli	luthuli	PROPN
ajlm-840	119	67	central	central	PROPN
ajlm-840	119	68	hospital	hospital	NOUN
ajlm-840	119	69	,	,	PUNCT
ajlm-840	119	70	durban	durban	PROPN
ajlm-840	119	71	,	,	PUNCT
ajlm-840	119	72	south	south	PROPN
ajlm-840	119	73	africa	africa	PROPN
ajlm-840	119	74	,	,	PUNCT
ajlm-840	119	75	january	january	PROPN
ajlm-840	119	76	2014	2014	NUM
ajlm-840	119	77	–	–	PUNCT
ajlm-840	119	78	june	june	PROPN
ajlm-840	119	79	2015	2015	NUM
ajlm-840	119	80	.	.	PUNCT
ajlm-840	120	1	most	most	ADJ
ajlm-840	120	2	(	(	PUNCT
ajlm-840	120	3	58/61	58/61	NUM
ajlm-840	120	4	,	,	PUNCT
ajlm-840	120	5	95	95	NUM
ajlm-840	120	6	%	%	NOUN
ajlm-840	120	7	)	)	PUNCT
ajlm-840	120	8	of	of	ADP
ajlm-840	120	9	the	the	DET
ajlm-840	120	10	xdr	xdr	PROPN
ajlm-840	120	11	isolates	isolate	NOUN
ajlm-840	120	12	displayed	display	VERB
ajlm-840	120	13	resistance	resistance	NOUN
ajlm-840	120	14	to	to	ADP
ajlm-840	120	15	para	para	NOUN
ajlm-840	120	16	-	-	PUNCT
ajlm-840	120	17	aminosalicyclic	aminosalicyclic	ADJ
ajlm-840	120	18	acid	acid	NOUN
ajlm-840	120	19	(	(	PUNCT
ajlm-840	120	20	figure	figure	NOUN
ajlm-840	120	21	4	4	NUM
ajlm-840	120	22	)	)	PUNCT
ajlm-840	120	23	.	.	PUNCT
ajlm-840	121	1	at	at	ADP
ajlm-840	121	2	an	an	DET
ajlm-840	121	3	mic	mic	NOUN
ajlm-840	121	4	of	of	ADP
ajlm-840	121	5	1	1	NUM
ajlm-840	121	6	µg	µg	NOUN
ajlm-840	121	7	/	/	SYM
ajlm-840	121	8	ml	ml	NOUN
ajlm-840	121	9	,	,	PUNCT
ajlm-840	121	10	76	76	NUM
ajlm-840	121	11	%	%	NOUN
ajlm-840	121	12	(	(	PUNCT
ajlm-840	121	13	19/25	19/25	NUM
ajlm-840	121	14	)	)	PUNCT
ajlm-840	121	15	of	of	ADP
ajlm-840	121	16	mdr	mdr	PROPN
ajlm-840	121	17	isolates	isolate	NOUN
ajlm-840	121	18	displayed	display	VERB
ajlm-840	121	19	susceptibility	susceptibility	NOUN
ajlm-840	121	20	to	to	ADP
ajlm-840	121	21	para	para	NOUN
ajlm-840	121	22	-	-	PUNCT
ajlm-840	121	23	aminosalicyclic	aminosalicyclic	ADJ
ajlm-840	121	24	acid	acid	NOUN
ajlm-840	121	25	(	(	PUNCT
ajlm-840	121	26	figure	figure	NOUN
ajlm-840	121	27	5	5	NUM
ajlm-840	121	28	)	)	PUNCT
ajlm-840	121	29	.	.	PUNCT
ajlm-840	122	1	resistance	resistance	NOUN
ajlm-840	122	2	to	to	ADP
ajlm-840	122	3	amikacin	amikacin	PROPN
ajlm-840	122	4	was	be	AUX
ajlm-840	122	5	observed	observe	VERB
ajlm-840	122	6	in	in	ADP
ajlm-840	122	7	46	46	NUM
ajlm-840	122	8	of	of	ADP
ajlm-840	122	9	the	the	DET
ajlm-840	122	10	62	62	NUM
ajlm-840	122	11	(	(	PUNCT
ajlm-840	122	12	74	74	NUM
ajlm-840	122	13	%	%	NOUN
ajlm-840	122	14	)	)	PUNCT
ajlm-840	122	15	xdr	xdr	PROPN
ajlm-840	122	16	isolates	isolate	NOUN
ajlm-840	122	17	(	(	PUNCT
ajlm-840	122	18	figure	figure	NOUN
ajlm-840	122	19	4	4	NUM
ajlm-840	122	20	)	)	PUNCT
ajlm-840	122	21	.	.	PUNCT
ajlm-840	123	1	most	most	ADJ
ajlm-840	123	2	(	(	PUNCT
ajlm-840	123	3	59/62	59/62	NUM
ajlm-840	123	4	,	,	PUNCT
ajlm-840	123	5	95	95	NUM
ajlm-840	123	6	%	%	NOUN
ajlm-840	123	7	)	)	PUNCT
ajlm-840	123	8	xdr	xdr	PROPN
ajlm-840	123	9	isolates	isolate	NOUN
ajlm-840	123	10	were	be	AUX
ajlm-840	123	11	resistant	resistant	ADJ
ajlm-840	123	12	to	to	PART
ajlm-840	123	13	ethambutol	ethambutol	VERB
ajlm-840	123	14	.	.	PUNCT
ajlm-840	124	1	conversely	conversely	ADV
ajlm-840	124	2	,	,	PUNCT
ajlm-840	124	3	91	91	NUM
ajlm-840	124	4	%	%	NOUN
ajlm-840	124	5	(	(	PUNCT
ajlm-840	124	6	21/23	21/23	PROPN
ajlm-840	124	7	)	)	PUNCT
ajlm-840	124	8	mdr	mdr	PROPN
ajlm-840	124	9	isolates	isolate	NOUN
ajlm-840	124	10	were	be	AUX
ajlm-840	124	11	susceptible	susceptible	ADJ
ajlm-840	124	12	to	to	ADP
ajlm-840	124	13	ethambutol	ethambutol	PROPN
ajlm-840	124	14	(	(	PUNCT
ajlm-840	124	15	figure	figure	NOUN
ajlm-840	124	16	5	5	NUM
ajlm-840	124	17	)	)	PUNCT
ajlm-840	124	18	.	.	PUNCT
ajlm-840	125	1	resistance	resistance	NOUN
ajlm-840	125	2	to	to	ADP
ajlm-840	125	3	amikacin	amikacin	PROPN
ajlm-840	125	4	was	be	AUX
ajlm-840	125	5	observed	observe	VERB
ajlm-840	125	6	in	in	ADP
ajlm-840	125	7	46	46	NUM
ajlm-840	125	8	of	of	ADP
ajlm-840	125	9	the	the	DET
ajlm-840	125	10	62	62	NUM
ajlm-840	125	11	(	(	PUNCT
ajlm-840	125	12	74	74	NUM
ajlm-840	125	13	%	%	NOUN
ajlm-840	125	14	)	)	PUNCT
ajlm-840	125	15	xdr	xdr	PROPN
ajlm-840	125	16	isolates	isolate	NOUN
ajlm-840	125	17	;	;	PUNCT
ajlm-840	125	18	the	the	DET
ajlm-840	125	19	majority	majority	NOUN
ajlm-840	125	20	(	(	PUNCT
ajlm-840	125	21	n	n	NOUN
ajlm-840	125	22	=	=	SYM
ajlm-840	125	23	23	23	NUM
ajlm-840	125	24	)	)	PUNCT
ajlm-840	125	25	of	of	ADP
ajlm-840	125	26	amikacin	amikacin	NOUN
ajlm-840	125	27	-	-	PUNCT
ajlm-840	125	28	resistant	resistant	ADJ
ajlm-840	125	29	isolates	isolate	NOUN
ajlm-840	125	30	had	have	VERB
ajlm-840	125	31	an	an	DET
ajlm-840	125	32	mic	mic	NOUN
ajlm-840	125	33	of	of	ADP
ajlm-840	125	34	greater	great	ADJ
ajlm-840	125	35	than	than	ADP
ajlm-840	125	36	16	16	NUM
ajlm-840	125	37	µg	µg	NOUN
ajlm-840	125	38	/	/	SYM
ajlm-840	125	39	ml	ml	PROPN
ajlm-840	125	40	(	(	PUNCT
ajlm-840	125	41	figure	figure	NOUN
ajlm-840	125	42	4	4	NUM
ajlm-840	125	43	)	)	PUNCT
ajlm-840	125	44	.	.	PUNCT
ajlm-840	126	1	in	in	ADP
ajlm-840	126	2	contrast	contrast	NOUN
ajlm-840	126	3	to	to	ADP
ajlm-840	126	4	this	this	PRON
ajlm-840	126	5	,	,	PUNCT
ajlm-840	126	6	all	all	PRON
ajlm-840	126	7	of	of	ADP
ajlm-840	126	8	the	the	DET
ajlm-840	126	9	25	25	NUM
ajlm-840	126	10	mdr	mdr	PROPN
ajlm-840	126	11	isolates	isolate	NOUN
ajlm-840	126	12	tested	test	VERB
ajlm-840	126	13	were	be	AUX
ajlm-840	126	14	susceptible	susceptible	ADJ
ajlm-840	126	15	to	to	ADP
ajlm-840	126	16	amikacin	amikacin	PROPN
ajlm-840	126	17	with	with	ADP
ajlm-840	126	18	a	a	DET
ajlm-840	126	19	large	large	ADJ
ajlm-840	126	20	proportion	proportion	NOUN
ajlm-840	126	21	76	76	NUM
ajlm-840	126	22	%	%	NOUN
ajlm-840	126	23	(	(	PUNCT
ajlm-840	126	24	19/25	19/25	NUM
ajlm-840	126	25	)	)	PUNCT
ajlm-840	126	26	showing	show	VERB
ajlm-840	126	27	an	an	DET
ajlm-840	126	28	mic	mic	NOUN
ajlm-840	126	29	of	of	ADP
ajlm-840	126	30	0.25	0.25	NUM
ajlm-840	126	31	µg	µg	NOUN
ajlm-840	126	32	/	/	SYM
ajlm-840	126	33	ml	ml	PROPN
ajlm-840	126	34	(	(	PUNCT
ajlm-840	126	35	figure	figure	NOUN
ajlm-840	126	36	5	5	NUM
ajlm-840	126	37	)	)	PUNCT
ajlm-840	126	38	.	.	PUNCT
ajlm-840	127	1	more	more	ADJ
ajlm-840	127	2	than	than	ADP
ajlm-840	127	3	half	half	NOUN
ajlm-840	127	4	(	(	PUNCT
ajlm-840	127	5	37/62	37/62	NUM
ajlm-840	127	6	,	,	PUNCT
ajlm-840	127	7	60	60	NUM
ajlm-840	127	8	%	%	NOUN
ajlm-840	127	9	)	)	PUNCT
ajlm-840	127	10	of	of	ADP
ajlm-840	127	11	xdr	xdr	PROPN
ajlm-840	127	12	isolates	isolate	NOUN
ajlm-840	127	13	were	be	AUX
ajlm-840	127	14	resistant	resistant	ADJ
ajlm-840	127	15	to	to	PART
ajlm-840	127	16	ethionamide	ethionamide	VERB
ajlm-840	127	17	with	with	ADP
ajlm-840	127	18	an	an	DET
ajlm-840	127	19	mic	mic	NOUN
ajlm-840	127	20	of	of	ADP
ajlm-840	127	21	40	40	NUM
ajlm-840	127	22	µg	µg	NOUN
ajlm-840	127	23	/	/	SYM
ajlm-840	127	24	ml	ml	NOUN
ajlm-840	127	25	or	or	CCONJ
ajlm-840	127	26	more	more	ADJ
ajlm-840	127	27	(	(	PUNCT
ajlm-840	127	28	figure	figure	NOUN
ajlm-840	127	29	4	4	NUM
ajlm-840	127	30	)	)	PUNCT
ajlm-840	127	31	.	.	PUNCT
ajlm-840	128	1	among	among	ADP
ajlm-840	128	2	the	the	DET
ajlm-840	128	3	ethionamide	ethionamide	NOUN
ajlm-840	128	4	susceptible	susceptible	ADJ
ajlm-840	128	5	isolates	isolate	NOUN
ajlm-840	128	6	,	,	PUNCT
ajlm-840	128	7	92	92	NUM
ajlm-840	128	8	%	%	NOUN
ajlm-840	128	9	(	(	PUNCT
ajlm-840	128	10	23/25	23/25	NUM
ajlm-840	128	11	)	)	PUNCT
ajlm-840	128	12	were	be	AUX
ajlm-840	128	13	mdr	mdr	PROPN
ajlm-840	128	14	with	with	ADP
ajlm-840	128	15	83	83	NUM
ajlm-840	128	16	%	%	NOUN
ajlm-840	128	17	(	(	PUNCT
ajlm-840	128	18	19/23	19/23	NUM
ajlm-840	128	19	)	)	PUNCT
ajlm-840	128	20	showing	show	VERB
ajlm-840	128	21	an	an	DET
ajlm-840	128	22	mic	mic	NOUN
ajlm-840	128	23	of	of	ADP
ajlm-840	128	24	0.6	0.6	NUM
ajlm-840	128	25	µg	µg	NOUN
ajlm-840	128	26	/	/	SYM
ajlm-840	128	27	ml	ml	PROPN
ajlm-840	128	28	(	(	PUNCT
ajlm-840	128	29	figure	figure	NOUN
ajlm-840	128	30	5	5	NUM
ajlm-840	128	31	)	)	PUNCT
ajlm-840	128	32	.	.	PUNCT
ajlm-840	129	1	resistance	resistance	NOUN
ajlm-840	129	2	to	to	ADP
ajlm-840	129	3	streptomycin	streptomycin	PROPN
ajlm-840	129	4	was	be	AUX
ajlm-840	129	5	observed	observe	VERB
ajlm-840	129	6	in	in	ADP
ajlm-840	129	7	90	90	NUM
ajlm-840	129	8	%	%	NOUN
ajlm-840	129	9	(	(	PUNCT
ajlm-840	129	10	54/60	54/60	NUM
ajlm-840	129	11	)	)	PUNCT
ajlm-840	129	12	of	of	ADP
ajlm-840	129	13	xdr	xdr	PROPN
ajlm-840	129	14	isolates	isolate	NOUN
ajlm-840	129	15	with	with	ADP
ajlm-840	129	16	a	a	DET
ajlm-840	129	17	large	large	ADJ
ajlm-840	129	18	proportion	proportion	NOUN
ajlm-840	129	19	of	of	ADP
ajlm-840	129	20	the	the	DET
ajlm-840	129	21	streptomycin	streptomycin	NOUN
ajlm-840	129	22	-	-	PUNCT
ajlm-840	129	23	resistant	resistant	ADJ
ajlm-840	129	24	isolates	isolate	NOUN
ajlm-840	129	25	,	,	PUNCT
ajlm-840	129	26	40	40	NUM
ajlm-840	129	27	%	%	NOUN
ajlm-840	129	28	(	(	PUNCT
ajlm-840	129	29	22/54	22/54	NUM
ajlm-840	129	30	)	)	PUNCT
ajlm-840	129	31	,	,	PUNCT
ajlm-840	129	32	showing	show	VERB
ajlm-840	129	33	an	an	DET
ajlm-840	129	34	mic	mic	NOUN
ajlm-840	129	35	of	of	ADP
ajlm-840	129	36	more	more	ADJ
ajlm-840	129	37	than	than	ADP
ajlm-840	129	38	32	32	NUM
ajlm-840	129	39	µg	µg	NOUN
ajlm-840	129	40	/	/	SYM
ajlm-840	129	41	ml	ml	PROPN
ajlm-840	129	42	(	(	PUNCT
ajlm-840	129	43	figure	figure	NOUN
ajlm-840	129	44	4	4	NUM
ajlm-840	129	45	)	)	PUNCT
ajlm-840	129	46	.	.	PUNCT
ajlm-840	130	1	a	a	DET
ajlm-840	130	2	susceptible	susceptible	ADJ
ajlm-840	130	3	streptomycin	streptomycin	PROPN
ajlm-840	130	4	mic	mic	NOUN
ajlm-840	130	5	of	of	ADP
ajlm-840	130	6	0.5	0.5	NUM
ajlm-840	130	7	µg	µg	NOUN
ajlm-840	130	8	/	/	SYM
ajlm-840	130	9	ml	ml	NOUN
ajlm-840	130	10	was	be	AUX
ajlm-840	130	11	observed	observe	VERB
ajlm-840	130	12	in	in	ADP
ajlm-840	130	13	19	19	NUM
ajlm-840	130	14	of	of	ADP
ajlm-840	130	15	the	the	DET
ajlm-840	130	16	25	25	NUM
ajlm-840	130	17	mdr	mdr	PROPN
ajlm-840	130	18	isolates	isolate	NOUN
ajlm-840	130	19	(	(	PUNCT
ajlm-840	130	20	figure	figure	NOUN
ajlm-840	130	21	5	5	NUM
ajlm-840	130	22	)	)	PUNCT
ajlm-840	130	23	.	.	PUNCT
ajlm-840	131	1	most	most	ADJ
ajlm-840	131	2	xdr	xdr	PROPN
ajlm-840	131	3	isolates	isolate	NOUN
ajlm-840	131	4	(	(	PUNCT
ajlm-840	131	5	54/61	54/61	NUM
ajlm-840	131	6	,	,	PUNCT
ajlm-840	131	7	80	80	NUM
ajlm-840	131	8	%	%	NOUN
ajlm-840	131	9	)	)	PUNCT
ajlm-840	131	10	and	and	CCONJ
ajlm-840	131	11	12	12	NUM
ajlm-840	131	12	%	%	NOUN
ajlm-840	131	13	(	(	PUNCT
ajlm-840	131	14	3/25	3/25	NUM
ajlm-840	131	15	)	)	PUNCT
ajlm-840	131	16	of	of	ADP
ajlm-840	131	17	mdr	mdr	PROPN
ajlm-840	131	18	isolates	isolate	NOUN
ajlm-840	131	19	had	have	VERB
ajlm-840	131	20	mics	mic	NOUN
ajlm-840	131	21	for	for	ADP
ajlm-840	131	22	cycloserine	cycloserine	NOUN
ajlm-840	131	23	of	of	ADP
ajlm-840	131	24	32	32	NUM
ajlm-840	131	25	µg	µg	NOUN
ajlm-840	131	26	/	/	SYM
ajlm-840	131	27	ml	ml	NOUN
ajlm-840	131	28	or	or	CCONJ
ajlm-840	131	29	more	more	ADJ
ajlm-840	131	30	(	(	PUNCT
ajlm-840	131	31	critical	critical	ADJ
ajlm-840	131	32	concentration	concentration	NOUN
ajlm-840	131	33	of	of	ADP
ajlm-840	131	34	30	30	NUM
ajlm-840	131	35	µg	µg	NOUN
ajlm-840	131	36	/	/	SYM
ajlm-840	131	37	ml	ml	NOUN
ajlm-840	131	38	;	;	PUNCT
ajlm-840	131	39	resistant	resistant	ADJ
ajlm-840	131	40	by	by	ADP
ajlm-840	131	41	apm	apm	NOUN
ajlm-840	131	42	)	)	PUNCT
ajlm-840	131	43	(	(	PUNCT
ajlm-840	131	44	figures	figure	NOUN
ajlm-840	131	45	4	4	NUM
ajlm-840	131	46	and	and	CCONJ
ajlm-840	131	47	5	5	NUM
ajlm-840	131	48	)	)	PUNCT
ajlm-840	131	49	.	.	PUNCT
ajlm-840	132	1	discussion	discussion	NOUN
ajlm-840	132	2	the	the	DET
ajlm-840	132	3	objective	objective	NOUN
ajlm-840	132	4	of	of	ADP
ajlm-840	132	5	tuberculosis	tuberculosis	NOUN
ajlm-840	132	6	dst	dst	NOUN
ajlm-840	132	7	is	be	AUX
ajlm-840	132	8	to	to	PART
ajlm-840	132	9	determine	determine	VERB
ajlm-840	132	10	resistant	resistant	ADJ
ajlm-840	132	11	strains	strain	NOUN
ajlm-840	132	12	that	that	PRON
ajlm-840	132	13	are	be	AUX
ajlm-840	132	14	prognostic	prognostic	ADJ
ajlm-840	132	15	of	of	ADP
ajlm-840	132	16	treatment	treatment	NOUN
ajlm-840	132	17	failure	failure	NOUN
ajlm-840	132	18	and	and	CCONJ
ajlm-840	132	19	relapse	relapse	NOUN
ajlm-840	132	20	.	.	PUNCT
ajlm-840	133	1	the	the	DET
ajlm-840	133	2	sensititre	sensititre	PROPN
ajlm-840	133	3	®	®	PROPN
ajlm-840	133	4	mycotb	mycotb	NOUN
ajlm-840	133	5	assay	assay	PROPN
ajlm-840	133	6	provides	provide	VERB
ajlm-840	133	7	a	a	DET
ajlm-840	133	8	faster	fast	ADJ
ajlm-840	133	9	method	method	NOUN
ajlm-840	133	10	of	of	ADP
ajlm-840	133	11	testing	testing	NOUN
ajlm-840	133	12	firstand	firstand	NOUN
ajlm-840	133	13	second	second	ADJ
ajlm-840	133	14	-	-	PUNCT
ajlm-840	133	15	line	line	NOUN
ajlm-840	133	16	tuberculosis	tuberculosis	NOUN
ajlm-840	133	17	drugs	drug	NOUN
ajlm-840	133	18	and	and	CCONJ
ajlm-840	133	19	displayed	display	VERB
ajlm-840	133	20	99.3	99.3	NUM
ajlm-840	133	21	%	%	NOUN
ajlm-840	133	22	concordance	concordance	NOUN
ajlm-840	133	23	with	with	ADP
ajlm-840	133	24	the	the	DET
ajlm-840	133	25	agar	agar	NOUN
ajlm-840	133	26	proportion	proportion	NOUN
ajlm-840	133	27	method	method	NOUN
ajlm-840	133	28	in	in	ADP
ajlm-840	133	29	prior	prior	ADJ
ajlm-840	133	30	studies.19	studies.19	NOUN
ajlm-840	133	31	in	in	ADP
ajlm-840	133	32	our	our	PRON
ajlm-840	133	33	study	study	NOUN
ajlm-840	133	34	,	,	PUNCT
ajlm-840	133	35	the	the	DET
ajlm-840	133	36	percentage	percentage	NOUN
ajlm-840	133	37	agreements	agreement	NOUN
ajlm-840	133	38	between	between	ADP
ajlm-840	133	39	sensititre	sensititre	NOUN
ajlm-840	133	40	plate	plate	NOUN
ajlm-840	133	41	and	and	CCONJ
ajlm-840	133	42	apm	apm	NOUN
ajlm-840	133	43	for	for	ADP
ajlm-840	133	44	resistant	resistant	ADJ
ajlm-840	133	45	isoniazid	isoniazid	NOUN
ajlm-840	133	46	(	(	PUNCT
ajlm-840	133	47	97	97	NUM
ajlm-840	133	48	%	%	NOUN
ajlm-840	133	49	)	)	PUNCT
ajlm-840	133	50	,	,	PUNCT
ajlm-840	133	51	rifampicin	rifampicin	VERB
ajlm-840	133	52	(	(	PUNCT
ajlm-840	133	53	98	98	NUM
ajlm-840	133	54	%	%	NOUN
ajlm-840	133	55	)	)	PUNCT
ajlm-840	133	56	,	,	PUNCT
ajlm-840	133	57	moxifloxacin	moxifloxacin	NUM
ajlm-840	133	58	(	(	PUNCT
ajlm-840	133	59	91	91	NUM
ajlm-840	133	60	%	%	NOUN
ajlm-840	133	61	)	)	PUNCT
ajlm-840	133	62	and	and	CCONJ
ajlm-840	133	63	ofloxacin	ofloxacin	NOUN
ajlm-840	133	64	(	(	PUNCT
ajlm-840	133	65	100	100	NUM
ajlm-840	133	66	%	%	NOUN
ajlm-840	133	67	)	)	PUNCT
ajlm-840	133	68	were	be	AUX
ajlm-840	133	69	found	find	VERB
ajlm-840	133	70	in	in	ADP
ajlm-840	133	71	similar	similar	ADJ
ajlm-840	133	72	studies	study	NOUN
ajlm-840	133	73	;	;	PUNCT
ajlm-840	133	74	however	however	ADV
ajlm-840	133	75	,	,	PUNCT
ajlm-840	133	76	kanamycin	kanamycin	PROPN
ajlm-840	133	77	had	have	VERB
ajlm-840	133	78	the	the	DET
ajlm-840	133	79	lowest	low	ADJ
ajlm-840	133	80	categorical	categorical	ADJ
ajlm-840	133	81	agreement	agreement	NOUN
ajlm-840	133	82	with	with	ADP
ajlm-840	133	83	the	the	DET
ajlm-840	133	84	apm	apm	NOUN
ajlm-840	133	85	(	(	PUNCT
ajlm-840	133	86	92%).19	92%).19	NUM
ajlm-840	133	87	discrepant	discrepant	VERB
ajlm-840	133	88	moxifloxacin	moxifloxacin	NOUN
ajlm-840	133	89	(	(	PUNCT
ajlm-840	133	90	apm	apm	NOUN
ajlm-840	133	91	susceptible	susceptible	ADJ
ajlm-840	133	92	)	)	PUNCT
ajlm-840	133	93	isolates	isolate	NOUN
ajlm-840	133	94	could	could	AUX
ajlm-840	133	95	be	be	AUX
ajlm-840	133	96	due	due	ADJ
ajlm-840	133	97	to	to	ADP
ajlm-840	133	98	the	the	DET
ajlm-840	133	99	subjectivity	subjectivity	NOUN
ajlm-840	133	100	of	of	ADP
ajlm-840	133	101	the	the	DET
ajlm-840	133	102	microtitre	microtitre	NOUN
ajlm-840	133	103	plate	plate	NOUN
ajlm-840	133	104	reading	reading	NOUN
ajlm-840	133	105	.	.	PUNCT
ajlm-840	134	1	a	a	DET
ajlm-840	134	2	discrepant	discrepant	ADJ
ajlm-840	134	3	analysis	analysis	NOUN
ajlm-840	134	4	would	would	AUX
ajlm-840	134	5	be	be	AUX
ajlm-840	134	6	useful	useful	ADJ
ajlm-840	134	7	to	to	PART
ajlm-840	134	8	clarify	clarify	VERB
ajlm-840	134	9	discordant	discordant	ADJ
ajlm-840	134	10	results	result	NOUN
ajlm-840	134	11	,	,	PUNCT
ajlm-840	134	12	for	for	ADP
ajlm-840	134	13	example	example	NOUN
ajlm-840	134	14	,	,	PUNCT
ajlm-840	134	15	repeat	repeat	NOUN
ajlm-840	134	16	testing	testing	NOUN
ajlm-840	134	17	of	of	ADP
ajlm-840	134	18	isolates	isolate	NOUN
ajlm-840	134	19	and	and	CCONJ
ajlm-840	134	20	ruling	rule	VERB
ajlm-840	134	21	out	out	ADP
ajlm-840	134	22	technical	technical	ADJ
ajlm-840	134	23	errors	error	NOUN
ajlm-840	134	24	.	.	PUNCT
ajlm-840	135	1	according	accord	VERB
ajlm-840	135	2	to	to	ADP
ajlm-840	135	3	the	the	DET
ajlm-840	135	4	who	who	PRON
ajlm-840	135	5	,	,	PUNCT
ajlm-840	135	6	current	current	ADJ
ajlm-840	135	7	critical	critical	ADJ
ajlm-840	135	8	concentrations	concentration	NOUN
ajlm-840	135	9	of	of	ADP
ajlm-840	135	10	all	all	DET
ajlm-840	135	11	anti	anti	ADJ
ajlm-840	135	12	-	-	ADJ
ajlm-840	135	13	tuberculosis	tuberculosis	ADJ
ajlm-840	135	14	drugs	drug	NOUN
ajlm-840	135	15	will	will	AUX
ajlm-840	135	16	be	be	AUX
ajlm-840	135	17	reviewed.1	reviewed.1	NOUN
ajlm-840	135	18	as	as	SCONJ
ajlm-840	135	19	phenotypic	phenotypic	ADJ
ajlm-840	135	20	dst	dst	NOUN
ajlm-840	135	21	is	be	AUX
ajlm-840	135	22	required	require	VERB
ajlm-840	135	23	for	for	ADP
ajlm-840	135	24	the	the	DET
ajlm-840	135	25	determination	determination	NOUN
ajlm-840	135	26	of	of	ADP
ajlm-840	135	27	moxifloxacin	moxifloxacin	ADJ
ajlm-840	135	28	susceptibility	susceptibility	NOUN
ajlm-840	135	29	(	(	PUNCT
ajlm-840	135	30	who	who	PRON
ajlm-840	135	31	recommendation	recommendation	VERB
ajlm-840	135	32	due	due	ADJ
ajlm-840	135	33	to	to	ADP
ajlm-840	135	34	poor	poor	ADJ
ajlm-840	135	35	concordance	concordance	NOUN
ajlm-840	135	36	of	of	ADP
ajlm-840	135	37	genotype	genotype	NOUN
ajlm-840	135	38	mtbdrsl	mtbdrsl	NOUN
ajlm-840	135	39	with	with	ADP
ajlm-840	135	40	apm	apm	NOUN
ajlm-840	135	41	)	)	PUNCT
ajlm-840	135	42	,	,	PUNCT
ajlm-840	135	43	this	this	PRON
ajlm-840	135	44	might	might	AUX
ajlm-840	135	45	prove	prove	VERB
ajlm-840	135	46	problematic	problematic	ADJ
ajlm-840	135	47	if	if	SCONJ
ajlm-840	135	48	the	the	DET
ajlm-840	135	49	sensititre	sensititre	NOUN
ajlm-840	135	50	®	®	PROPN
ajlm-840	135	51	mycotb	mycotb	PROPN
ajlm-840	135	52	assay	assay	PROPN
ajlm-840	135	53	is	be	AUX
ajlm-840	135	54	used.1	used.1	NOUN
ajlm-840	135	55	the	the	DET
ajlm-840	135	56	distribution	distribution	NOUN
ajlm-840	135	57	of	of	ADP
ajlm-840	135	58	mic	mic	NOUN
ajlm-840	135	59	with	with	ADP
ajlm-840	135	60	regard	regard	NOUN
ajlm-840	135	61	to	to	ADP
ajlm-840	135	62	second	second	ADJ
ajlm-840	135	63	-	-	PUNCT
ajlm-840	135	64	line	line	NOUN
ajlm-840	135	65	tuberculosis	tuberculosis	NOUN
ajlm-840	135	66	antimicrobials	antimicrobial	NOUN
ajlm-840	135	67	among	among	ADP
ajlm-840	135	68	mdr	mdr	PROPN
ajlm-840	135	69	and	and	CCONJ
ajlm-840	135	70	xdr	xdr	PROPN
ajlm-840	135	71	isolates	isolate	NOUN
ajlm-840	135	72	was	be	AUX
ajlm-840	135	73	clearly	clearly	ADV
ajlm-840	135	74	evident	evident	ADJ
ajlm-840	135	75	as	as	ADP
ajlm-840	135	76	rising	rise	VERB
ajlm-840	135	77	mic	mic	ADJ
ajlm-840	135	78	values	value	NOUN
ajlm-840	135	79	with	with	ADP
ajlm-840	135	80	the	the	DET
ajlm-840	135	81	increasingly	increasingly	ADV
ajlm-840	135	82	mdr	mdr	PROPN
ajlm-840	135	83	strains	strain	NOUN
ajlm-840	135	84	.	.	PUNCT
ajlm-840	136	1	resistance	resistance	NOUN
ajlm-840	136	2	to	to	ADP
ajlm-840	136	3	capreomycin	capreomycin	PROPN
ajlm-840	136	4	has	have	AUX
ajlm-840	136	5	been	be	AUX
ajlm-840	136	6	documented	document	VERB
ajlm-840	136	7	in	in	ADP
ajlm-840	136	8	kwazulu	kwazulu	NOUN
ajlm-840	136	9	-	-	PUNCT
ajlm-840	136	10	natal	natal	NOUN
ajlm-840	136	11	in	in	ADP
ajlm-840	136	12	approximately	approximately	ADV
ajlm-840	136	13	90	90	NUM
ajlm-840	136	14	%	%	NOUN
ajlm-840	136	15	of	of	ADP
ajlm-840	136	16	xdr	xdr	PROPN
ajlm-840	136	17	isolates	isolate	NOUN
ajlm-840	136	18	of	of	ADP
ajlm-840	136	19	newly	newly	ADV
ajlm-840	136	20	diagnosed	diagnose	VERB
ajlm-840	136	21	individuals.17,19	individuals.17,19	NOUN
ajlm-840	136	22	both	both	PRON
ajlm-840	136	23	ethambutol	ethambutol	ADJ
ajlm-840	136	24	and	and	CCONJ
ajlm-840	136	25	pyrazinamide	pyrazinamide	VERB
ajlm-840	136	26	resistance	resistance	NOUN
ajlm-840	136	27	has	have	AUX
ajlm-840	136	28	been	be	AUX
ajlm-840	136	29	reported	report	VERB
ajlm-840	136	30	as	as	ADP
ajlm-840	136	31	exceeding	exceed	VERB
ajlm-840	136	32	60	60	NUM
ajlm-840	136	33	%	%	NOUN
ajlm-840	136	34	,	,	PUNCT
ajlm-840	136	35	the	the	DET
ajlm-840	136	36	first	first	ADJ
ajlm-840	136	37	-	-	PUNCT
ajlm-840	136	38	line	line	NOUN
ajlm-840	136	39	drugs	drug	NOUN
ajlm-840	136	40	composing	compose	VERB
ajlm-840	136	41	the	the	DET
ajlm-840	136	42	bangladesh	bangladesh	NOUN
ajlm-840	136	43	regimen	regiman	NOUN
ajlm-840	136	44	,	,	PUNCT
ajlm-840	136	45	as	as	SCONJ
ajlm-840	136	46	described	describe	VERB
ajlm-840	136	47	in	in	ADP
ajlm-840	136	48	previous	previous	ADJ
ajlm-840	136	49	studies.8	studies.8	PROPN
ajlm-840	136	50	the	the	DET
ajlm-840	136	51	sensititre	sensititre	PROPN
ajlm-840	136	52	®	®	PROPN
ajlm-840	136	53	mycotb	mycotb	PROPN
ajlm-840	136	54	plate	plate	NOUN
ajlm-840	136	55	rapidly	rapidly	ADV
ajlm-840	136	56	produced	produce	VERB
ajlm-840	136	57	results	result	NOUN
ajlm-840	136	58	in	in	ADP
ajlm-840	136	59	comparison	comparison	NOUN
ajlm-840	136	60	to	to	ADP
ajlm-840	136	61	the	the	DET
ajlm-840	136	62	apm	apm	NOUN
ajlm-840	136	63	,	,	PUNCT
ajlm-840	136	64	however	however	ADV
ajlm-840	136	65	,	,	PUNCT
ajlm-840	136	66	it	it	PRON
ajlm-840	136	67	produced	produce	VERB
ajlm-840	136	68	44	44	NUM
ajlm-840	136	69	%	%	NOUN
ajlm-840	136	70	(	(	PUNCT
ajlm-840	136	71	15/34	15/34	NUM
ajlm-840	136	72	)	)	PUNCT
ajlm-840	136	73	false	false	ADJ
ajlm-840	136	74	rifampicin	rifampicin	NOUN
ajlm-840	136	75	-	-	PUNCT
ajlm-840	136	76	resistant	resistant	ADJ
ajlm-840	136	77	isolates	isolate	NOUN
ajlm-840	136	78	(	(	PUNCT
ajlm-840	136	79	sensitive	sensitive	ADJ
ajlm-840	136	80	by	by	ADP
ajlm-840	136	81	apm	apm	NOUN
ajlm-840	136	82	)	)	PUNCT
ajlm-840	136	83	.	.	PUNCT
ajlm-840	137	1	the	the	DET
ajlm-840	137	2	treatment	treatment	NOUN
ajlm-840	137	3	implication	implication	NOUN
ajlm-840	137	4	would	would	AUX
ajlm-840	137	5	include	include	VERB
ajlm-840	137	6	patients	patient	NOUN
ajlm-840	137	7	who	who	PRON
ajlm-840	137	8	were	be	AUX
ajlm-840	137	9	mismanaged	mismanage	VERB
ajlm-840	137	10	with	with	ADP
ajlm-840	137	11	prolonged	prolonged	ADJ
ajlm-840	137	12	,	,	PUNCT
ajlm-840	137	13	toxic	toxic	ADJ
ajlm-840	137	14	second	second	ADJ
ajlm-840	137	15	-	-	PUNCT
ajlm-840	137	16	line	line	NOUN
ajlm-840	137	17	therapy	therapy	NOUN
ajlm-840	137	18	in	in	ADP
ajlm-840	137	19	an	an	DET
ajlm-840	137	20	mdr	mdr	PROPN
ajlm-840	137	21	facility	facility	NOUN
ajlm-840	137	22	.	.	PUNCT
ajlm-840	138	1	the	the	DET
ajlm-840	138	2	rema	rema	PROPN
ajlm-840	138	3	assay	assay	VERB
ajlm-840	138	4	had	have	VERB
ajlm-840	138	5	a	a	DET
ajlm-840	138	6	relatively	relatively	ADV
ajlm-840	138	7	short	short	ADJ
ajlm-840	138	8	turnaround	turnaround	NOUN
ajlm-840	138	9	time	time	NOUN
ajlm-840	138	10	of	of	ADP
ajlm-840	138	11	9	9	NUM
ajlm-840	138	12	days.21	days.21	ADJ
ajlm-840	138	13	delays	delay	NOUN
ajlm-840	138	14	in	in	ADP
ajlm-840	138	15	results	result	NOUN
ajlm-840	138	16	retrieval	retrieval	NOUN
ajlm-840	138	17	and	and	CCONJ
ajlm-840	138	18	therefore	therefore	ADV
ajlm-840	138	19	suitable	suitable	ADJ
ajlm-840	138	20	treatment	treatment	NOUN
ajlm-840	138	21	options	option	NOUN
ajlm-840	138	22	for	for	ADP
ajlm-840	138	23	resistant	resistant	ADJ
ajlm-840	138	24	tuberculosis	tuberculosis	NOUN
ajlm-840	138	25	may	may	AUX
ajlm-840	138	26	result	result	VERB
ajlm-840	138	27	in	in	ADP
ajlm-840	138	28	the	the	DET
ajlm-840	138	29	further	further	ADJ
ajlm-840	138	30	selection	selection	NOUN
ajlm-840	138	31	of	of	ADP
ajlm-840	138	32	resistant	resistant	ADJ
ajlm-840	138	33	m.	m.	NOUN
ajlm-840	138	34	tuberculosis	tuberculosis	NOUN
ajlm-840	138	35	,	,	PUNCT
ajlm-840	138	36	morbidity	morbidity	NOUN
ajlm-840	138	37	and	and	CCONJ
ajlm-840	138	38	mortality	mortality	NOUN
ajlm-840	138	39	in	in	ADP
ajlm-840	138	40	patients	patient	NOUN
ajlm-840	138	41	afflicted	afflict	VERB
ajlm-840	138	42	with	with	ADP
ajlm-840	138	43	the	the	DET
ajlm-840	138	44	disease	disease	NOUN
ajlm-840	138	45	.	.	PUNCT
ajlm-840	139	1	advantages	advantage	NOUN
ajlm-840	139	2	of	of	ADP
ajlm-840	139	3	the	the	DET
ajlm-840	139	4	rema	rema	NOUN
ajlm-840	139	5	format	format	NOUN
ajlm-840	139	6	are	be	AUX
ajlm-840	139	7	that	that	SCONJ
ajlm-840	139	8	it	it	PRON
ajlm-840	139	9	is	be	AUX
ajlm-840	139	10	faster	fast	ADJ
ajlm-840	139	11	,	,	PUNCT
ajlm-840	139	12	low	low	ADJ
ajlm-840	139	13	cost	cost	NOUN
ajlm-840	139	14	,	,	PUNCT
ajlm-840	139	15	easy	easy	ADJ
ajlm-840	139	16	to	to	PART
ajlm-840	139	17	interpret	interpret	VERB
ajlm-840	139	18	and	and	CCONJ
ajlm-840	139	19	does	do	AUX
ajlm-840	139	20	not	not	PART
ajlm-840	139	21	need	need	VERB
ajlm-840	139	22	special	special	ADJ
ajlm-840	139	23	equipment.21	equipment.21	NOUN
ajlm-840	139	24	a	a	DET
ajlm-840	139	25	disadvantage	disadvantage	NOUN
ajlm-840	139	26	of	of	ADP
ajlm-840	139	27	this	this	DET
ajlm-840	139	28	method	method	NOUN
ajlm-840	139	29	is	be	AUX
ajlm-840	139	30	the	the	DET
ajlm-840	139	31	potential	potential	NOUN
ajlm-840	139	32	for	for	ADP
ajlm-840	139	33	aerosolisation	aerosolisation	NOUN
ajlm-840	139	34	since	since	SCONJ
ajlm-840	139	35	the	the	DET
ajlm-840	139	36	plates	plate	NOUN
ajlm-840	139	37	utilise	utilise	VERB
ajlm-840	139	38	a	a	DET
ajlm-840	139	39	liquid	liquid	ADJ
ajlm-840	139	40	medium	medium	NOUN
ajlm-840	139	41	resulting	result	VERB
ajlm-840	139	42	in	in	ADP
ajlm-840	139	43	a	a	DET
ajlm-840	139	44	biosafety	biosafety	NOUN
ajlm-840	139	45	hazard.15	hazard.15	NOUN
ajlm-840	139	46	in	in	ADP
ajlm-840	139	47	our	our	PRON
ajlm-840	139	48	study	study	NOUN
ajlm-840	139	49	,	,	PUNCT
ajlm-840	139	50	rema	rema	PROPN
ajlm-840	139	51	proved	prove	VERB
ajlm-840	139	52	to	to	PART
ajlm-840	139	53	be	be	AUX
ajlm-840	139	54	labour	labour	NOUN
ajlm-840	139	55	-	-	PUNCT
ajlm-840	139	56	intensive	intensive	ADJ
ajlm-840	139	57	,	,	PUNCT
ajlm-840	139	58	requiring	require	VERB
ajlm-840	139	59	individual	individual	ADJ
ajlm-840	139	60	drug	drug	NOUN
ajlm-840	139	61	and	and	CCONJ
ajlm-840	139	62	dye	dye	NOUN
ajlm-840	139	63	preparation	preparation	NOUN
ajlm-840	139	64	,	,	PUNCT
ajlm-840	139	65	as	as	ADV
ajlm-840	139	66	well	well	ADV
ajlm-840	139	67	as	as	ADP
ajlm-840	139	68	tedious	tedious	ADJ
ajlm-840	139	69	microtitre	microtitre	NOUN
ajlm-840	139	70	plate	plate	NOUN
ajlm-840	139	71	inoculation	inoculation	NOUN
ajlm-840	139	72	.	.	PUNCT
ajlm-840	140	1	the	the	DET
ajlm-840	140	2	current	current	ADJ
ajlm-840	140	3	study	study	NOUN
ajlm-840	140	4	showed	show	VERB
ajlm-840	140	5	the	the	DET
ajlm-840	140	6	sensitivity	sensitivity	NOUN
ajlm-840	140	7	and	and	CCONJ
ajlm-840	140	8	specificity	specificity	NOUN
ajlm-840	140	9	of	of	ADP
ajlm-840	140	10	the	the	DET
ajlm-840	140	11	rema	rema	NOUN
ajlm-840	140	12	are	be	AUX
ajlm-840	140	13	comparable	comparable	ADJ
ajlm-840	140	14	to	to	ADP
ajlm-840	140	15	that	that	PRON
ajlm-840	140	16	of	of	ADP
ajlm-840	140	17	the	the	DET
ajlm-840	140	18	apm	apm	NOUN
ajlm-840	140	19	for	for	ADP
ajlm-840	140	20	isoniazid	isoniazid	NOUN
ajlm-840	140	21	,	,	PUNCT
ajlm-840	140	22	rifampicin	rifampicin	VERB
ajlm-840	140	23	,	,	PUNCT
ajlm-840	140	24	capreomycin	capreomycin	PROPN
ajlm-840	140	25	,	,	PUNCT
ajlm-840	140	26	moxifloxacin	moxifloxacin	NOUN
ajlm-840	140	27	and	and	CCONJ
ajlm-840	140	28	kanamycin	kanamycin	NOUN
ajlm-840	140	29	to	to	PART
ajlm-840	140	30	be	be	AUX
ajlm-840	140	31	comparable	comparable	ADJ
ajlm-840	140	32	to	to	ADP
ajlm-840	140	33	previous	previous	ADJ
ajlm-840	140	34	studies.21	studies.21	PROPN
ajlm-840	140	35	agreement	agreement	NOUN
ajlm-840	140	36	between	between	ADP
ajlm-840	140	37	rema	rema	NOUN
ajlm-840	140	38	and	and	CCONJ
ajlm-840	140	39	the	the	DET
ajlm-840	140	40	apm	apm	NOUN
ajlm-840	140	41	was	be	AUX
ajlm-840	140	42	over	over	ADP
ajlm-840	140	43	90	90	NUM
ajlm-840	140	44	%	%	NOUN
ajlm-840	140	45	for	for	ADP
ajlm-840	140	46	resistance	resistance	NOUN
ajlm-840	140	47	testing	testing	NOUN
ajlm-840	140	48	among	among	ADP
ajlm-840	140	49	mdr	mdr	PROPN
ajlm-840	140	50	and	and	CCONJ
ajlm-840	140	51	xdr	xdr	PROPN
ajlm-840	140	52	isolates	isolate	NOUN
ajlm-840	140	53	(	(	PUNCT
ajlm-840	140	54	isoniazid	isoniazid	NOUN
ajlm-840	140	55	95	95	NUM
ajlm-840	140	56	%	%	NOUN
ajlm-840	140	57	,	,	PUNCT
ajlm-840	140	58	capreomycin	capreomycin	VERB
ajlm-840	140	59	93	93	NUM
ajlm-840	140	60	%	%	NOUN
ajlm-840	140	61	,	,	PUNCT
ajlm-840	140	62	moxifloxacin	moxifloxacin	NOUN
ajlm-840	140	63	91	91	NUM
ajlm-840	140	64	%	%	NOUN
ajlm-840	140	65	)	)	PUNCT
ajlm-840	140	66	.	.	PUNCT
ajlm-840	141	1	limitations	limitation	NOUN
ajlm-840	141	2	a	a	DET
ajlm-840	141	3	limitation	limitation	NOUN
ajlm-840	141	4	with	with	ADP
ajlm-840	141	5	the	the	DET
ajlm-840	141	6	apm	apm	NOUN
ajlm-840	141	7	is	be	AUX
ajlm-840	141	8	that	that	SCONJ
ajlm-840	141	9	the	the	DET
ajlm-840	141	10	test	test	NOUN
ajlm-840	141	11	provides	provide	VERB
ajlm-840	141	12	single	single	ADJ
ajlm-840	141	13	set	set	VERB
ajlm-840	141	14	critical	critical	ADJ
ajlm-840	141	15	concentrations	concentration	NOUN
ajlm-840	141	16	and	and	CCONJ
ajlm-840	141	17	not	not	PART
ajlm-840	141	18	clear	clear	ADV
ajlm-840	141	19	-	-	PUNCT
ajlm-840	141	20	cut	cut	VERB
ajlm-840	141	21	mic	mic	ADJ
ajlm-840	141	22	results	result	NOUN
ajlm-840	141	23	for	for	ADP
ajlm-840	141	24	each	each	DET
ajlm-840	141	25	drug	drug	NOUN
ajlm-840	141	26	in	in	ADP
ajlm-840	141	27	comparison	comparison	NOUN
ajlm-840	141	28	to	to	ADP
ajlm-840	141	29	the	the	DET
ajlm-840	141	30	sensititre	sensititre	NOUN
ajlm-840	141	31	®	®	PROPN
ajlm-840	141	32	mycotb	mycotb	ADJ
ajlm-840	141	33	plate	plate	NOUN
ajlm-840	141	34	method	method	NOUN
ajlm-840	141	35	.	.	PUNCT
ajlm-840	142	1	minimum	minimum	ADJ
ajlm-840	142	2	inhibitory	inhibitory	ADJ
ajlm-840	142	3	concentration	concentration	NOUN
ajlm-840	142	4	values	value	NOUN
ajlm-840	142	5	obtained	obtain	VERB
ajlm-840	142	6	from	from	ADP
ajlm-840	142	7	using	use	VERB
ajlm-840	142	8	the	the	DET
ajlm-840	142	9	sensititre	sensititre	NOUN
ajlm-840	142	10	®	®	PROPN
ajlm-840	142	11	mycotb	mycotb	ADJ
ajlm-840	142	12	plate	plate	NOUN
ajlm-840	142	13	could	could	AUX
ajlm-840	142	14	possibly	possibly	ADV
ajlm-840	142	15	be	be	AUX
ajlm-840	142	16	a	a	DET
ajlm-840	142	17	prospective	prospective	ADJ
ajlm-840	142	18	guide	guide	NOUN
ajlm-840	142	19	to	to	ADP
ajlm-840	142	20	establishing	establish	VERB
ajlm-840	142	21	definite	definite	ADJ
ajlm-840	142	22	mic	mic	ADJ
ajlm-840	142	23	breakpoint	breakpoint	NOUN
ajlm-840	142	24	values	value	NOUN
ajlm-840	142	25	for	for	ADP
ajlm-840	142	26	anti	anti	ADJ
ajlm-840	142	27	-	-	ADJ
ajlm-840	142	28	tuberculosis	tuberculosis	ADJ
ajlm-840	142	29	drugs	drug	NOUN
ajlm-840	142	30	in	in	ADP
ajlm-840	142	31	the	the	DET
ajlm-840	142	32	future	future	NOUN
ajlm-840	142	33	as	as	SCONJ
ajlm-840	142	34	there	there	PRON
ajlm-840	142	35	are	be	VERB
ajlm-840	142	36	no	no	DET
ajlm-840	142	37	interpretive	interpretive	ADJ
ajlm-840	142	38	mic	mic	ADJ
ajlm-840	142	39	breakpoints	breakpoint	NOUN
ajlm-840	142	40	that	that	PRON
ajlm-840	142	41	correlate	correlate	VERB
ajlm-840	142	42	with	with	ADP
ajlm-840	142	43	critical	critical	ADJ
ajlm-840	142	44	concentrations	concentration	NOUN
ajlm-840	142	45	.	.	PUNCT
ajlm-840	143	1	a	a	DET
ajlm-840	143	2	lack	lack	NOUN
ajlm-840	143	3	of	of	ADP
ajlm-840	143	4	apm	apm	NOUN
ajlm-840	143	5	results	result	NOUN
ajlm-840	143	6	for	for	ADP
ajlm-840	143	7	most	most	ADJ
ajlm-840	143	8	of	of	ADP
ajlm-840	143	9	the	the	DET
ajlm-840	143	10	second	second	ADJ
ajlm-840	143	11	-	-	PUNCT
ajlm-840	143	12	line	line	NOUN
ajlm-840	143	13	antimicrobials	antimicrobial	NOUN
ajlm-840	143	14	meant	mean	VERB
ajlm-840	143	15	that	that	SCONJ
ajlm-840	143	16	the	the	DET
ajlm-840	143	17	performance	performance	NOUN
ajlm-840	143	18	of	of	ADP
ajlm-840	143	19	the	the	DET
ajlm-840	143	20	sensititre	sensititre	NOUN
ajlm-840	143	21	®	®	PROPN
ajlm-840	143	22	mycotb	mycotb	PROPN
ajlm-840	143	23	method	method	NOUN
ajlm-840	143	24	in	in	ADP
ajlm-840	143	25	conjunction	conjunction	NOUN
ajlm-840	143	26	with	with	ADP
ajlm-840	143	27	the	the	DET
ajlm-840	143	28	apm	apm	NOUN
ajlm-840	143	29	could	could	AUX
ajlm-840	143	30	only	only	ADV
ajlm-840	143	31	be	be	AUX
ajlm-840	143	32	calculated	calculate	VERB
ajlm-840	143	33	and	and	CCONJ
ajlm-840	143	34	assessed	assess	VERB
ajlm-840	143	35	against	against	ADP
ajlm-840	143	36	a	a	DET
ajlm-840	143	37	limited	limited	ADJ
ajlm-840	143	38	number	number	NOUN
ajlm-840	143	39	of	of	ADP
ajlm-840	143	40	antimicrobials	antimicrobial	NOUN
ajlm-840	143	41	.	.	PUNCT
ajlm-840	144	1	results	result	NOUN
ajlm-840	144	2	for	for	ADP
ajlm-840	144	3	second	second	ADJ
ajlm-840	144	4	-	-	PUNCT
ajlm-840	144	5	line	line	NOUN
ajlm-840	144	6	drugs	drug	NOUN
ajlm-840	144	7	did	do	AUX
ajlm-840	144	8	show	show	VERB
ajlm-840	144	9	elevated	elevated	ADJ
ajlm-840	144	10	mics	mic	NOUN
ajlm-840	144	11	for	for	ADP
ajlm-840	144	12	mdr	mdr	PROPN
ajlm-840	144	13	and	and	CCONJ
ajlm-840	144	14	xdr	xdr	PROPN
ajlm-840	144	15	isolates	isolate	NOUN
ajlm-840	144	16	with	with	ADP
ajlm-840	144	17	the	the	DET
ajlm-840	144	18	majority	majority	NOUN
ajlm-840	144	19	of	of	ADP
ajlm-840	144	20	xdr	xdr	PROPN
ajlm-840	144	21	isolates	isolate	NOUN
ajlm-840	144	22	being	be	AUX
ajlm-840	144	23	resistant	resistant	ADJ
ajlm-840	144	24	.	.	PUNCT
ajlm-840	145	1	conclusion	conclusion	NOUN
ajlm-840	145	2	the	the	DET
ajlm-840	145	3	sensititre	sensititre	PROPN
ajlm-840	145	4	®	®	PROPN
ajlm-840	145	5	mycotb	mycotb	PROPN
ajlm-840	145	6	assay	assay	PROPN
ajlm-840	145	7	is	be	AUX
ajlm-840	145	8	a	a	DET
ajlm-840	145	9	desirable	desirable	ADJ
ajlm-840	145	10	alternative	alternative	ADJ
ajlm-840	145	11	method	method	NOUN
ajlm-840	145	12	compared	compare	VERB
ajlm-840	145	13	to	to	ADP
ajlm-840	145	14	the	the	DET
ajlm-840	145	15	apm	apm	NOUN
ajlm-840	145	16	for	for	ADP
ajlm-840	145	17	tuberculosis	tuberculosis	NOUN
ajlm-840	145	18	dst	dst	PROPN
ajlm-840	145	19	.	.	PUNCT
ajlm-840	146	1	simultaneous	simultaneous	ADJ
ajlm-840	146	2	firstand	firstand	ADJ
ajlm-840	146	3	second	second	ADJ
ajlm-840	146	4	-	-	PUNCT
ajlm-840	146	5	line	line	NOUN
ajlm-840	146	6	antimicrobial	antimicrobial	ADJ
ajlm-840	146	7	testing	testing	NOUN
ajlm-840	146	8	eradicates	eradicate	NOUN
ajlm-840	146	9	the	the	DET
ajlm-840	146	10	need	need	NOUN
ajlm-840	146	11	to	to	PART
ajlm-840	146	12	set	set	VERB
ajlm-840	146	13	up	up	ADP
ajlm-840	146	14	and	and	CCONJ
ajlm-840	146	15	maintain	maintain	VERB
ajlm-840	146	16	antimicrobial	antimicrobial	ADJ
ajlm-840	146	17	drug	drug	NOUN
ajlm-840	146	18	solutions	solution	NOUN
ajlm-840	146	19	(	(	PUNCT
ajlm-840	146	20	rema	rema	PROPN
ajlm-840	146	21	)	)	PUNCT
ajlm-840	146	22	.	.	PUNCT
ajlm-840	147	1	the	the	DET
ajlm-840	147	2	rema	rema	NOUN
ajlm-840	147	3	is	be	AUX
ajlm-840	147	4	ideal	ideal	ADJ
ajlm-840	147	5	for	for	ADP
ajlm-840	147	6	use	use	NOUN
ajlm-840	147	7	in	in	ADP
ajlm-840	147	8	resource	resource	NOUN
ajlm-840	147	9	-	-	PUNCT
ajlm-840	147	10	poor	poor	ADJ
ajlm-840	147	11	settings	setting	NOUN
ajlm-840	147	12	due	due	ADP
ajlm-840	147	13	to	to	ADP
ajlm-840	147	14	its	its	PRON
ajlm-840	147	15	low	low	ADJ
ajlm-840	147	16	cost	cost	NOUN
ajlm-840	147	17	and	and	CCONJ
ajlm-840	147	18	lack	lack	NOUN
ajlm-840	147	19	of	of	ADP
ajlm-840	147	20	instrumentation.12	instrumentation.12	NOUN
ajlm-840	147	21	in	in	ADP
ajlm-840	147	22	comparison	comparison	NOUN
ajlm-840	147	23	to	to	ADP
ajlm-840	147	24	the	the	DET
ajlm-840	147	25	apm	apm	NOUN
ajlm-840	147	26	,	,	PUNCT
ajlm-840	147	27	which	which	PRON
ajlm-840	147	28	has	have	VERB
ajlm-840	147	29	a	a	DET
ajlm-840	147	30	short	short	ADJ
ajlm-840	147	31	shelf	shelf	NOUN
ajlm-840	147	32	life	life	NOUN
ajlm-840	147	33	,	,	PUNCT
ajlm-840	147	34	the	the	DET
ajlm-840	147	35	sensititre	sensititre	NOUN
ajlm-840	147	36	®	®	PROPN
ajlm-840	147	37	mycotb	mycotb	ADJ
ajlm-840	147	38	mic	mic	ADJ
ajlm-840	147	39	plate	plate	NOUN
ajlm-840	147	40	can	can	AUX
ajlm-840	147	41	last	last	VERB
ajlm-840	147	42	for	for	ADP
ajlm-840	147	43	up	up	ADP
ajlm-840	147	44	to	to	PART
ajlm-840	147	45	2	2	NUM
ajlm-840	147	46	years	year	NOUN
ajlm-840	147	47	at	at	ADP
ajlm-840	147	48	room	room	NOUN
ajlm-840	147	49	temperature	temperature	NOUN
ajlm-840	147	50	.	.	PUNCT
ajlm-840	148	1	the	the	DET
ajlm-840	148	2	sensititre	sensititre	NOUN
ajlm-840	148	3	plate	plate	NOUN
ajlm-840	148	4	may	may	AUX
ajlm-840	148	5	be	be	AUX
ajlm-840	148	6	used	use	VERB
ajlm-840	148	7	together	together	ADV
ajlm-840	148	8	with	with	ADP
ajlm-840	148	9	rapid	rapid	ADJ
ajlm-840	148	10	molecular	molecular	ADJ
ajlm-840	148	11	tests	test	NOUN
ajlm-840	148	12	immediately	immediately	ADV
ajlm-840	148	13	targeting	target	VERB
ajlm-840	148	14	firstand	firstand	ADJ
ajlm-840	148	15	second	second	ADJ
ajlm-840	148	16	-	-	PUNCT
ajlm-840	148	17	line	line	NOUN
ajlm-840	148	18	drug	drug	NOUN
ajlm-840	148	19	testing	testing	NOUN
ajlm-840	148	20	in	in	ADP
ajlm-840	148	21	scenarios	scenario	NOUN
ajlm-840	148	22	of	of	ADP
ajlm-840	148	23	mdr	mdr	PROPN
ajlm-840	148	24	and	and	CCONJ
ajlm-840	148	25	xdr	xdr	PROPN
ajlm-840	148	26	tuberculosis.18	tuberculosis.18	VERB
ajlm-840	148	27	little	little	ADJ
ajlm-840	148	28	information	information	NOUN
ajlm-840	148	29	is	be	AUX
ajlm-840	148	30	available	available	ADJ
ajlm-840	148	31	to	to	ADP
ajlm-840	148	32	date	date	NOUN
ajlm-840	148	33	on	on	ADP
ajlm-840	148	34	a	a	DET
ajlm-840	148	35	worldwide	worldwide	ADJ
ajlm-840	148	36	,	,	PUNCT
ajlm-840	148	37	regional	regional	ADJ
ajlm-840	148	38	and	and	CCONJ
ajlm-840	148	39	local	local	ADJ
ajlm-840	148	40	scale	scale	NOUN
ajlm-840	148	41	on	on	ADP
ajlm-840	148	42	the	the	DET
ajlm-840	148	43	use	use	NOUN
ajlm-840	148	44	of	of	ADP
ajlm-840	148	45	the	the	DET
ajlm-840	148	46	sensititre	sensititre	NOUN
ajlm-840	148	47	plate	plate	NOUN
ajlm-840	148	48	.	.	PUNCT
ajlm-840	149	1	the	the	DET
ajlm-840	149	2	comparative	comparative	ADJ
ajlm-840	149	3	performance	performance	NOUN
ajlm-840	149	4	of	of	ADP
ajlm-840	149	5	sensititre	sensititre	PROPN
ajlm-840	149	6	®	®	PROPN
ajlm-840	149	7	mycotb	mycotb	NOUN
ajlm-840	149	8	assay	assay	PROPN
ajlm-840	149	9	to	to	ADP
ajlm-840	149	10	apm	apm	PROPN
ajlm-840	149	11	did	do	AUX
ajlm-840	149	12	show	show	VERB
ajlm-840	149	13	much	much	ADJ
ajlm-840	149	14	discordance	discordance	NOUN
ajlm-840	149	15	in	in	ADP
ajlm-840	149	16	this	this	DET
ajlm-840	149	17	study	study	NOUN
ajlm-840	149	18	and	and	CCONJ
ajlm-840	149	19	therefore	therefore	ADV
ajlm-840	149	20	can	can	AUX
ajlm-840	149	21	not	not	PART
ajlm-840	149	22	be	be	AUX
ajlm-840	149	23	recommended	recommend	VERB
ajlm-840	149	24	as	as	ADP
ajlm-840	149	25	a	a	DET
ajlm-840	149	26	replacement	replacement	NOUN
ajlm-840	149	27	of	of	ADP
ajlm-840	149	28	the	the	DET
ajlm-840	149	29	current	current	ADJ
ajlm-840	149	30	gold	gold	NOUN
ajlm-840	149	31	standard	standard	NOUN
ajlm-840	149	32	.	.	PUNCT
ajlm-840	150	1	in	in	ADP
ajlm-840	150	2	future	future	NOUN
ajlm-840	150	3	,	,	PUNCT
ajlm-840	150	4	more	more	ADJ
ajlm-840	150	5	studies	study	NOUN
ajlm-840	150	6	will	will	AUX
ajlm-840	150	7	have	have	VERB
ajlm-840	150	8	to	to	PART
ajlm-840	150	9	be	be	AUX
ajlm-840	150	10	performed	perform	VERB
ajlm-840	150	11	to	to	PART
ajlm-840	150	12	determine	determine	VERB
ajlm-840	150	13	anti	anti	ADJ
ajlm-840	150	14	-	-	ADJ
ajlm-840	150	15	tuberculous	tuberculous	ADJ
ajlm-840	150	16	drug	drug	NOUN
ajlm-840	150	17	mic	mic	ADJ
ajlm-840	150	18	interpretive	interpretive	ADJ
ajlm-840	150	19	breakpoints	breakpoint	NOUN
ajlm-840	150	20	using	use	VERB
ajlm-840	150	21	wild	wild	ADJ
ajlm-840	150	22	type	type	NOUN
ajlm-840	150	23	and	and	CCONJ
ajlm-840	150	24	non	non	ADJ
ajlm-840	150	25	-	-	ADJ
ajlm-840	150	26	wild	wild	ADJ
ajlm-840	150	27	type	type	NOUN
ajlm-840	150	28	isolates	isolate	NOUN
ajlm-840	150	29	,	,	PUNCT
ajlm-840	150	30	as	as	ADV
ajlm-840	150	31	well	well	ADV
ajlm-840	150	32	as	as	ADP
ajlm-840	150	33	discordant	discordant	ADJ
ajlm-840	150	34	analysis	analysis	NOUN
ajlm-840	150	35	,	,	PUNCT
ajlm-840	150	36	in	in	ADP
ajlm-840	150	37	order	order	NOUN
ajlm-840	150	38	to	to	PART
ajlm-840	150	39	increase	increase	VERB
ajlm-840	150	40	its	its	PRON
ajlm-840	150	41	use	use	NOUN
ajlm-840	150	42	in	in	ADP
ajlm-840	150	43	high	high	ADJ
ajlm-840	150	44	-	-	PUNCT
ajlm-840	150	45	burden	burden	NOUN
ajlm-840	150	46	areas	area	NOUN
ajlm-840	150	47	both	both	CCONJ
ajlm-840	150	48	locally	locally	ADV
ajlm-840	150	49	and	and	CCONJ
ajlm-840	150	50	nationally	nationally	ADV
ajlm-840	150	51	,	,	PUNCT
ajlm-840	150	52	especially	especially	ADV
ajlm-840	150	53	in	in	ADP
ajlm-840	150	54	the	the	DET
ajlm-840	150	55	province	province	NOUN
ajlm-840	150	56	of	of	ADP
ajlm-840	150	57	kwazulu	kwazulu	PROPN
ajlm-840	150	58	-	-	PUNCT
ajlm-840	150	59	natal	natal	NOUN
ajlm-840	150	60	.	.	PUNCT
ajlm-840	151	1	acknowledgements	acknowledgement	NOUN
ajlm-840	151	2	competing	compete	VERB
ajlm-840	151	3	interests	interest	NOUN
ajlm-840	151	4	the	the	DET
ajlm-840	151	5	authors	author	NOUN
ajlm-840	151	6	declare	declare	VERB
ajlm-840	151	7	that	that	SCONJ
ajlm-840	151	8	they	they	PRON
ajlm-840	151	9	have	have	VERB
ajlm-840	151	10	no	no	DET
ajlm-840	151	11	financial	financial	ADJ
ajlm-840	151	12	or	or	CCONJ
ajlm-840	151	13	personal	personal	ADJ
ajlm-840	151	14	relationships	relationship	NOUN
ajlm-840	151	15	that	that	PRON
ajlm-840	151	16	may	may	AUX
ajlm-840	151	17	have	have	AUX
ajlm-840	151	18	inappropriately	inappropriately	ADV
ajlm-840	151	19	influenced	influence	VERB
ajlm-840	151	20	them	they	PRON
ajlm-840	151	21	in	in	ADP
ajlm-840	151	22	writing	write	VERB
ajlm-840	151	23	this	this	DET
ajlm-840	151	24	article	article	NOUN
ajlm-840	151	25	.	.	PUNCT
ajlm-840	152	1	authors	author	NOUN
ajlm-840	152	2	’	’	PART
ajlm-840	152	3	contributions	contribution	NOUN
ajlm-840	152	4	p.j	p.j	PROPN
ajlm-840	152	5	.	.	PROPN
ajlm-840	152	6	was	be	AUX
ajlm-840	152	7	the	the	DET
ajlm-840	152	8	principal	principal	ADJ
ajlm-840	152	9	investigator	investigator	NOUN
ajlm-840	152	10	.	.	PUNCT
ajlm-840	153	1	m.p	m.p	PROPN
ajlm-840	153	2	.	.	PROPN
ajlm-840	153	3	was	be	AUX
ajlm-840	153	4	the	the	DET
ajlm-840	153	5	scientist	scientist	NOUN
ajlm-840	153	6	involved	involve	VERB
ajlm-840	153	7	in	in	ADP
ajlm-840	153	8	study	study	NOUN
ajlm-840	153	9	methodology	methodology	NOUN
ajlm-840	153	10	and	and	CCONJ
ajlm-840	153	11	design	design	NOUN
ajlm-840	153	12	.	.	PUNCT
ajlm-840	154	1	k.m	k.m	PROPN
ajlm-840	154	2	.	.	PROPN
ajlm-840	154	3	was	be	AUX
ajlm-840	154	4	the	the	DET
ajlm-840	154	5	supervisor	supervisor	NOUN
ajlm-840	154	6	and	and	CCONJ
ajlm-840	154	7	was	be	AUX
ajlm-840	154	8	responsible	responsible	ADJ
ajlm-840	154	9	for	for	ADP
ajlm-840	154	10	revision	revision	NOUN
ajlm-840	154	11	of	of	ADP
ajlm-840	154	12	the	the	DET
ajlm-840	154	13	manuscript	manuscript	NOUN
ajlm-840	154	14	.	.	PUNCT
ajlm-840	155	1	sources	source	NOUN
ajlm-840	155	2	of	of	ADP
ajlm-840	155	3	support	support	NOUN
ajlm-840	155	4	this	this	DET
ajlm-840	155	5	study	study	NOUN
ajlm-840	155	6	was	be	AUX
ajlm-840	155	7	supported	support	VERB
ajlm-840	155	8	by	by	ADP
ajlm-840	155	9	a	a	DET
ajlm-840	155	10	grant	grant	NOUN
ajlm-840	155	11	that	that	PRON
ajlm-840	155	12	was	be	AUX
ajlm-840	155	13	obtained	obtain	VERB
ajlm-840	155	14	from	from	ADP
ajlm-840	155	15	the	the	DET
ajlm-840	155	16	university	university	NOUN
ajlm-840	155	17	of	of	ADP
ajlm-840	155	18	kwazulu	kwazulu	PROPN
ajlm-840	155	19	-	-	PUNCT
ajlm-840	155	20	natal	natal	NOUN
ajlm-840	155	21	by	by	ADP
ajlm-840	155	22	dr	dr	PROPN
ajlm-840	155	23	prenika	prenika	PROPN
ajlm-840	155	24	jaglal	jaglal	PROPN
ajlm-840	155	25	as	as	ADP
ajlm-840	155	26	a	a	DET
ajlm-840	155	27	principal	principal	ADJ
ajlm-840	155	28	investigator	investigator	NOUN
ajlm-840	155	29	for	for	ADP
ajlm-840	155	30	research	research	NOUN
ajlm-840	155	31	purposes	purpose	NOUN
ajlm-840	155	32	,	,	PUNCT
ajlm-840	155	33	cs28	cs28	PROPN
ajlm-840	155	34	cost	cost	NOUN
ajlm-840	155	35	centre	centre	NOUN
ajlm-840	155	36	.	.	PUNCT
ajlm-840	156	1	data	datum	NOUN
ajlm-840	156	2	availability	availability	NOUN
ajlm-840	156	3	statement	statement	NOUN
ajlm-840	156	4	data	datum	NOUN
ajlm-840	156	5	sharing	sharing	NOUN
ajlm-840	156	6	is	be	AUX
ajlm-840	156	7	not	not	PART
ajlm-840	156	8	applicable	applicable	ADJ
ajlm-840	156	9	to	to	ADP
ajlm-840	156	10	this	this	DET
ajlm-840	156	11	article	article	NOUN
ajlm-840	156	12	as	as	SCONJ
ajlm-840	156	13	no	no	DET
ajlm-840	156	14	new	new	ADJ
ajlm-840	156	15	data	datum	NOUN
ajlm-840	156	16	were	be	AUX
ajlm-840	156	17	created	create	VERB
ajlm-840	156	18	or	or	CCONJ
ajlm-840	156	19	analysed	analyse	VERB
ajlm-840	156	20	in	in	ADP
ajlm-840	156	21	this	this	DET
ajlm-840	156	22	study	study	NOUN
ajlm-840	156	23	.	.	PUNCT
ajlm-840	157	1	disclaimer	disclaimer	VERB
ajlm-840	157	2	the	the	DET
ajlm-840	157	3	views	view	NOUN
ajlm-840	157	4	and	and	CCONJ
ajlm-840	157	5	opinions	opinion	NOUN
ajlm-840	157	6	expressed	express	VERB
ajlm-840	157	7	in	in	ADP
ajlm-840	157	8	this	this	DET
ajlm-840	157	9	article	article	NOUN
ajlm-840	157	10	are	be	AUX
ajlm-840	157	11	those	those	PRON
ajlm-840	157	12	of	of	ADP
ajlm-840	157	13	the	the	DET
ajlm-840	157	14	authors	author	NOUN
ajlm-840	157	15	and	and	CCONJ
ajlm-840	157	16	do	do	AUX
ajlm-840	157	17	not	not	PART
ajlm-840	157	18	necessarily	necessarily	ADV
ajlm-840	157	19	reflect	reflect	VERB
ajlm-840	157	20	the	the	DET
ajlm-840	157	21	official	official	ADJ
ajlm-840	157	22	policy	policy	NOUN
ajlm-840	157	23	or	or	CCONJ
ajlm-840	157	24	position	position	NOUN
ajlm-840	157	25	of	of	ADP
ajlm-840	157	26	any	any	DET
ajlm-840	157	27	affiliated	affiliated	ADJ
ajlm-840	157	28	agency	agency	NOUN
ajlm-840	157	29	of	of	ADP
ajlm-840	157	30	the	the	DET
ajlm-840	157	31	authors	author	NOUN
ajlm-840	157	32	.	.	PUNCT
ajlm-840	158	1	references	reference	NOUN
ajlm-840	158	2	world	world	PROPN
ajlm-840	158	3	health	health	NOUN
ajlm-840	158	4	organization	organization	NOUN
ajlm-840	159	1	[	[	X
ajlm-840	159	2	home	home	NOUN
ajlm-840	159	3	page	page	NOUN
ajlm-840	159	4	on	on	ADP
ajlm-840	159	5	the	the	DET
ajlm-840	159	6	internet	internet	NOUN
ajlm-840	159	7	]	]	PUNCT
ajlm-840	159	8	,	,	PUNCT
ajlm-840	159	9	global	global	ADJ
ajlm-840	159	10	tuberculosis	tuberculosis	NOUN
ajlm-840	159	11	report	report	NOUN
ajlm-840	159	12	2018	2018	NUM
ajlm-840	159	13	.	.	PUNCT
ajlm-840	160	1	accessed	access	VERB
ajlm-840	160	2	18	18	NUM
ajlm-840	160	3	september	september	PROPN
ajlm-840	160	4	2018	2018	NUM
ajlm-840	160	5	,	,	PUNCT
ajlm-840	160	6	from	from	ADP
ajlm-840	160	7	:	:	PUNCT
ajlm-840	160	8	https://www.who.int/tb/publications/global_report/en/.	https://www.who.int/tb/publications/global_report/en/.	PROPN
ajlm-840	160	9	parsons	parson	NOUN
ajlm-840	160	10	linda	linda	PROPN
ajlm-840	160	11	m	m	PROPN
ajlm-840	160	12	,	,	PUNCT
ajlm-840	160	13	somoskovi	somoskovi	VERB
ajlm-840	160	14	a	a	PRON
ajlm-840	160	15	,	,	PUNCT
ajlm-840	160	16	gutierrez	gutierrez	PROPN
ajlm-840	160	17	c.	c.	PROPN
ajlm-840	160	18	laboratory	laboratory	PROPN
ajlm-840	160	19	diagnosis	diagnosis	NOUN
ajlm-840	160	20	of	of	ADP
ajlm-840	160	21	tuberculosis	tuberculosis	NOUN
ajlm-840	160	22	in	in	ADP
ajlm-840	160	23	resource	resource	NOUN
ajlm-840	160	24	-	-	PUNCT
ajlm-840	160	25	poor	poor	ADJ
ajlm-840	160	26	countries	country	NOUN
ajlm-840	160	27	:	:	PUNCT
ajlm-840	160	28	challenges	challenge	NOUN
ajlm-840	160	29	and	and	CCONJ
ajlm-840	160	30	opportunities	opportunity	NOUN
ajlm-840	160	31	.	.	PUNCT
ajlm-840	161	1	clin	clin	PROPN
ajlm-840	161	2	microbiol	microbiol	PROPN
ajlm-840	161	3	rev	rev	VERB
ajlm-840	161	4	.	.	PROPN
ajlm-840	161	5	2011;24(2):314–350	2011;24(2):314–350	NUM
ajlm-840	161	6	.	.	PUNCT
ajlm-840	162	1	https://doi.org/10.1128/cmr.00059-10	https://doi.org/10.1128/cmr.00059-10	ADP
ajlm-840	162	2	africa	africa	PROPN
ajlm-840	162	3	millennium	millennium	PROPN
ajlm-840	162	4	development	development	NOUN
ajlm-840	162	5	goals	goal	NOUN
ajlm-840	162	6	6	6	NUM
ajlm-840	162	7	:	:	PUNCT
ajlm-840	162	8	combat	combat	NOUN
ajlm-840	162	9	hiv	hiv	PROPN
ajlm-840	162	10	/	/	SYM
ajlm-840	162	11	aids	aids	PROPN
ajlm-840	162	12	,	,	PUNCT
ajlm-840	162	13	malaria	malaria	NOUN
ajlm-840	162	14	and	and	CCONJ
ajlm-840	162	15	other	other	ADJ
ajlm-840	162	16	diseases	disease	NOUN
ajlm-840	162	17	2015	2015	NUM
ajlm-840	162	18	/	/	SYM
ajlm-840	162	19	statistics	statistics	PROPN
ajlm-840	162	20	south	south	PROPN
ajlm-840	162	21	africa	africa	PROPN
ajlm-840	163	1	[	[	X
ajlm-840	163	2	homepage	homepage	NOUN
ajlm-840	163	3	on	on	ADP
ajlm-840	163	4	the	the	DET
ajlm-840	163	5	internet	internet	NOUN
ajlm-840	163	6	]	]	PUNCT
ajlm-840	163	7	.	.	PUNCT
ajlm-840	164	1	millenium	millenium	PROPN
ajlm-840	164	2	development	development	NOUN
ajlm-840	164	3	goals	goal	NOUN
ajlm-840	164	4	.	.	PUNCT
ajlm-840	165	1	2015	2015	NUM
ajlm-840	165	2	.	.	PUNCT
ajlm-840	165	3	accessed	access	VERB
ajlm-840	165	4	15	15	NUM
ajlm-840	165	5	november	november	PROPN
ajlm-840	165	6	2016	2016	NUM
ajlm-840	165	7	,	,	PUNCT
ajlm-840	165	8	from	from	ADP
ajlm-840	165	9	:	:	PUNCT
ajlm-840	165	10	www.mdgmonitor.org/mdg-6-combat-hiv-aids-malaria-and-other-diseases	www.mdgmonitor.org/mdg-6-combat-hiv-aids-malaria-and-other-diseases	PROPN
ajlm-840	165	11	.	.	PUNCT
ajlm-840	166	1	brust	brust	PROPN
ajlm-840	166	2	jcm	jcm	PROPN
ajlm-840	166	3	,	,	PUNCT
ajlm-840	166	4	gandhi	gandhi	PROPN
ajlm-840	166	5	nr	nr	PROPN
ajlm-840	166	6	,	,	PUNCT
ajlm-840	166	7	carrara	carrara	PROPN
ajlm-840	166	8	h.	h.	PROPN
ajlm-840	166	9	high	high	ADJ
ajlm-840	166	10	treatment	treatment	NOUN
ajlm-840	166	11	failure	failure	NOUN
ajlm-840	166	12	and	and	CCONJ
ajlm-840	166	13	default	default	NOUN
ajlm-840	166	14	rates	rate	NOUN
ajlm-840	166	15	for	for	ADP
ajlm-840	166	16	patients	patient	NOUN
ajlm-840	166	17	with	with	ADP
ajlm-840	166	18	multidrug	multidrug	NOUN
ajlm-840	166	19	-	-	PUNCT
ajlm-840	166	20	resistant	resistant	ADJ
ajlm-840	166	21	tuberculosis	tuberculosis	NOUN
ajlm-840	166	22	in	in	ADP
ajlm-840	166	23	kwazulu	kwazulu	NOUN
ajlm-840	166	24	-	-	PUNCT
ajlm-840	166	25	natal	natal	ADJ
ajlm-840	166	26	,	,	PUNCT
ajlm-840	166	27	south	south	PROPN
ajlm-840	166	28	africa	africa	PROPN
ajlm-840	166	29	,	,	PUNCT
ajlm-840	166	30	2000–2003	2000–2003	NUM
ajlm-840	166	31	.	.	PUNCT
ajlm-840	166	32	int	int	PROPN
ajlm-840	166	33	j	j	PROPN
ajlm-840	166	34	tuberc	tuberc	PROPN
ajlm-840	166	35	lung	lung	PROPN
ajlm-840	166	36	dis	dis	PROPN
ajlm-840	166	37	2010;14(4):413–419	2010;14(4):413–419	NUM
ajlm-840	166	38	.	.	PUNCT
ajlm-840	167	1	martin	martin	PROPN
ajlm-840	167	2	a	a	PRON
ajlm-840	167	3	,	,	PUNCT
ajlm-840	167	4	camacho	camacho	PROPN
ajlm-840	167	5	m	m	PROPN
ajlm-840	167	6	,	,	PUNCT
ajlm-840	167	7	portaels	portaels	PROPN
ajlm-840	167	8	f.	f.	PROPN
ajlm-840	167	9	resazurin	resazurin	PROPN
ajlm-840	167	10	microtitre	microtitre	PROPN
ajlm-840	167	11	assay	assay	VERB
ajlm-840	167	12	ilate	ilate	NOUN
ajlm-840	167	13	testing	testing	NOUN
ajlm-840	167	14	of	of	ADP
ajlm-840	167	15	mycobacterium	mycobacterium	NOUN
ajlm-840	167	16	tuberculosis	tuberculosis	NOUN
ajlm-840	167	17	susceptibilities	susceptibility	NOUN
ajlm-840	167	18	to	to	ADP
ajlm-840	167	19	second	second	ADJ
ajlm-840	167	20	-	-	PUNCT
ajlm-840	167	21	line	line	NOUN
ajlm-840	167	22	drugs	drug	NOUN
ajlm-840	167	23	:	:	PUNCT
ajlm-840	167	24	rapid	rapid	ADJ
ajlm-840	167	25	,	,	PUNCT
ajlm-840	167	26	simple	simple	ADJ
ajlm-840	167	27	and	and	CCONJ
ajlm-840	167	28	inexpensive	inexpensive	ADJ
ajlm-840	167	29	method	method	NOUN
ajlm-840	167	30	.	.	PUNCT
ajlm-840	168	1	j	j	PROPN
ajlm-840	168	2	antimicrob	antimicrob	PROPN
ajlm-840	168	3	agents	agents	PROPN
ajlm-840	168	4	chemother	chemother	PROPN
ajlm-840	168	5	.	.	PUNCT
ajlm-840	169	1	2003;47(11):3616–3619	2003;47(11):3616–3619	NUM
ajlm-840	169	2	.	.	PUNCT
ajlm-840	170	1	https://doi.org/10.1128/aac.47.11.3616-3619.2003	https://doi.org/10.1128/aac.47.11.3616-3619.2003	ADJ
ajlm-840	170	2	yajko	yajko	ADJ
ajlm-840	170	3	dm	dm	NOUN
ajlm-840	170	4	,	,	PUNCT
ajlm-840	170	5	madej	madej	PROPN
ajlm-840	170	6	jj	jj	PROPN
ajlm-840	170	7	,	,	PUNCT
ajlm-840	170	8	lancaster	lancaster	PROPN
ajlm-840	170	9	mv	mv	PROPN
ajlm-840	170	10	.	.	PROPN
ajlm-840	170	11	colorimetric	colorimetric	ADJ
ajlm-840	170	12	method	method	NOUN
ajlm-840	170	13	for	for	ADP
ajlm-840	170	14	determining	determine	VERB
ajlm-840	170	15	mics	mic	NOUN
ajlm-840	170	16	of	of	ADP
ajlm-840	170	17	antimicrobial	antimicrobial	ADJ
ajlm-840	170	18	agents	agent	NOUN
ajlm-840	170	19	for	for	ADP
ajlm-840	170	20	mycobacterium	mycobacterium	NOUN
ajlm-840	170	21	tuberculosis	tuberculosis	NOUN
ajlm-840	170	22	.	.	PUNCT
ajlm-840	171	1	j	j	PROPN
ajlm-840	171	2	clin	clin	PROPN
ajlm-840	171	3	microbiol	microbiol	PROPN
ajlm-840	171	4	.	.	PUNCT
ajlm-840	172	1	1995;33(9):2324–2327	1995;33(9):2324–2327	PROPN
ajlm-840	172	2	.	.	PUNCT
ajlm-840	173	1	world	world	NOUN
ajlm-840	173	2	global	global	ADJ
ajlm-840	173	3	tb	tb	ADP
ajlm-840	173	4	report	report	NOUN
ajlm-840	173	5	[	[	X
ajlm-840	173	6	homepage	homepage	NOUN
ajlm-840	173	7	on	on	ADP
ajlm-840	173	8	the	the	DET
ajlm-840	173	9	internet	internet	NOUN
ajlm-840	173	10	]	]	PUNCT
ajlm-840	173	11	.	.	PUNCT
ajlm-840	174	1	world	world	PROPN
ajlm-840	174	2	health	health	PROPN
ajlm-840	174	3	organization	organization	NOUN
ajlm-840	174	4	;	;	PUNCT
ajlm-840	174	5	2016	2016	NUM
ajlm-840	174	6	.	.	PUNCT
ajlm-840	174	7	accessed	access	VERB
ajlm-840	174	8	12	12	NUM
ajlm-840	174	9	october	october	NOUN
ajlm-840	174	10	2016	2016	NUM
ajlm-840	174	11	,	,	PUNCT
ajlm-840	174	12	from	from	ADP
ajlm-840	174	13	:	:	PUNCT
ajlm-840	174	14	www.who.int/tb/publications/global_report/gtbr	www.who.int/tb/publications/global_report/gtbr	NOUN
ajlm-840	174	15	.	.	PUNCT
ajlm-840	175	1	sotgiu	sotgiu	NOUN
ajlm-840	175	2	g	g	PROPN
ajlm-840	175	3	,	,	PUNCT
ajlm-840	175	4	tiberib	tiberib	PROPN
ajlm-840	175	5	s	s	PROPN
ajlm-840	175	6	,	,	PUNCT
ajlm-840	175	7	centisc	centisc	PROPN
ajlm-840	175	8	r.	r.	PROPN
ajlm-840	175	9	applicability	applicability	NOUN
ajlm-840	175	10	of	of	ADP
ajlm-840	175	11	the	the	DET
ajlm-840	175	12	shorter	short	ADJ
ajlm-840	175	13	‘	'	PUNCT
ajlm-840	175	14	bangladesh	bangladesh	NOUN
ajlm-840	175	15	regimen	regiman	NOUN
ajlm-840	175	16	’	'	PUNCT
ajlm-840	175	17	in	in	ADP
ajlm-840	175	18	high	high	ADJ
ajlm-840	175	19	multidrug	multidrug	NOUN
ajlm-840	175	20	-	-	PUNCT
ajlm-840	175	21	resistant	resistant	ADJ
ajlm-840	175	22	tuberculosis	tuberculosis	NOUN
ajlm-840	175	23	settings	setting	NOUN
ajlm-840	175	24	.	.	PUNCT
ajlm-840	176	1	int	int	NOUN
ajlm-840	176	2	j	j	PROPN
ajlm-840	176	3	infect	infect	VERB
ajlm-840	176	4	dis	dis	PROPN
ajlm-840	176	5	.	.	PUNCT
ajlm-840	177	1	2016;56:190–193	2016;56:190–193	NOUN
ajlm-840	177	2	.	.	PUNCT
ajlm-840	178	1	montoro	montoro	PROPN
ajlm-840	178	2	e	e	NOUN
ajlm-840	178	3	,	,	PUNCT
ajlm-840	178	4	lemus	lemus	PROPN
ajlm-840	178	5	d	d	PROPN
ajlm-840	178	6	,	,	PUNCT
ajlm-840	178	7	echemendia	echemendia	PROPN
ajlm-840	178	8	m.	m.	NOUN
ajlm-840	178	9	comparative	comparative	ADJ
ajlm-840	178	10	evaluation	evaluation	NOUN
ajlm-840	178	11	of	of	ADP
ajlm-840	178	12	the	the	DET
ajlm-840	178	13	nitrate	nitrate	NOUN
ajlm-840	178	14	reduction	reduction	NOUN
ajlm-840	178	15	assay	assay	VERB
ajlm-840	178	16	,	,	PUNCT
ajlm-840	178	17	the	the	DET
ajlm-840	178	18	mtt	mtt	NOUN
ajlm-840	178	19	test	test	NOUN
ajlm-840	178	20	,	,	PUNCT
ajlm-840	178	21	and	and	CCONJ
ajlm-840	178	22	the	the	DET
ajlm-840	178	23	resazurin	resazurin	NOUN
ajlm-840	178	24	microtitre	microtitre	PROPN
ajlm-840	178	25	assay	assay	VERB
ajlm-840	178	26	for	for	ADP
ajlm-840	178	27	the	the	DET
ajlm-840	178	28	drug	drug	NOUN
ajlm-840	178	29	susceptibility	susceptibility	NOUN
ajlm-840	178	30	testing	testing	NOUN
ajlm-840	178	31	of	of	ADP
ajlm-840	178	32	clinical	clinical	ADJ
ajlm-840	178	33	isolates	isolate	NOUN
ajlm-840	178	34	of	of	ADP
ajlm-840	178	35	mycobacterium	mycobacterium	NOUN
ajlm-840	178	36	tuberculosis	tuberculosis	NOUN
ajlm-840	178	37	.	.	PUNCT
ajlm-840	179	1	j	j	PROPN
ajlm-840	179	2	antimicrob	antimicrob	PROPN
ajlm-840	179	3	agents	agents	PROPN
ajlm-840	179	4	chemother	chemother	PROPN
ajlm-840	179	5	.	.	PUNCT
ajlm-840	180	1	2005;55(february):500–505	2005;55(february):500–505	NUM
ajlm-840	180	2	.	.	PUNCT
ajlm-840	181	1	https://doi.org/10.1093/jac/dki023	https://doi.org/10.1093/jac/dki023	PROPN
ajlm-840	181	2	palomino	palomino	ADJ
ajlm-840	181	3	jc	jc	PROPN
ajlm-840	181	4	,	,	PUNCT
ajlm-840	181	5	martin	martin	PROPN
ajlm-840	181	6	a	a	DET
ajlm-840	181	7	,	,	PUNCT
ajlm-840	181	8	camacho	camacho	PROPN
ajlm-840	181	9	m.	m.	PROPN
ajlm-840	181	10	resazurin	resazurin	PROPN
ajlm-840	181	11	microtitre	microtitre	PROPN
ajlm-840	181	12	assay	assay	PROPN
ajlm-840	181	13	plate	plate	NOUN
ajlm-840	181	14	:	:	PUNCT
ajlm-840	181	15	simple	simple	ADJ
ajlm-840	181	16	and	and	CCONJ
ajlm-840	181	17	inexpensive	inexpensive	ADJ
ajlm-840	181	18	methods	method	NOUN
ajlm-840	181	19	for	for	ADP
ajlm-840	181	20	detection	detection	NOUN
ajlm-840	181	21	of	of	ADP
ajlm-840	181	22	drug	drug	NOUN
ajlm-840	181	23	resistance	resistance	NOUN
ajlm-840	181	24	in	in	ADP
ajlm-840	181	25	mycobacterium	mycobacterium	NOUN
ajlm-840	181	26	tuberculosis	tuberculosis	NOUN
ajlm-840	181	27	.	.	PUNCT
ajlm-840	182	1	j	j	PROPN
ajlm-840	182	2	antimicrob	antimicrob	PROPN
ajlm-840	182	3	agents	agents	PROPN
ajlm-840	182	4	chemother	chemother	PROPN
ajlm-840	182	5	.	.	PUNCT
ajlm-840	183	1	2002(46):2720–2722	2002(46):2720–2722	X
ajlm-840	183	2	.	.	PUNCT
ajlm-840	184	1	nichols	nichols	PROPN
ajlm-840	184	2	mp	mp	PROPN
ajlm-840	184	3	.	.	PUNCT
ajlm-840	185	1	new	new	ADJ
ajlm-840	185	2	developments	development	NOUN
ajlm-840	185	3	in	in	ADP
ajlm-840	185	4	the	the	DET
ajlm-840	185	5	laboratory	laboratory	NOUN
ajlm-840	185	6	diagnosis	diagnosis	NOUN
ajlm-840	185	7	of	of	ADP
ajlm-840	185	8	tuberculosis	tuberculosis	NOUN
ajlm-840	185	9	.	.	PUNCT
ajlm-840	186	1	contin	contin	PROPN
ajlm-840	186	2	med	med	PROPN
ajlm-840	186	3	educ	educ	PROPN
ajlm-840	186	4	.	.	PUNCT
ajlm-840	187	1	2010;6(june):246–251	2010;6(june):246–251	X
ajlm-840	187	2	.	.	PUNCT
ajlm-840	188	1	martin	martin	PROPN
ajlm-840	188	2	a	a	DET
ajlm-840	188	3	,	,	PUNCT
ajlm-840	188	4	morcillo	morcillo	PROPN
ajlm-840	188	5	c	c	NOUN
ajlm-840	188	6	,	,	PUNCT
ajlm-840	188	7	lemus	lemus	PROPN
ajlm-840	188	8	d.	d.	PROPN
ajlm-840	188	9	multicenter	multicenter	PROPN
ajlm-840	188	10	study	study	NOUN
ajlm-840	188	11	of	of	ADP
ajlm-840	188	12	mtt	mtt	NOUN
ajlm-840	188	13	and	and	CCONJ
ajlm-840	188	14	resazurin	resazurin	NOUN
ajlm-840	188	15	assays	assay	NOUN
ajlm-840	188	16	for	for	ADP
ajlm-840	188	17	testing	test	VERB
ajlm-840	188	18	susceptibility	susceptibility	NOUN
ajlm-840	188	19	to	to	ADP
ajlm-840	188	20	first	first	ADJ
ajlm-840	188	21	-	-	PUNCT
ajlm-840	188	22	line	line	NOUN
ajlm-840	188	23	anti	anti	ADJ
ajlm-840	188	24	-	-	ADJ
ajlm-840	188	25	tuberculosis	tuberculosis	ADJ
ajlm-840	188	26	drugs	drug	NOUN
ajlm-840	188	27	.	.	PUNCT
ajlm-840	189	1	int	int	PROPN
ajlm-840	189	2	j	j	PROPN
ajlm-840	189	3	tuberc	tuberc	PROPN
ajlm-840	189	4	lung	lung	PROPN
ajlm-840	189	5	dis	dis	PROPN
ajlm-840	189	6	.	.	PUNCT
ajlm-840	190	1	2005;9(8):901–906	2005;9(8):901–906	NUM
ajlm-840	190	2	.	.	PROPN
ajlm-840	190	3	franzblau	franzblau	PROPN
ajlm-840	190	4	sg	sg	PROPN
ajlm-840	190	5	,	,	PUNCT
ajlm-840	190	6	witzig	witzig	PROPN
ajlm-840	190	7	rs	rs	PROPN
ajlm-840	190	8	,	,	PUNCT
ajlm-840	190	9	mclaughlin	mclaughlin	PROPN
ajlm-840	190	10	jc	jc	PROPN
ajlm-840	190	11	.	.	PROPN
ajlm-840	191	1	rapid	rapid	ADJ
ajlm-840	191	2	,	,	PUNCT
ajlm-840	191	3	low	low	ADJ
ajlm-840	191	4	-	-	PUNCT
ajlm-840	191	5	technology	technology	NOUN
ajlm-840	191	6	mic	mic	ADJ
ajlm-840	191	7	determination	determination	NOUN
ajlm-840	191	8	with	with	ADP
ajlm-840	191	9	clinical	clinical	ADJ
ajlm-840	191	10	mycobacterium	mycobacterium	NOUN
ajlm-840	191	11	tuberculosis	tuberculosis	NOUN
ajlm-840	191	12	by	by	ADP
ajlm-840	191	13	using	use	VERB
ajlm-840	191	14	the	the	DET
ajlm-840	191	15	microplate	microplate	NOUN
ajlm-840	191	16	alamar	alamar	PROPN
ajlm-840	191	17	blue	blue	PROPN
ajlm-840	191	18	assay	assay	VERB
ajlm-840	191	19	.	.	PUNCT
ajlm-840	192	1	j	j	PROPN
ajlm-840	192	2	clin	clin	PROPN
ajlm-840	192	3	microbiol	microbiol	PROPN
ajlm-840	192	4	.	.	PUNCT
ajlm-840	193	1	1998;36(2):362–366	1998;36(2):362–366	NUM
ajlm-840	193	2	.	.	PUNCT
ajlm-840	193	3	hall	hall	PROPN
ajlm-840	193	4	l	l	PROPN
ajlm-840	193	5	,	,	PUNCT
ajlm-840	193	6	jude	jude	PROPN
ajlm-840	193	7	kp	kp	PROPN
ajlm-840	193	8	,	,	PUNCT
ajlm-840	193	9	clark	clark	PROPN
ajlm-840	193	10	sl	sl	PROPN
ajlm-840	193	11	.	.	PROPN
ajlm-840	193	12	antimicrobial	antimicrobial	ADJ
ajlm-840	193	13	susceptibility	susceptibility	NOUN
ajlm-840	193	14	testing	testing	NOUN
ajlm-840	193	15	of	of	ADP
ajlm-840	193	16	mycobacterium	mycobacterium	NOUN
ajlm-840	193	17	tuberculosis	tuberculosis	NOUN
ajlm-840	193	18	complex	complex	NOUN
ajlm-840	193	19	for	for	ADP
ajlm-840	193	20	first	first	ADJ
ajlm-840	193	21	and	and	CCONJ
ajlm-840	193	22	second	second	ADJ
ajlm-840	193	23	line	line	NOUN
ajlm-840	193	24	drugs	drug	NOUN
ajlm-840	193	25	by	by	ADP
ajlm-840	193	26	broth	broth	ADJ
ajlm-840	193	27	bilution	bilution	NOUN
ajlm-840	193	28	in	in	ADP
ajlm-840	193	29	a	a	DET
ajlm-840	193	30	microtiter	microtiter	ADJ
ajlm-840	193	31	plate	plate	NOUN
ajlm-840	193	32	format	format	NOUN
ajlm-840	193	33	.	.	PUNCT
ajlm-840	194	1	j	j	PROPN
ajlm-840	194	2	vis	vis	X
ajlm-840	194	3	exp	exp	NOUN
ajlm-840	194	4	2011;52(11):3094	2011;52(11):3094	NUM
ajlm-840	194	5	.	.	PUNCT
ajlm-840	195	1	coban	coban	PROPN
ajlm-840	195	2	ay	ay	NOUN
ajlm-840	195	3	,	,	PUNCT
ajlm-840	195	4	cehan	cehan	ADP
ajlm-840	195	5	cc	cc	PROPN
ajlm-840	195	6	,	,	PUNCT
ajlm-840	195	7	bilgan	bilgan	VERB
ajlm-840	195	8	k.	k.	PROPN
ajlm-840	195	9	rapid	rapid	ADJ
ajlm-840	195	10	susceptibility	susceptibility	NOUN
ajlm-840	195	11	test	test	NOUN
ajlm-840	195	12	for	for	ADP
ajlm-840	195	13	mycobacterium	mycobacterium	NOUN
ajlm-840	195	14	tuberculosis	tuberculosis	NOUN
ajlm-840	195	15	to	to	ADP
ajlm-840	195	16	isoniazid	isoniazid	NOUN
ajlm-840	195	17	and	and	CCONJ
ajlm-840	195	18	rifampicin	rifampicin	VERB
ajlm-840	195	19	with	with	ADP
ajlm-840	195	20	resazurin	resazurin	NOUN
ajlm-840	195	21	method	method	NOUN
ajlm-840	195	22	in	in	ADP
ajlm-840	195	23	screw	screw	NOUN
ajlm-840	195	24	cap	cap	PROPN
ajlm-840	195	25	tubes	tube	NOUN
ajlm-840	195	26	.	.	PUNCT
ajlm-840	196	1	j	j	PROPN
ajlm-840	196	2	chemother	chemother	PROPN
ajlm-840	196	3	.	.	PUNCT
ajlm-840	197	1	2006;18(2):140–143	2006;18(2):140–143	X
ajlm-840	197	2	.	.	PUNCT
ajlm-840	198	1	https://doi.org/10.1179/joc.2006.18.2.140	https://doi.org/10.1179/joc.2006.18.2.140	PROPN
ajlm-840	198	2	abuali	abuali	PROPN
ajlm-840	198	3	mm	mm	PROPN
ajlm-840	198	4	,	,	PUNCT
ajlm-840	198	5	katariwala	katariwala	PROPN
ajlm-840	198	6	a	a	PROPN
ajlm-840	198	7	,	,	PUNCT
ajlm-840	198	8	labombardi	labombardi	PROPN
ajlm-840	198	9	vj	vj	PROPN
ajlm-840	198	10	.	.	PUNCT
ajlm-840	199	1	a	a	DET
ajlm-840	199	2	comparison	comparison	NOUN
ajlm-840	199	3	of	of	ADP
ajlm-840	199	4	the	the	DET
ajlm-840	199	5	sensititre	sensititre	NOUN
ajlm-840	199	6	mycotb	mycotb	PROPN
ajlm-840	199	7	panel	panel	NOUN
ajlm-840	199	8	and	and	CCONJ
ajlm-840	199	9	the	the	DET
ajlm-840	199	10	agar	agar	NOUN
ajlm-840	199	11	proportion	proportion	NOUN
ajlm-840	199	12	method	method	NOUN
ajlm-840	199	13	for	for	ADP
ajlm-840	199	14	drug	drug	NOUN
ajlm-840	199	15	susceptibility	susceptibility	NOUN
ajlm-840	199	16	testing	testing	NOUN
ajlm-840	199	17	of	of	ADP
ajlm-840	199	18	mycobacterium	mycobacterium	NOUN
ajlm-840	199	19	tuberculosis	tuberculosis	NOUN
ajlm-840	199	20	.	.	PUNCT
ajlm-840	200	1	eur	eur	PROPN
ajlm-840	200	2	j	j	PROPN
ajlm-840	200	3	clin	clin	PROPN
ajlm-840	200	4	microbiol	microbiol	PROPN
ajlm-840	200	5	infect	infect	VERB
ajlm-840	200	6	dis	dis	PROPN
ajlm-840	200	7	.	.	PUNCT
ajlm-840	201	1	2012;31(5):835–839	2012;31(5):835–839	X
ajlm-840	201	2	.	.	PUNCT
ajlm-840	202	1	https://doi.org/10.1007/s10096-011-1382-z	https://doi.org/10.1007/s10096-011-1382-z	PROPN
ajlm-840	202	2	o’donnell	o’donnell	PROPN
ajlm-840	202	3	mr	mr	PROPN
ajlm-840	202	4	,	,	PUNCT
ajlm-840	202	5	pillay	pillay	PROPN
ajlm-840	202	6	m	m	PROPN
ajlm-840	202	7	,	,	PUNCT
ajlm-840	202	8	pillay	pillay	PROPN
ajlm-840	202	9	m.	m.	PROPN
ajlm-840	202	10	primary	primary	PROPN
ajlm-840	202	11	capreomycin	capreomycin	PROPN
ajlm-840	202	12	resistance	resistance	NOUN
ajlm-840	202	13	is	be	AUX
ajlm-840	202	14	common	common	ADJ
ajlm-840	202	15	and	and	CCONJ
ajlm-840	202	16	associated	associate	VERB
ajlm-840	202	17	with	with	ADP
ajlm-840	202	18	early	early	ADJ
ajlm-840	202	19	mortality	mortality	NOUN
ajlm-840	202	20	in	in	ADP
ajlm-840	202	21	patients	patient	NOUN
ajlm-840	202	22	with	with	ADP
ajlm-840	202	23	extensively	extensively	ADV
ajlm-840	202	24	drug	drug	NOUN
ajlm-840	202	25	-	-	PUNCT
ajlm-840	202	26	resistant	resistant	ADJ
ajlm-840	202	27	tuberculosis	tuberculosis	NOUN
ajlm-840	202	28	in	in	ADP
ajlm-840	202	29	kwazulu	kwazulu	NOUN
ajlm-840	202	30	-	-	PUNCT
ajlm-840	202	31	natal	natal	ADJ
ajlm-840	202	32	,	,	PUNCT
ajlm-840	202	33	south	south	PROPN
ajlm-840	202	34	africa	africa	PROPN
ajlm-840	202	35	.	.	PUNCT
ajlm-840	203	1	j	j	PROPN
ajlm-840	203	2	acquir	acquir	PROPN
ajlm-840	203	3	immune	immune	VERB
ajlm-840	203	4	defic	defic	ADJ
ajlm-840	203	5	syndr	syndr	NOUN
ajlm-840	203	6	.	.	PUNCT
ajlm-840	204	1	2015;69(5):536–543	2015;69(5):536–543	X
ajlm-840	204	2	.	.	PUNCT
ajlm-840	205	1	https://doi.org/10.1097/qai.0000000000000650	https://doi.org/10.1097/qai.0000000000000650	PROPN
ajlm-840	205	2	lee	lee	PROPN
ajlm-840	205	3	j	j	PROPN
ajlm-840	205	4	,	,	PUNCT
ajlm-840	205	5	armstrong	armstrong	PROPN
ajlm-840	205	6	dt	dt	PROPN
ajlm-840	205	7	,	,	PUNCT
ajlm-840	205	8	ssengooba	ssengooba	PROPN
ajlm-840	205	9	w	w	PROPN
ajlm-840	205	10	,	,	PUNCT
ajlm-840	205	11	park	park	NOUN
ajlm-840	205	12	.	.	PUNCT
ajlm-840	206	1	sensititre	sensititre	PROPN
ajlm-840	206	2	mycotb	mycotb	ADJ
ajlm-840	206	3	mic	mic	ADJ
ajlm-840	206	4	plate	plate	NOUN
ajlm-840	206	5	for	for	ADP
ajlm-840	206	6	testing	test	VERB
ajlm-840	206	7	mycobacterium	mycobacterium	NOUN
ajlm-840	206	8	tuberculosis	tuberculosis	NOUN
ajlm-840	206	9	susceptibility	susceptibility	NOUN
ajlm-840	206	10	to	to	ADP
ajlm-840	206	11	firstand	firstand	NOUN
ajlm-840	206	12	second	second	ADJ
ajlm-840	206	13	-	-	PUNCT
ajlm-840	206	14	line	line	NOUN
ajlm-840	206	15	drugs	drug	NOUN
ajlm-840	206	16	.	.	PUNCT
ajlm-840	207	1	j	j	PROPN
ajlm-840	207	2	antimicrob	antimicrob	PROPN
ajlm-840	207	3	agents	agents	PROPN
ajlm-840	207	4	chemother	chemother	PROPN
ajlm-840	207	5	.	.	PUNCT
ajlm-840	208	1	2014;51(8):11–15	2014;51(8):11–15	X
ajlm-840	208	2	.	.	PUNCT
ajlm-840	209	1	https://doi.org/10.1128/aac.01209-13	https://doi.org/10.1128/aac.01209-13	PROPN
ajlm-840	209	2	abdel	abdel	PROPN
ajlm-840	209	3	-	-	PUNCT
ajlm-840	209	4	rahman	rahman	PROPN
ajlm-840	209	5	sm	sm	PROPN
ajlm-840	209	6	,	,	PUNCT
ajlm-840	209	7	abdel	abdel	PROPN
ajlm-840	209	8	-	-	PUNCT
ajlm-840	209	9	latif	latif	PROPN
ajlm-840	209	10	w	w	PROPN
ajlm-840	209	11	,	,	PUNCT
ajlm-840	209	12	kholeif	kholeif	PROPN
ajlm-840	209	13	h	h	PROPN
ajlm-840	209	14	,	,	PUNCT
ajlm-840	209	15	erfan	erfan	PROPN
ajlm-840	209	16	d.	d.	PROPN
ajlm-840	209	17	evaluation	evaluation	NOUN
ajlm-840	209	18	of	of	ADP
ajlm-840	209	19	sensititre	sensititre	PROPN
ajlm-840	209	20	®	®	PROPN
ajlm-840	209	21	mycotb	mycotb	PROPN
ajlm-840	209	22	panel	panel	NOUN
ajlm-840	209	23	for	for	ADP
ajlm-840	209	24	the	the	DET
ajlm-840	209	25	susceptibility	susceptibility	NOUN
ajlm-840	209	26	testing	testing	NOUN
ajlm-840	209	27	of	of	ADP
ajlm-840	209	28	mycobacterium	mycobacterium	NOUN
ajlm-840	209	29	tuberculosis	tuberculosis	NOUN
ajlm-840	209	30	to	to	ADP
ajlm-840	209	31	first	first	ADJ
ajlm-840	209	32	and	and	CCONJ
ajlm-840	209	33	second	second	ADJ
ajlm-840	209	34	lines	line	NOUN
ajlm-840	209	35	anti	anti	ADJ
ajlm-840	209	36	-	-	ADJ
ajlm-840	209	37	tuberculosis	tuberculosis	ADJ
ajlm-840	209	38	drugs	drug	NOUN
ajlm-840	209	39	.	.	PUNCT
ajlm-840	210	1	j	j	PROPN
ajlm-840	210	2	clin	clin	PROPN
ajlm-840	210	3	med	med	PROPN
ajlm-840	210	4	diagn	diagn	PROPN
ajlm-840	210	5	.	.	PUNCT
ajlm-840	211	1	2016;6(1):13–19	2016;6(1):13–19	NUM
ajlm-840	211	2	.	.	PUNCT
ajlm-840	212	1	parrish	parrish	PROPN
ajlm-840	212	2	nm	nm	PROPN
ajlm-840	212	3	,	,	PUNCT
ajlm-840	212	4	carroll	carroll	PROPN
ajlm-840	212	5	kc	kc	PROPN
ajlm-840	212	6	.	.	PUNCT
ajlm-840	213	1	role	role	NOUN
ajlm-840	213	2	of	of	ADP
ajlm-840	213	3	the	the	DET
ajlm-840	213	4	clinical	clinical	ADJ
ajlm-840	213	5	mycobacteriology	mycobacteriology	NOUN
ajlm-840	213	6	laboratory	laboratory	NOUN
ajlm-840	213	7	in	in	ADP
ajlm-840	213	8	diagnosis	diagnosis	NOUN
ajlm-840	213	9	and	and	CCONJ
ajlm-840	213	10	management	management	NOUN
ajlm-840	213	11	of	of	ADP
ajlm-840	213	12	tuberculosis	tuberculosis	NOUN
ajlm-840	213	13	in	in	ADP
ajlm-840	213	14	low	low	ADJ
ajlm-840	213	15	-	-	PUNCT
ajlm-840	213	16	prevalence	prevalence	NOUN
ajlm-840	213	17	settings	setting	NOUN
ajlm-840	213	18	.	.	PUNCT
ajlm-840	214	1	j	j	PROPN
ajlm-840	214	2	clin	clin	PROPN
ajlm-840	214	3	microbiol	microbiol	PROPN
ajlm-840	214	4	.	.	PUNCT
ajlm-840	215	1	2011;49(3):772–776	2011;49(3):772–776	NUM
ajlm-840	215	2	.	.	PUNCT
ajlm-840	216	1	https://doi.org/10.1128/jcm.02451-10	https://doi.org/10.1128/jcm.02451-10	DET
ajlm-840	216	2	khalifa	khalifa	PROPN
ajlm-840	216	3	ra	ra	PROPN
ajlm-840	216	4	,	,	PUNCT
ajlm-840	216	5	nasser	nasser	PROPN
ajlm-840	216	6	ms	ms	PROPN
ajlm-840	216	7	,	,	PUNCT
ajlm-840	216	8	gomaa	gomaa	ADJ
ajlm-840	216	9	aa	aa	NOUN
ajlm-840	216	10	.	.	PUNCT
ajlm-840	217	1	resazurin	resazurin	NOUN
ajlm-840	217	2	microtiter	microtiter	PROPN
ajlm-840	217	3	assay	assay	VERB
ajlm-840	217	4	plate	plate	NOUN
ajlm-840	217	5	method	method	NOUN
ajlm-840	217	6	for	for	ADP
ajlm-840	217	7	detection	detection	NOUN
ajlm-840	217	8	of	of	ADP
ajlm-840	217	9	susceptibility	susceptibility	NOUN
ajlm-840	217	10	of	of	ADP
ajlm-840	217	11	multidrug	multidrug	NOUN
ajlm-840	217	12	resistant	resistant	ADJ
ajlm-840	217	13	mycobacterium	mycobacterium	NOUN
ajlm-840	217	14	tuberculosis	tuberculosis	NOUN
ajlm-840	217	15	to	to	ADP
ajlm-840	217	16	second	second	ADJ
ajlm-840	217	17	-	-	PUNCT
ajlm-840	217	18	line	line	NOUN
ajlm-840	217	19	anti	anti	ADJ
ajlm-840	217	20	-	-	ADJ
ajlm-840	217	21	tuberculosis	tuberculosis	ADJ
ajlm-840	217	22	drugs	drug	NOUN
ajlm-840	217	23	.	.	PUNCT
ajlm-840	218	1	egyptian	egyptian	PROPN
ajlm-840	218	2	j	j	PROPN
ajlm-840	218	3	chest	chest	PROPN
ajlm-840	218	4	dis	dis	PROPN
ajlm-840	218	5	tuberc	tuberc	NOUN
ajlm-840	218	6	.	.	PUNCT
ajlm-840	219	1	2013;62(2):241–247	2013;62(2):241–247	X
ajlm-840	219	2	.	.	PUNCT
ajlm-840	220	1	https://doi.org/10.1016/j.ejcdt.2013.05.008	https://doi.org/10.1016/j.ejcdt.2013.05.008	NOUN